

CITATION REPORT

List of articles citing

New diagnostic criteria for multiple sclerosis:
guidelines for research protocols

DOI: 10.1002/ana.410130302
Annals of Neurology, 1983, 13, 227-31.

Source: <https://exaly.com/paper-pdf/16229893/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2312	Klinik und Therapie der Multiplen Sklerose.		
2311	Multiple sclerosis: the present position. 1983 , 68, 65-76		27
2310	Multiple sclerosis. The spectrum of severity. 1983 , 40, 531-2		20
2309	Neurophysiology in Multiple Sclerosis. 1983 , 1, 615-630		6
2308	Clinical Spectrum of Multiple Sclerosis. 1983 , 1, 573-600		16
2307	Visual, Brainstem Auditory and Somatosensory Evoked Potentials: Clinical Uses. 1984 , 24, 213-229		2
2306	Therapeutic trials in multiple sclerosis. 1984 , 11, 355-62		14
2305	Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. 1984 , 47, 1182-91		99
2304	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-1984. A 47-year-old man with coronary-artery disease and variable neurologic abnormalities. 1984 , 310, 106-14		26
2303	A neurologic rating scale (NRS) for use in multiple sclerosis. 1984 , 34, 1368-72		206
2302	Die Messung der Luminol-abhängigen Chemilumineszenz zur Bestimmung der spontanen Aktivität von peripheren Blut-Monozyten am Beispiel von Multiple Sklerose-Patienten und gesunden Probanden*. 1984 , 11, 77-81		3
2301	Multiple sclerosis presenting with progressive visual failure. 1984 , 47, 943-6		18
2300	Deficient learning and memory in early and middle phases of multiple sclerosis. 1984 , 47, 250-5		114
2299	Pattern electroretinogram in multiple sclerosis. 1984 , 47, 879-83		14
2298	Quantitative measurement of blood-brain barrier permeability using rubidium-82 and positron emission tomography. 1984 , 4, 535-45		73
2297	Optic neuritis. 1984 , 13, 1061-4		4
2296	Multiple sclerosis immune complexes: an analysis of component antigens and antibodies. <i>Annals of Neurology</i> , 1984 , 16, 660-7	9.4	26

2295	Isoelectric focusing of CSF proteins and the future evolution of multiple sclerosis: a clinical follow-up. 1984 , 231, 117-21	11
2294	Local and systemic immune response in multiple sclerosis: analysis of CSF inflammatory changes and peripheral blood T-cell subsets. 1984 , 231, 126-9	13
2293	Taxonomy and diagnostic parameters in multiple sclerosis. 1984 , 436, 233-46	15
2292	The failure of monoclonal antibody-defined lymphocyte subsets to monitor disease activity in patients with multiple sclerosis. 1984 , 436, 271-80	11
2291	Magnetic resonance imaging and CT scanning in multiple sclerosis. 1984 , 436, 294-314	17
2290	Multiple sclerosis bladder. Studies and care. 1984 , 436, 328-46	27
2289	Clinical trial of natural alpha interferon in multiple sclerosis. 1984 , 436, 382-8	15
2288	Total lymphoid irradiation in chronic progressive multiple sclerosis. A preliminary report. 1984 , 436, 397-409	6
2287	Eye damage from Christmas trees. 1984 , 2, 1335	3
2286	Papanicolaou smears and risk of cervical neoplasia. 1984 , 2, 1335	1
2285	Spine and scalp somatosensory evoked potentials in normal subjects and patients with spinal cord disease: evaluation of afferent transmission. 1984 , 59, 374-87	44
2284	Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8. 1984 , 6, 75-84	57
2283	NMR in multiple sclerosis and cerebral vascular disease. 1984 , 2, 1334-5	31
2282	HLA antigens in multiple sclerosis in coloured South Africans. 1984 , 66, 175-81	4
2281	Abnormalities in central motor pathway conduction in multiple sclerosis. 1984 , 2, 304-7	135
2280	Agarose electrophoresis and immunonephelometric quantitation of cerebrospinal fluid immunoglobulins: criteria for application in the diagnosis of neurologic disease. 1984 , 81, 575-80	7
2279	Adrenoleukodystrophy mimicking multiple sclerosis. 1985 , 12, 73-4	28
2278	Cerebrospinal fluid in multiple sclerosis: relationships between immunoglobulins, leucocytes and clinical features. 1985 , 232, 250-9	21

2277	Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon. <i>Annals of Neurology</i> , 1985 , 18, 434-8	9.4	23
2276	Immunological complications in multiple sclerosis patients receiving interferon. <i>Annals of Neurology</i> , 1985 , 18, 439-42	9.4	15
2275	Blocking mechanisms of impulse propagation along CNS fibres studied by means of evoked cortical responses. 1985 , 45, 97-100		
2274	Humoral Immunity in Multiple Sclerosis Clinical and Investigative Aspects. 1985 , 5, 107-116		6
2273	Misdiagnosis of Multiple Sclerosis. 1985 , 5, 94-98		18
2272	Clinical Features of Multiple Sclerosis. 1985 , 5, 85-93		13
2271	Treatment of pathologic laughing and weeping with amitriptyline. 1985 , 312, 1480-2		230
2270	Suppressor T cell changes in active multiple sclerosis: analysis with three different monoclonal antibodies. 1985 , 48, 1062-4		7
2269	Hyperbaric oxygen in chronic progressive multiple sclerosis: visual evoked potentials and clinical effects. 1985 , 48, 497-500		18
2268	Multiple sclerosis: incorporation of results of laboratory techniques in the diagnosis. 1985 , 87, 187-92		11
2267	An unusual CT-scan appearance in multiple sclerosis. 1985 , 71, 129-34		5
2266	Short-latency scalp somatosensory evoked potentials and central spine to scalp propagation characteristics during peroneal and median nerve stimulation in multiple sclerosis. 1985 , 60, 197-206		21
2265	Multiple sclerosis: psychiatric and psychometric abnormalities. 1986 , 30, 3-11		28
2264	An evaluation of laboratory investigations in patients with multiple sclerosis. 1986 , 39, 767-74		4
2263	Gm allotypes in multiple sclerosis: influence susceptibility in HLA-DQw1-positive patients from the North-East of Scotland. 1986 , 41, 409-16		17
2262	MULTIPLE SCLEROSIS ASSOCIATED WITH SINUSITIS. 1986 , 327, 1096-1098		1
2261	Measurement of central motor conduction in multiple sclerosis by magnetic brain stimulation. 1986 , 2, 355-8		112
2260	Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. 1986 , 2, 1411-3		80

2259	Addendum. 1986 , 327, 1409	
2258	MULTIPLE SCLEROSIS AND SINUSITIS. 1986 , 327, 1158-1160	
2257	Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. 1986 , 1, 1409-11	117
2256	Clinical evaluation of conduction time measurements in central motor pathways using magnetic stimulation of human brain. 1986 , 1, 1325-6	164
2255	T-lymphocyte subpopulations in peripheral blood of patients with multiple sclerosis, patients with other neurological diseases and healthy controls. 1986 , 88, 181-7	1
2254	Radioactivity in breast milk after Chernobyl. 1986 , 1, 1326	3
2253	Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. 1986 , 1, 1405-9	76
2252	Determination of interferon-gamma in the peripheral blood of multiple sclerosis patients in remission, using a chemiluminescence technique. 1986 , 13, 9-18	10
2251	The diagnosis of multiple sclerosis. Contribution of non-clinical tests. 1986 , 72, 273-85	9
2250	The spontaneous burst activity of peripheral blood monocytes in patients with acute polyradiculoneuritis, lymphocytic meningoencephalitis, and multiple sclerosis. A comparison. 1986 , 72, 287-97	9
2249	Immunoglobulin allotypes and susceptibility to multiple sclerosis. An epidemiological and genetic study in the Hautes-Pyrénées county of France. 1986 , 75, 1-5	18
2248	Paraesthesiae in multiple sclerosis. 1986 , 74, 297-305	25
2247	Blood-cerebrospinal fluid barrier permeability to serum IgG subfractions and measurement of intrathecal IgG synthesis. 1986 , 73, 325-38	1
2246	Dorsal midbrain syndrome in multiple sclerosis with magnetic resonance imaging correlation. 1986 , 13, 62-5	9
2245	Multiple sclerosis: neuroimmunologic puzzle. 1986 , 6, 103-16	2
2244	Monocytes constitute the only peripheral blood cell population showing an increased burst activity in multiple sclerosis patients. 1986 , 81, 230-4	18
2243	A Clinical and Laboratory Study of Benign Multiple Sclerosis. 1986 ,	
2242	"Mineral transporter" therapy for multiple sclerosis complicated by bacterial endocarditis. <i>Annals of Neurology</i> , 1986 , 19, 203	9-4

2241	Tetrabenazine and dystonia in primates. <i>Annals of Neurology</i> , 1986 , 19, 203-4	9.4	4
2240	Free kappa light chains in multiple sclerosis spinal fluid. <i>Annals of Neurology</i> , 1986 , 20, 63-9	9.4	43
2239	Reply. <i>Annals of Neurology</i> , 1986 , 20, 373-374	9.4	3
2238	Absence of antibody to HTLV I and III in sera of Canadian patients with multiple sclerosis and chronic myelopathy. <i>Annals of Neurology</i> , 1986 , 20, 533-4	9.4	28
2237	Evaluation of patients with multiple sclerosis by evoked potentials and magnetic resonance imaging: a comparative study. <i>Annals of Neurology</i> , 1986 , 20, 645-8	9.4	61
2236	Spin-lattice relaxation (T1) times of cerebral white matter in multiple sclerosis. 1986 , 3, 194-202		46
2235	Cell-mediated immunological status in multiple sclerosis patients. 1986 , 73, 408-14		6
2234	Search for HTLV-I and LAV/HTLV-III antibodies in serum and CSF of multiple sclerosis patients. 1986 , 74, 161-4		18
2233	Plasma cells in cerebrospinal fluid and multiple sclerosis: diagnostic yield and clinicobiological correlations. 1986 , 74, 432-8		1
2232	Lymphocytoplastapheresis in multiple sclerosis: one-year results in 6 patients. 1986 , 7, 119-23		2
2231	Neuropsychology of multiple sclerosis: a critical review. 1986 , 8, 503-42		295
2230	Peripheral blood T lymphocyte changes in multiple sclerosis: a marker of disease progression rather than of relapse?. 1986 , 49, 905-12		25
2229	Multiple sclerosis in Kuwait: clinical and epidemiological study. 1986 , 49, 928-31		21
2228	Paroxysmal atrial fibrillation associated with an attack of multiple sclerosis. 1986 , 62, 385-7		18
2227	Disseminated lesions at presentation in patients with optic neuritis. 1986 , 49, 124-7		83
2226	Evaluation of evoked potentials and lymphocyte subsets as possible markers of multiple sclerosis: one year follow up of 30 patients. 1986 , 49, 913-9		22
2225	Absence of immunoreactive interferon-alpha in CSF from patients with multiple sclerosis. 1986 , 49, 102-3		2
2224	Magnetic resonance imaging in clinically isolated lesions of the brain stem. 1986 , 49, 737-43		72

2223	Silent brain lesions in patients with isolated idiopathic optic neuritis. A clinical and nuclear magnetic resonance imaging study. 1986 , 43, 452-5	109
2222	Exposure times for colour discrimination in the parafoveal field: a new procedure to detect subtle visual dysfunction in multiple sclerosis patients. 1986 , 49, 400-4	
2221	Parity as a factor in incontinence in multiple sclerosis. 1987 , 44, 504-8	39
2220	Transdermal effects of a synthetic alpha-melanotropin/corticotropin analog in multiple sclerosis. 1987 , 44, 995	3
2219	Increased beta 2-microglobulin in CSF of multiple sclerosis. 1987 , 50, 1238	4
2218	Disease Characteristics and Psychological Status in Multiple Sclerosis. 1987 , 1, 171-178	3
2217	MRI in optic neuritis. 1987 , 7, 267-272	2
2216	Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. 1987 , 110 (Pt 2), 405-14	147
2215	Low-dose total-body irradiation in the management of refractory rheumatoid arthritis. 1987 , 60, 297-9	1
2214	Multiple sclerosis in north-east Scotland. An association with HLA-DQw1. 1987 , 110 (Pt 1), 181-96	68
2213	Prediction of Functional Impairment from Patient Evaluations of Multiple Sclerosis Symptoms and Symptom Change. 1987 , 1, 79-86	
2212	Aphemia as a first symptom of multiple sclerosis. 1987 , 50, 499-500	10
2211	The clinical use of cerebrospinal fluid studies in demyelinating neurological diseases. 1987 , 63, 735-40	5
2210	Job Retention Among People with Multiple Sclerosis. 1987 , 1, 131-135	1
2209	McArdle's sign in multiple sclerosis. 1987 , 50, 1691-3	2
2208	Bronchiectasis with ulcerative colitis and myelopathy. 1987 , 42, 155-6	24
2207	Chronic relapsing course of encephalomyeloradiculopathy in a 6-year-old boy. 1987 , 18, 235-8	1
2206	The role of delayed computed tomographic scanning using high doses of contrast material in detecting cerebral demyelination in patients with multiple sclerosis in relapse and remission. 1987 , 60, 295-7	

2205	Erstmanifestation der Encephalomyelitis disseminata: Kernspintomographische Verlaufskontrollen*. 1987 , 14, 5-8	2
2204	Immunomodulatory factors in cerebrospinal fluid of patients with multiple sclerosis and controls. 1987 , 77, 341-51	
2203	Detection and isolation of immune complexes in multiple sclerosis cerebrospinal fluid. 1987 , 15, 97-107	12
2202	Viral specificity of multiple sclerosis tear immunoglobulins. 1987 , 14, 197-203	15
2201	Multiple sclerosis on islands. 1987 , 1, 1199	5
2200	A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. 1987 , 317, 408-14	396
2199	The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. 1987 , 110 (Pt 6), 1579-616	432
2198	Increased cerebrospinal fluid concentrations of C- but not N-terminal cholecystokinin fragments in multiple sclerosis. 1987 , 409, 364-6	6
2197	Magnetic resonance imaging and clinical relationships in multiple sclerosis. 1987 , 62, 174-84	23
2196	Multiple sclerosis (not tropical spastic paraparesis) on Key West, Florida. 1987 , 1, 1199	1
2195	Oligoclonal antibodies in CSF of patients with meningopolyneuritis Garin-Bujadoux-Bannwarth: Ig class, light chain type and specificity. 1987 , 263, 307-13	2
2194	Natural seric anti-fatty acid antibodies in multiple sclerosis. 1987 , 80, 235-9	12
2193	Sudden death in cocaine abusers: relation to neuroleptic malignant syndrome. 1987 , 1, 1198-9	26
2192	Magnetic resonance imaging of optic tract involvement in multiple sclerosis. 1987 , 104, 74-9	20
2191	Chronic demyelinating peripheral neuropathy associated with multifocal central nervous system demyelination. 1987 , 110 (Pt 1), 53-76	137
2190	Balance of T1-weighted images before and after application of a paramagnetic substance (Gd-DTPA). 1987 , 10, 117-22	2
2189	Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study. 1987 , 234, 19-22	25
2188	Multiple sclerosis and Hashimoto's thyroiditis. 1987 , 234, 23-4	14

2187	The behaviour of OKT3-, OKT4- and OKT8-positive cells during phases of elevated spontaneous chemiluminescence activity (CL-A) in multiple sclerosis patients. A serial study. 1987 , 234, 25-30		4
2186	Trauma and multiple sclerosis. An hypothesis. 1987 , 234, 155-9		21
2185	Free light chains in the CSF in multiple sclerosis. 1987 , 234, 303-7		40
2184	STIR sequences in NMR imaging of the optic nerve. 1987 , 29, 238-45		68
2183	Magnetic resonance imaging and cognitive functioning in multiple sclerosis. 1987 , 235, 86-9		34
2182	Mapping the magnitude of multiple sclerosis in Europe. 1987 , 234, 193-4		1
2181	Phagocytic activity of CSF monocytes in neurological diseases. 1987 , 234, 257-8		1
2180	Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. <i>Annals of Neurology</i> , 1987 , 21, 123-30	9.4	187
2179	Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. <i>Annals of Neurology</i> , 1987 , 21, 300-6	9.4	83
2178	Total lymphoid irradiation in multiple sclerosis: blood lymphocytes and clinical course. <i>Annals of Neurology</i> , 1987 , 22, 634-8	9.4	31
2177	Magnetic resonance imaging in isolated noncompressive spinal cord syndromes. <i>Annals of Neurology</i> , 1987 , 22, 714-23	9.4	113
2176	Magnetic brain stimulation: central motor conduction studies in multiple sclerosis. <i>Annals of Neurology</i> , 1987 , 22, 744-52	9.4	257
2175	Diagnostic criteria for multiple sclerosis: an addendum. <i>Annals of Neurology</i> , 1987 , 22, 773	9.4	18
2174	Abstracts-part II (Continue in Part III). 1987 , 1987, 97-145		1
2173	Alteration of the visual evoked potential by macular holes: comparison with optic neuritis. 1987 , 225, 123-8		12
2172	Enhancement and dynamic time warping of somatosensory evoked potential components applied to patients with multiple sclerosis. 1987 , 34, 397-405		9
2171	Relevance of platelet factor four (PF4) plasma levels in multiple sclerosis. 1987 , 76, 79-85		15
2170	Linoleic acid levels in white blood cells, platelets, and serum of multiple sclerosis patients. 1987 , 76, 241-5		18

2169	Myelopathy patients studied with magnetic resonance for multiple sclerosis plaques. 1987 , 76, 272-7	18
2168	Bed rest and ACTH in the treatment of exacerbations in multiple sclerosis patients. 1987 , 76, 346-50	5
2167	Serum antibodies to HTLV-I in human demyelinating disease. 1987 , 75, 231-3	15
2166	Course and prognosis of chronic progressive multiple sclerosis. Results of an epidemiological study. 1988 , 78, 10-5	107
2165	Lymphocytes subclasses and function in patients with optic neuritis in childhood with special reference to multiple sclerosis. 1988 , 78, 58-64	7
2164	Increased level of cerebrospinal fluid beta 2-microglobulin is related to neurologic impairment in multiple sclerosis. 1988 , 78, 72-5	14
2163	Absence of antibodies to HTLV-1 in sera from Hungarian MS patients. 1988 , 78, 177-80	1
2162	Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations?. 1988 , 78, 318-23	378
2161	Thyroid function in patients with multiple sclerosis. 1988 , 77, 269	8
2160	Detection of brainstem lesions in multiple sclerosis: comparison of brainstem auditory evoked potentials with nuclear magnetic resonance imaging. 1988 , 77, 283-8	5
2159	Magnetic resonance imaging, evoked responses and cerebrospinal fluid findings in a follow-up study of children with optic neuritis. 1988 , 77, 44-9	26
2158	REFERENCES. 1988 , 77, 85-103	
2157	Alpha-1-antitrypsin (Pi) types in multiple sclerosis and lack of interaction with immunoglobulin (Gm) markers. 1988 , 15, 251-5	8
2156	Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. <i>Annals of Neurology</i> , 1988 , 24, 795-7	9-4 56
2155	Hemiballism in multiple sclerosis. 1988 , 3, 88-94	63
2154	Movement disorders in multiple sclerosis. 1988 , 3, 109-16	39
2153	Multiple sclerosis presenting as adult onset dystonia. 1988 , 3, 329-32	22
2152	Unusual findings in Creutzfeldt-Jakob disease. Case report. 1988 , 9, 279-82	3

2151	Failure to find HTLV I and HIV I serum antibodies in MS patients. 1988 , 9, 301-2	
2150	Monocyte and polymorphonuclear leukocyte toxic oxygen metabolite production in multiple sclerosis. 1988 , 12, 123-31	39
2149	Anti-galactocerebroside antibodies in human cerebrospinal fluids determined by enzyme-linked immunosorbent assay (ELISA). 1988 , 13, 203-7	10
2148	Poster session III: June 22, 1988. 1988 , 235, S81-S94	1
2147	Cerebrospinal fluid protein analysis in diseases of the nervous system. 1988 , 429, 345-58	21
2146	Intravenous natural beta interferon treatment of chronic exacerbating-remitting multiple sclerosis: clinical response and MRI/CSF findings. 1988 , 235, 171-3	16
2145	Chronic intractable pain: an atypical presentation of multiple sclerosis. 1988 , 235, 226-8	13
2144	Incidence of multiple sclerosis: a periodic or stable phenomenon. 1988 , 235, 241-4	20
2143	MRI appearances of the CNS manifestations of Mycoplasma pneumoniae: a report of two cases. 1988 , 235, 441-3	27
2142	Magnetic resonance imaging in the evaluation of treatment in multiple sclerosis. 1988 , 30, 299-302	58
2141	MRI parameters in multiple sclerosis patients. 1988 , 30, 219-23	5
2140	Immunological determination of galactosylceramide level in blood as a serum index of active demyelination. 1988 , 51, 380-4	7
2139	Irregular pupil cycling as a characteristic abnormality in patients with demyelinating optic neuropathy. 1988 , 105, 402-7	14
2138	The sensitivity of multimodal evoked potentials in multiple sclerosis. A comparison with magnetic resonance imaging and cerebrospinal fluid analysis. 1988 , 70, 230-8	16
2137	Hypergammaglobulinemic purpura associated with multiple sclerosis. 1988 , 113, 331-3	4
2136	Magnetic resonance imaging and clinical correlations in multiple sclerosis. 1988 , 86, 1-12	29
2135	Immunocytochemical analysis of immunoglobulin-containing cells in CSF and blood in inflammatory disorders of the central nervous system. 1988 , 86, 61-72	6
2134	Familial multiple sclerosis. 1988 , 83, 259-68	7

2133	Absence of antibodies to HTLV-I and HIV in serum and cerebrospinal fluid of Italian patients with multiple sclerosis. 1988 , 84, 337-9	3
2132	Reaction time in ambulant multiple sclerosis patients. Part I. Influence of prolonged cognitive effort. 1988 , 85, 173-86	41
2131	Blood-brain barrier damage restricts the reliability of quantitative formulae and isoelectric focusing in detecting intrathecally synthesized IgG. 1988 , 84, 87-93	24
2130	Free kappa and lambda light chain levels in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. 1988 , 19, 119-32	64
2129	T-cell subsets in the cerebrospinal fluid and blood of patients with multiple sclerosis. 1988 , 20, 229-32	11
2128	Prognostic relevance of initial clinical and paraclinical parameters for the course of multiple sclerosis. 1988 , 20, 247-50	5
2127	A parametric scale for BAEP latencies in multiple sclerosis. 1988 , 71, 33-9	3
2126	Central motor conduction in multiple sclerosis: evaluation of abnormalities revealed by transcutaneous magnetic stimulation of the brain. 1988 , 51, 487-94	137
2125	Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. 1988 , 111 (Pt 4), 927-39	342
2124	Comparative study of natural autoantibodies in the serum and cerebrospinal fluid of normal individuals and patients with multiple sclerosis and other neurological diseases. 1988 , 139, 99-108	37
2123	Magnetic resonance imaging and early diagnosis of multiple sclerosis. 1988 , 2, 1202-3	10
2122	Myelin basic protein-specific CD4+ cytolytic T-lymphocyte clones isolated from multiple sclerosis patients. 1988 , 22, 97-109	25
2121	The role of NMR imaging in the assessment of multiple sclerosis. 1988 , 90, 3-9	7
2120	Pelvic pain: an undescribed paroxysmal manifestation of multiple sclerosis. 1988 , 32, 73-75	9
2119	No apparent association between HLA and multiple sclerosis in southern Chinese. 1988 , 51, 443-5	14
2118	Using the wechsler memory scale-revised to detect and characterize memory deficits in multiple sclerosis. 1988 , 2, 149-172	54
2117	Multiple sclerosis: correlation of magnetic resonance imaging with cerebrospinal fluid findings. 1988 , 51, 277-80	9
2116	Borrelia burgdorferi antibodies in patients with relapsing/remitting form and chronic progressive form of multiple sclerosis. 1988 , 51, 1215-8	24

2115	Pulmonary function and dysfunction in multiple sclerosis. 1988 , 45, 1245-9	59
2114	The early risk of multiple sclerosis after optic neuritis. 1988 , 51, 1569-71	64
2113	Multiple sclerosis in Malaysia. 1988 , 45, 624-7	32
2112	Sound lateralization, brainstem auditory evoked potentials and magnetic resonance imaging in multiple sclerosis. 1988 , 111 (Pt 6), 1453-74	39
2111	Multiple sclerosis in children: report of clinical and paraclinical features of 19 cases. 1988 , 19, 118-23	59
2110	Veränderungen multilokal abgeleiteter Muskelantworten nach Kortextstimulation bei Patienten mit multipler Sklerose. 1988 , 19, 241-246	
2109	[Multiple sclerosis in the Bern canton (Switzerland). An epidemiologic study]. 1988 , 56, 394-401	7
2108	Multiple memory deficits in patients with multiple sclerosis. Exploring the working memory system. 1988 , 45, 607-10	137
2107	Effects of Intravenous Physostigmine and Lecithin on Memory Loss in Multiple Sclerosis: Report of a Pilot Study. 1988 , 2, 123-129	2
2106	Intermittent pyramidal claudication as presenting and sole symptom in multiple sclerosis. 1988 , 51, 147-8	2
2105	Recovery after optic neuritis in childhood. 1988 , 51, 1253-8	91
2104	Histocompatibility antigens in multiple sclerosis patients participating in a multicentre trial of azathioprine. British & Dutch Multiple Sclerosis Azathioprine Trial Group. 1988 , 51, 412-5	8
2103	The prevalence of multiple sclerosis in south east Wales. 1988 , 51, 1520-4	61
2102	Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis. 1988 , 15, 15-9	74
2101	[Early detection of multiple sclerosis: MR findings in the initial manifestations of multiple sclerosis]. 1988 , 149, 63-8	2
2100	Psychiatric morbidity in patients with clinically isolated lesions of the type seen in multiple sclerosis: a clinical and MRI study. 1988 , 18, 355-64	28
2099	Zentrale motorische Leitungszeit bei Multipler Sklerose: Ein Vergleich mit visuell und somatosensorisch evozierten Potentialen in Abhängigkeit vom Verlaufstyp. 1988 , 19, 247-254	
2098	MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. 1988 , 38, 180-5	548

2097	Multiple sclerosis presenting at 4 years of age: clinical and MRI correlations. 1988 , 27, 32-7	10
2096	Brainstem auditory-evoked potentials studied with paired stimuli in multiple sclerosis patients. 1988 , 28, 131-4	1
2095	Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. 1988 , 15, 266-72	53
2094	Sensory (VEP, BAEP, SEP) and motor-evoked potentials, liquoral and magnetic resonance findings in multiple sclerosis. 1989 , 29, 41-7	30
2093	Multiple sclerosis in Key West, Florida. 1989 , 130, 935-49	31
2092	Lesion detection in MS patients with and without clinical brainstem disorders: magnetic resonance imaging and brainstem auditory evoked potentials compared. 1989 , 29, 317-22	8
2091	[Histochemical study of the skeletal muscle in multiple sclerosis]. 1989 , 47, 337-45	2
2090	Magnetic resonance imaging of spinal cord lesions in multiple sclerosis. 1989 , 52, 459-66	50
2089	Diagnosis of multiple sclerosis. 1989 , 299, 635-7	13
2088	Subtle encephalomyelitis in children: a variant of acute disseminated encephalomyelitis. 1989 , 4, 214-7	15
2087	Access to semantic memory in Parkinson's disease and multiple sclerosis. 1989 , 2, 153-62	17
2086	Single central nervous system lesions can simulate multiple sclerosis. 1989 , 65, 656-9	1
2085	Parkinsonian symptoms in a patient with AIDS and cerebral toxoplasmosis. 1989 , 52, 1445-7	26
2084	Sleep Apnea in Multiple Sclerosis. 1989 , 3, 133-136	4
2083	Molecular genetics of colorectal carcinoma. 1989 , 299, 637-8	8
2082	Cyclosporin A curtails the progression of free light chain synthesis in the CSF of patients with multiple sclerosis. 1989 , 52, 529-31	4
2081	Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis. 1989 , 39, 161-6	431
2080	Quantitative magnetic resonance imaging in multiple sclerosis: the effect of high dose intravenous methylprednisolone. 1989 , 52, 14-7	56

2079	CT ring sign imitating tumour, disclosed as multiple sclerosis by MRI: a case report. 1989 , 52, 903-6	19
2078	Development of HTLV-I associated myelopathy (HAM) in a seroconverted patient for antibody to HTLV-I. 1989 , 52, 1445	8
2077	Lexical processing in Parkinson's disease and multiple sclerosis. 1989 , 2, 145-52	28
2076	Interobserver agreement in the diagnosis of multiple sclerosis. 1989 , 46, 289-92	6
2075	Cerebral disconnection in multiple sclerosis. Relationship to atrophy of the corpus callosum. 1989 , 46, 918-20	83
2074	The incidence and mortality of multiple sclerosis in south east Wales. 1989 , 52, 1085-9	21
2073	Paroxysmal dysarthria and ataxia: associated MRI abnormality. 1989 , 52, 1444-5	20
2072	Severely threatening events and marked life difficulties preceding onset or exacerbation of multiple sclerosis. 1989 , 52, 8-13	130
2071	Information processing speed in patients with multiple sclerosis. 1989 , 11, 471-7	143
2070	Ocular inflammatory changes in established multiple sclerosis. 1989 , 52, 1360-3	46
2069	The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. 1989 , 112 (Pt 1), 133-46	1179
2068	The value of measuring saccadic eye movement in the investigation of non-compressive myelopathy. 1989 , 52, 1157-61	3
2067	Magnetic resonance imaging studies in multiple sclerosis twins. 1989 , 52, 1417-9	16
2066	Role of saccadic analysis in the diagnosis of multiple sclerosis in the era of magnetic resonance imaging. 1989 , 52, 967-9	7
2065	Cerebrospinal fluid immunoglobulins and multiple sclerosis. Correspondence with magnetic resonance imaging and visually evoked potential changes. 1989 , 46, 367-71	15
2064	A possible new genetic marker associated with a severe course of multiple sclerosis, located on chromosome 2: Km. 1989 , 320, 467	8
2063	Improved sensitivity of MRI in multiple sclerosis by use of extensive standardized procedures. 1989 , 7, 241-9	11
2062	REFERENCES. 1989 , 80, 113-121	1

2061	Cytoproteic CSF findings in 33 MS patients: usefulness for diagnosis. 1989 , 79, 170-2	1
2060	Critical fusion frequency in MS during mild induced hyperthermia. 1989 , 79, 510-4	12
2059	Risk factors in multiple sclerosis: a population-based case-control study in Hautes-Pyrénées, France. 1989 , 80, 46-50	66
2058	Electronystagmography in the diagnosis of multiple sclerosis. 1989 , 80, 193-200	12
2057	Diagnostic investigations in MS: which is the most sensitive?. 1989 , 80, 394-9	7
2056	The role of infection and vaccination in the genesis of optic neuritis and multiple sclerosis in children. 1989 , 80, 425-31	48
2055	Myelopathy of unknown etiology. A clinical follow-up and MRI study of 57 cases. 1989 , 80, 455-60	17
2054	Magnetic resonance imaging of the brain in patients with acute monosymptomatic optic neuritis. 1989 , 80, 512-7	39
2053	Nonathymulin treatment of multiple sclerosis: double-blind pilot study. 1989 , 80, 575-8	
2052	HLA-DP antigens and HTLV-1 antibody status among Japanese with multiple sclerosis: evidence for an increased frequency of HLA-DPw4. 1989 , 16, 467-73	15
2051	Multiple sclerosis patients have a high frequency of an HLA-DQ beta epitope defined by a human-human hybridoma antibody. 1989 , 33, 546-9	2
2050	Multiple sclerosis is associated with HLA-DR2 antigen in Spain. 1989 , 34, 309-11	7
2049	Study of human cerebrospinal fluid proteins by size exclusion-high performance liquid chromatography and two-dimensional gel electrophoresis. 1989 , 10, 480-8	16
2048	Human T lymphocyte response to myelin basic protein: selection of T lymphocyte lines from MBP-responsive donors. 1989 , 23, 21-30	29
2047	HLA-DR beta, -DQ alpha, and -DQ beta restriction fragment length polymorphisms in multiple sclerosis. 1989 , 23, 46-54	16
2046	Precise relaxation time measurements of normal-appearing white matter in inflammatory central nervous system disease. 1989 , 11, 331-6	103
2045	Abstracts-part IV (Continue in Part V). 1989 , 1989, 701-750	2
2044	Benign versus chronic progressive multiple sclerosis: magnetic resonance imaging features. <i>Annals of Neurology</i> , 1989 , 25, 74-81	9-4 73

2043	Isolation of herpes simplex virus type 1 during first attack of multiple sclerosis. <i>Annals of Neurology</i> , 1989 , 26, 283-5	9.4	46
2042	Galactosylceramide: a reliable serum index of demyelination in multiple sclerosis. <i>Annals of Neurology</i> , 1989 , 26, 407-9	9.4	15
2041	Low-titer antibodies reactive with HTLV-I gag p19 in patients with chronic myeloneuropathy. <i>Annals of Neurology</i> , 1989 , 26, 515-22	9.4	11
2040	Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. <i>Annals of Neurology</i> , 1989 , 26, 787-9	9.4	76
2039	Correlation between multimodal evoked potentials and magnetic resonance imaging in multiple sclerosis. 1989 , 236, 4-8		37
2038	Clinically definite multiple sclerosis in a Zañian woman of mixed race. 1989 , 236, 187-8		
2037	Degenerative neurological disorders associated with deficiency of glutamate dehydrogenase. 1989 , 236, 111-4		12
2036	Multiple sclerosis, sleep latencies and HLA antigens. 1989 , 236, 309-10		7
2035	Cell count and ratio of helper/inducer to suppressor/cytotoxic T-cells in the cerebrospinal fluid of patients with multiple sclerosis. 1989 , 236, 424-6		10
2034	The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE). 1989 , 31, 203-12		63
2033	Visual function in multiple sclerosis. 1989 , 73, 209-24		23
2032	No evidence of HTLV-1 infection in Japanese multiple sclerosis patients in polymerase chain reaction. 1989 , 80, 1017-20		6
2031	Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. 1989 , 339, 620-2		210
2030	The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. 1989 , 112 (Pt 6), 1419-28		498
2029	The germline repertoire of T-cell receptor beta-chain genes in patients with multiple sclerosis. 1989 , 140, 212-5; discussion 245-8		97
2028	Multiple sclerosis: update in diagnosis and review of prognostic factors. 1989 , 64, 577-86		31
2027	Patients with multiple sclerosis carry DQB1 genes which encode shared polymorphic amino acid sequences. 1989 , 25, 103-10		86
2026	Multiple sclerosis and brain tumor: a diagnostic challenge. 1989 , 7, 241-4		25

2025	Update on the epidemiology of multiple sclerosis. 1989 , 64, 808-17	29
2024	Infantile multiple sclerosis with extensive white matter lesions. 1989 , 5, 317-9	16
2023	Lyme borreliosis and multiple sclerosis. 1989 , 43, 415-9	4
2022	Pathogenesis of progressive multiple sclerosis. 1989 , 1, 1322-3	25
2021	Frontal lobe dysfunction and memory impairment in patients with chronic progressive multiple sclerosis. 1989 , 11, 73-86	82
2020	An allelic cluster of DQ alpha restriction fragments is associated with multiple sclerosis: evidence that a second haplotype may influence disease susceptibility. 1989 , 25, 111-23	28
2019	The contribution of saccadic eye movements analysis, visual and auditory evoked responses to the diagnosis of multiple sclerosis. 1989 , 91, 123-8	4
2018	Multiple sclerosis or blood-brain barrier disease. 1989 , 1, 46	9
2017	F responses and central motor conduction in multiple sclerosis. 1989 , 74, 438-43	10
2016	Contributions of magnetic resonance imaging to the diagnosis of MS in isolated optic neuritis. 1989 , 29, 295-6	4
2015	Cardiovascular autonomic function in multiple sclerosis. 1989 , 26, 77-84	53
2014	In vitro functional blocking of myelin basic protein-specific cytolytic human T lymphocyte clones by immunosuppressive drugs and monoclonal antibodies. 1989 , 22, 1-9	4
2013	Absence of a correlation between T lymphocyte subsets and clinical activity in relapsing-remitting multiple sclerosis. 1989 , 22, 41-5	5
2012	Molecular analysis of IgA in multiple sclerosis. 1989 , 22, 83-92	17
2011	Identification and characterization of anti-conjugated azelaic acid antibodies in multiple sclerosis. 1989 , 22, 129-34	24
2010	Human B cell lines secreting IgM antibody specific for myelin basic protein. 1989 , 23, 249-56	9
2009	Tumor necrosis factor alpha (TNF alpha) and neurological diseases. Failure in detecting TNF alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex, and brain tumours. 1989 , 23, 41-4	71
2008	Human B cell lines secreting IgM antibody specific for myelin basic protein. 1989 , 24, 9-16	1

2007	Chronic progressive multiple sclerosis: changes in phenotype and function of T helper subsets. 1989 , 24, 163-8	1
2006	Brain tumors: detection of B-cell stimulatory factor-2/interleukin-6 in the absence of oligoclonal bands of immunoglobulins. 1989 , 24, 259-64	29
2005	DNA repair, sensitivity to gamma radiation and to heat shock in lymphocytes from acute, untreated multiple sclerosis patients. 1989 , 21, 23-9	4
2004	The germline repertoire of T cell receptor beta-chain genes in patients with chronic progressive multiple sclerosis. 1989 , 21, 59-66	135
2003	Visuospatial problem solving, conceptual reasoning and sorting behaviour in multiple sclerosis out-patients. 1989 , 90, 187-201	16
2002	Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. 1989 , 92, 9-15	81
2001	Immunoglobulin light chain patterns in the cerebrospinal fluid. A study with special reference to the occurrence of free light chains in cerebrospinal fluid with and without oligoclonal immunoglobulin G. 1989 , 94, 241-53	20
2000	Affective judgments by patients with Parkinson's disease or chronic progressive multiple sclerosis. 1989 , 27, 361-364	45
1999	On the nature of memory disturbance in multiple sclerosis. 1989 , 11, 699-712	143
1998	Multiple sclerosis amongst Chinese in Hong Kong. 1989 , 112 (Pt 6), 1445-67	59
1997	Amantadine treatment of fatigue associated with multiple sclerosis. 1989 , 46, 676-80	175
1996	Comparative impact of paraclinical studies in establishing the diagnosis of multiple sclerosis. 1989 , 73, 433-42	10
1995	The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord. <i>Annals of Neurology</i> , 1989 , 26, 635-9	9.4 97
1994	Material immune responses and recurrent miscarriage. 1989 , 1, 45-6	5
1993	Interleukin-2 receptor levels indicating relapse in multiple sclerosis. 1989 , 1, 559-60	40
1992	Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. 1989 , 112 (Pt 4), 1057-90	118
1991	T-lymphocyte subpopulations in acute unilateral optic neuritis. 1989 , 96, 1054-7	1
1990	Detection of sequences homologous to human retroviral DNA in multiple sclerosis by gene amplification. 1989 , 86, 2878-82	84

1989	Oligoclonal Bands and the IgG Index in Multiple Sclerosis: Uses and Limitations. 1989 , 26, 317-323	6
1988	Psychiatric morbidity in multiple sclerosis: a clinical and MRI study. 1989 , 19, 887-95	112
1987	PCR analysis of DNA from multiple sclerosis patients for the presence of HTLV-I. 1989 , 246, 821-824	42
1986	Connective tissue disease mimicking multiple sclerosis. 1989 , 19, 469-72	9
1985	Cognitive impairment in patients with clinically isolated lesions of the type seen in multiple sclerosis. A psychometric and MRI study. 1989 , 112 (Pt 2), 361-74	102
1984	Deficiencies of polyunsaturated fatty acids and replacement by nonessential fatty acids in plasma lipids in multiple sclerosis. 1989 , 86, 4720-4	89
1983	Acute cerebellar ataxia after influenza vaccination with recurrence and marked cerebellar atrophy. 1989 , 158, 95-103	26
1982	Vascular headache: a presenting symptom of multiple sclerosis. 1989 , 16, 63-6	48
1981	Resuscitation decisions in a general hospital. 1990 , 300, 1271-1272	
1980	Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. 1990 , 300, 631-4	199
1979	Helping patients live with multiple sclerosis. What primary care physicians can do. 1990 , 88, 197-200, 203-4, 207	5
1978	Cerebrospinal fluid oligoclonal IgM in multiple sclerosis: analytical problems and clinical limitations. 1990 , 27 (Pt 3), 199-207	11
1977	Psychophysical measures of central auditory dysfunction in multiple sclerosis: neurophysiological and neuroanatomical correlates. 1990 , 11, 403-16	28
1976	Cerebrospinal fluid biochemistry in the diagnosis of multiple sclerosis. 1990 , 27 (Pt 3), 195-8	1
1975	Visual loss in multiple sclerosis and its relation to previous optic neuritis, disease duration and clinical classification. 1990 , 113 (Pt 4), 975-87	17
1974	Measles vaccination does not prevent multiple sclerosis. 1990 , 9, 248-54	9
1973	Depressive illness in multiple sclerosis. Clinical and theoretical aspects of the association. 1990 , 156, 10-6	38
1972	Axonal degeneration of the peripheral nerves and postganglionic anhidrosis in a patient with multiple sclerosis. 1990 , 162, 279-91	9

1971	Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. 1990 , 40, 229-35		177
1970	CD4+, CD8+, and CD4- CD8- T cells in CSF and blood of patients with multiple sclerosis and tension headache. 1990 , 31, 493-501		30
1969	Incidence of MS during two fifteen-year periods in the Gothenburg region of Sweden. 1990 , 82, 161-8		80
1968	Long-term follow-up of MS: disease activity detected clinically and by MRI. 1990 , 82, 191-6		11
1967	Four year double-blind controlled study of levamisole in multiple sclerosis. 1990 , 11, 595-9		2
1966	Deep sylvian meningioma in a child. 1990 , 6, 228-30		23
1965	Hemiballismus revealing multiple sclerosis in an infant. 1990 , 6, 236-8		9
1964	Electroencephalographic vigilance dynamics in multiple sclerosis during an acute episode and after remission. 1990 , 239, 320-4		8
1963	Acute- and insidious-onset myelopathy of undetermined aetiology: contribution of paraclinical tests to the diagnosis of multiple sclerosis. 1990 , 237, 171-6		10
1962	Devic's neuromyelitis optica: long-term follow-up and serial CSF findings in two cases. 1990 , 237, 262-4		23
1961	Headaches and multiple sclerosis: a clinical study and review of the literature. 1990 , 237, 300-2		57
1960	Search for retroviral sequences in peripheral blood mononuclear cells and brain tissue of multiple sclerosis patients. 1990 , 237, 352-5		8
1959	Brain-stem auditory evoked potentials in multiple sclerosis: the relation to VEP, SEP and CSF immunoglobulins. 1990 , 237, 376-8		7
1958	Sympathetic skin responses are decreased and lymphocyte beta-adrenergic receptors are increased in progressive multiple sclerosis. <i>Annals of Neurology</i> , 1990 , 27, 366-72	9-4	73
1957	Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1990 , 27, 421-7	9-4	62
1956	Prevalence of primary Sjögren's syndrome in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1990 , 27, 582-4	9-4	41
1955	Multiple sclerosis and Sjögren's syndrome: a problem in diagnosis or in definition of two disorders of unknown etiology?. <i>Annals of Neurology</i> , 1990 , 27, 585-6	9-4	5
1954	Reply. <i>Annals of Neurology</i> , 1990 , 27, 587-588	9-4	3

1953	Cellular immunoregulatory mechanisms in the central nervous system: characterization of noninflammatory and inflammatory cerebrospinal fluid lymphocytes. <i>Annals of Neurology</i> , 1990 , 27, 647-54	21
1952	Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. <i>Annals of Neurology</i> , 1990 , 28, 687-91	9-4 43
1951	The separation and detection of alkaline oligoclonal IgG bands in cerebrospinal fluid using immobilised pH gradients. 1990 , 11, 813-8	12
1950	Multiple sclerosis and HLA class II susceptibility and resistance genes. 1990 , 26, 66-73	19
1949	"Screening" for disability. 1990 , 113, 557-8	
1948	Oligoclonal bands in cerebrospinal fluid detected by PhastSystem isoelectric focusing. 1990 , 36, 123-125	12
1947	Multiple sclerosis in French Canadians: evidence for HLA class II susceptibility and resistance genes. 1990 , 17, 382-6	7
1946	Pituitary "incidentalomas". 1990 , 113, 558-9	4
1945	Hepatitis C virus in Italian drug addicts. 1990 , 113, 559-60	5
1944	Corticosteroids and bone mass. 1990 , 113, 560	
1943	Payment for Pap smears. 1990 , 113, 560-1	
1942	Patterns of disease activity in multiple sclerosis. 1990 , 300, 1272	1
1941	MRI of thoracic cord in tropical spastic paraparesis. 1990 , 53, 1110-1	7
1940	Some clinical and pathologic observations on chronic myelopathy: a variant of multiple sclerosis. 1990 , 53, 146-9	9
1939	Electrocutaneous reflexes and multimodality evoked potentials in multiple sclerosis. 1990 , 53, 391-7	7
1938	An empirical model for analysing and interpreting ventricular measures. 1990 , 53, 411-5	3
1937	Lewy bodies and subacute sclerosing panencephalitis. 1990 , 53, 710-1	10
1936	Changes in central motor conduction with physiotherapy in multiple sclerosis: a case report. 1990 , 4, 57-62	2

1935	HLA antigens in multiple sclerosis of northern Spanish population. 1990 , 53, 434-5	6
1934	Hemiparetic multiple sclerosis. 1990 , 53, 675-80	11
1933	Neuropsychological assessment in patients with relapsing-remitting multiple sclerosis and mild functional impairment: correlation with magnetic resonance imaging. 1990 , 53, 142-5	46
1932	. 1990 , 53, 710-710	1
1931	Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. 1990 , 113 (Pt 2), 291-302	349
1930	No evidence for human T-cell leukemia virus type I or human T-cell leukemia virus type II infection in patients with multiple sclerosis. 1990 , 47, 1061-3	6
1929	Internuclear ophthalmoplegia in 14 patients: Clinical and topographic correlation using magnetic resonance imaging. 1990 , 10, 319-325	6
1928	Laboratory investigation of cerebrospinal fluid proteins. 1990 , 27 (Pt 5), 425-35	67
1927	Semantic priming in multiple sclerosis. 1990 , 28, 397-400	24
1926	Targeting assessments of magnetic resonance imaging in suspected multiple sclerosis. 1990 , 10, 77-94	15
1925	Multiple sclerosis: relations between MRI and CT findings, cerebrospinal fluid parameters and clinical features. 1990 , 92, 49-56	6
1924	Epidemiology of multiple sclerosis in Arabs in Kuwait: a comparative study between Kuwaitis and Palestinians. 1990 , 100, 137-41	66
1923	Bickerstaff brainstem encephalitis. A grave non-demyelinating disease with benign prognosis. 1990 , 96, 29-40	27
1922	Improved correlation of magnetic resonance imaging (MRI) with clinical status in multiple sclerosis (MS) by use of an extensive standardized imaging-protocol. 1990 , 96, 173-82	28
1921	Detection of myelin basic protein-like material in cerebrospinal fluid of multiple sclerosis patients by immunoblot assay. 1990 , 99, 321-6	
1920	Familial occurrence of multiple sclerosis with thyroid disease and systemic lupus erythematosus. 1990 , 97, 163-71	40
1919	Decreased suppressor-inducer T lymphocytes in multiple sclerosis and other neurological diseases. 1990 , 28, 161-6	15
1918	Discontinuous distribution of IgG oligoclonal bands in cerebrospinal fluid from multiple sclerosis patients. 1990 , 30, 129-34	6

1917	Macrophage-colony stimulating factor (M-CSF) in the cerebrospinal fluid. 1990 , 29, 105-12	38
1916	Isoelectric focusing versus quantitative measurements in the detection of intrathecal local synthesis of IgG. 1990 , 187, 297-308	36
1915	A case of systemic lupus erythematosus--its clinical and MRI resemblance to multiple sclerosis. 1990 , 44, 601-5	2
1914	Characterization of in vivo-activated T cell clones from peripheral blood of multiple sclerosis patients. 1991 , 58, 46-55	6
1913	The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. 1991 , 337, 441-446	256
1912	HLA-DQA1 and HLA-DQB1 genes may jointly determine susceptibility to develop multiple sclerosis. 1991 , 30, 69-75	126
1911	Memory and learning disturbances in multiple sclerosis. MRI lesions and neuropsychological correlation. 1991 , 13, 220-4	17
1910	Anterior corpus callosum atrophy and verbal fluency in multiple sclerosis. 1991 , 27, 441-5	77
1909	Multiple sclerosis in childhood: report of 15 cases. 1991 , 13, 410-6	81
1908	From The Lancet. 1991 , 337, 446	
1907	Antibodies to myelin basic protein and measles virus in multiple sclerosis: precursor frequency analysis of the antibody producing B cells. 1991 , 11, 27-34	9
1906	Metamemory in multiple sclerosis. 1991 , 13, 309-27	69
1905	Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. 1991 , 325, 467-72	691
1904	Memory for temporal order in multiple sclerosis. 1991 , 29, 10-12	17
1903	Emotional stress and coping in multiple sclerosis (MS) exacerbations. 1991 , 35, 37-47	102
1902	CD5+ B cells and CD4-8-T cells in neuroimmunological diseases. 1991 , 32, 123-32	28
1901	Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor-alpha levels. 1991 , 33, 29-36	55
1900	Peripheral blood mononuclear cells from multiple sclerosis patients recognize myelin proteolipid protein and selected peptides. 1991 , 33, 55-62	58

1899	Oligoclonal free kappa and lambda bands in the cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. An immunoaffinity-mediated capillary blot study. 1991 , 33, 63-72	47
1898	CD8+ high CD11b+ low T cells (T suppressor-effectors) in multiple sclerosis cerebrospinal fluid are increased during high dose corticosteroid treatment. 1991 , 31, 221-8	16
1897	The relationship of interleukin-2 and soluble interleukin-2 receptors to intrathecal immunoglobulin synthesis in patients with multiple sclerosis. 1991 , 32, 43-51	27
1896	Oligonucleotide dot-blot analysis of HLA-DQ beta alleles associated with multiple sclerosis. 1991 , 32, 61-5	10
1895	Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. 1991 , 32, 67-74	279
1894	Cerebrospinal fluid levels of myelin basic protein-like material and soluble interleukin-2 receptor in multiple sclerosis. 1991 , 34, 77-80	12
1893	HLA-DPB1 gene polymorphism and multiple sclerosis: a large case-control study in the southwest of France. 1991 , 34, 215-22	8
1892	Antibodies to brain tissue in sera of patients with chronic progressive multiple sclerosis. 1991 , 34, 223-7	15
1891	Elevated levels of a soluble form of the T cell activation antigen CD27 in cerebrospinal fluid of multiple sclerosis patients. 1991 , 35, 211-7	54
1890	Vaccination of patients with encephalomyelitis disseminata. 1991 , 9, 228-30	7
1889	Variability of cortically evoked motor responses in multiple sclerosis. 1991 , 81, 186-94	65
1888	Three-dimensional human pattern visual evoked potentials. II. Multiple sclerosis patients. 1991 , 80, 339-46	6
1887	Saccade metrics in multiple sclerosis: versional velocity disconjugacy as the best clue?. 1991 , 102, 144-9	26
1886	Sensitivity of eye movement registration and visual evoked potentials in evaluation of therapy in patients with multiple sclerosis. 1991 , 102, 25-31	9
1885	Hyperprolactinemia in multiple sclerosis. 1991 , 102, 61-6	72
1884	The role of magnetic stimulation in the diagnosis of multiple sclerosis. 1991 , 106, 25-30	23
1883	The role of magnetic stimulation as a quantifier of motor disability in patients with multiple sclerosis. 1991 , 106, 31-4	30
1882	Long term follow-up of multiple sclerosis by standardized, non-contrast-enhanced magnetic resonance imaging. 1991 , 106, 35-40	15

1881	Multiple sclerosis in Cyprus. 1991 , 103, 29-36	23
1880	Amplifications of multiple regions of the HTLV-I genome from DNA of an Italian spastic paraparesis patient but not from DNA of multiple sclerosis patients. 1991 , 103, 82-9	5
1879	Cardiovascular autonomic function in multiple sclerosis. 1991 , 104, 129-34	63
1878	Nuclear magnetic resonance T2 relaxation times in multiple sclerosis. 1991 , 104, 176-81	22
1877	Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders. 1991 , 104, 215-21	79
1876	Multiple sclerosis and HLA: is the susceptibility gene really HLA-DR or -DQ?. 1991 , 32, 119-24	56
1875	Viral antibody titers, immunogenetic markers, and their interrelations in multiple sclerosis patients and controls. 1991 , 31, 94-9	8
1874	Human T-cell lymphotropic virus type I sequences detected by nested polymerase chain reactions are not associated with multiple sclerosis. 1991 , 66, 665-80	10
1873	Transcranial magnetic stimulation in peripheral facial nerve palsy of central origin. 1991 , 93, 45-9	6
1872	The risk of multiple sclerosis developing in patients with isolated idiopathic optic neuritis in Brazil. 1991 , 49, 377-83	3
1871	Aggression and multiple sclerosis. 1991 , 159, 736	1
1870	[Multiple sclerosis: objective criteria of diagnosis]. 1991 , 49, 33-42	0
1869	The efficacy of azathioprine in relapsing-remitting multiple sclerosis. 1991 , 41, 20-5	73
1868	Evidence for early lower urinary tract dysfunction in clinically silent multiple sclerosis. 1991 , 145, 1219-24	79
1867	Multiple sclerosis in black children. 1991 , 6, 53-7	16
1866	Multiple sclerosis: changing times. 1991 , 10, 1-8	31
1865	Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. 1991 , 10, 62-5	73
1864	Psychiatric aspects of multiple sclerosis. 1991 , 83, 292-6	23

- 1863 Die magnetresonanztomographische Diagnostik bei MS ist sinnvoll. **1991**, 18, 105-108
- 1862 Veränderungen der Reizantworten motorischer Einheiten auf transkranielle Magnetstimulation bei Patienten mit multipler Sklerose und zerebralem Insult. **1991**, 22, 28-36
- 1861 The visual defect in multiple sclerosis and optic neuritis. A combined psychophysical and electrophysiological investigation. **1991**, 114 (Pt 6), 2419-35 32
- 1860 Correlation of SEP abnormalities with brain and cervical cord MRI in multiple sclerosis. **1991**, 114 (Pt 1B), 663-81 36
- 1859 Anorectal sensory and motor function in neurogenic fecal incontinence. Comparison between multiple sclerosis and diabetes mellitus. **1991**, 100, 465-70 107
- 1858 In vivo determination of multiexponential T2 relaxation in the brain of patients with multiple sclerosis. **1991**, 9, 107-13 78
- 1857 Analysis of cerebrospinal fluid proteins by electrophoresis. **1991**, 569, 281-96 5
- 1856 Differential responses of CD4+CD45RA+ and CD4+CD29+ subsets to activated CD8+ cells: enhanced stimulation of the CD4+CD45RA+ subset by cells from patients with multiple sclerosis. **1991**, 133, 306-16 9
- 1855 Anorectal dysfunction in patients with urologic disturbance due to multiple sclerosis. **1991**, 34, 136-9 27
- 1854 Origin of the secondary increase in firing probability of human motor neurons following transcranial magnetic stimulation. Studies in healthy subjects, type I hereditary motor and sensory neuropathy and multiple sclerosis. **1991**, 114 (Pt 6), 2451-63 35
- 1853 HLA-DRB1, -DQA1, -DQB1, -DPA1 and -DPB1 genes in Japanese multiple sclerosis patients. **1991**, 37, 171-3 19
- 1852 Impact of magnetic resonance imaging (MRI) on the epidemiology of MS. **1991**, 83, 172-5 7
- 1851 MRI, VEP, SEP and biothesiometry suggest monosymptomatic acute optic neuritis to be a first manifestation of multiple sclerosis. **1991**, 83, 343-50 56
- 1850 Sjögren's syndrome in patients with multiple sclerosis. **1991**, 84, 68-9 5
- 1849 Sclerosis multiplex in gypsies. **1991**, 84, 181-5 26
- 1848 Acute and chronic pain syndromes in multiple sclerosis. **1991**, 84, 197-200 136
- 1847 Serum soluble interleukin-2 receptor levels in chronic progressive, stable and steroid-treated multiple sclerosis. **1991**, 84, 282-5 24
- 1846 TGF-beta-like activity produced during regression of exacerbations in multiple sclerosis. **1991**, 84, 452-5 35

1845	Plasmapheresis in chronic progressive multiple sclerosis: pro. 1991 , 6, 207-10		1
1844	Analysis of circulating immune complexes isolated from plasma, cerebrospinal fluid and urine. 1991 , 12, 478-86		9
1843	Magnetic resonance imaging and laboratory aids in the diagnosis of multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 3-5	9.4	42
1842	Correlation of phasic muscle strength and corticomotoneuron conduction time in multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 6-12	9.4	59
1841	Major differences in the dynamics of primary and secondary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 53-62	9.4	436
1840	The predictive value of intrathecal immunoglobulin synthesis and magnetic resonance imaging in acute isolated syndromes for subsequent development of multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 147-51	9.4	78
1839	Analysis of retroviral sequences in the spinal form of multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 333-6	9.4	8
1838	Sjögren's syndrome and multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 29, 455-6	9.4	1
1837	Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. <i>Annals of Neurology</i> , 1991 , 29, 548-55	9.4	273
1836	Increased lymphocyte beta-adrenergic receptor density in progressive multiple sclerosis is specific for the CD8+, CD28- suppressor cell. <i>Annals of Neurology</i> , 1991 , 30, 42-7	9.4	63
1835	Serum interleukin-2 concentrations in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy: comparison with other neurological diseases of presumed immunopathogenesis. <i>Annals of Neurology</i> , 1991 , 30, 48-53	9.4	123
1834	Uhthoff's symptom in optic neuritis: relationship to magnetic resonance imaging and development of multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 30, 180-4	9.4	37
1833	Discordance of T-cell receptor beta-chain genes in familial multiple sclerosis. <i>Annals of Neurology</i> , 1991 , 30, 402-10	9.4	51
1832	Thalamic demyelination and paroxysmal dystonia in multiple sclerosis. 1991 , 6, 379-81		38
1831	Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. 1991 , 17, 357-67		1184
1830	Human brain proton localized NMR spectroscopy in multiple sclerosis. 1991 , 18, 199-206		57
1829	CT scan changes in multiple sclerosis among Malaysian patients. 1991 , 33, 494-8		1
1828	Korsakoff's syndrome as the initial presentation of multiple sclerosis. 1991 , 238, 351-4		14

1827	Neuropsychological assessment in multiple sclerosis: a follow-up study with magnetic resonance imaging. 1991 , 238, 395-400	49
1826	Sympathetic skin response in patients with multiple sclerosis compared with patients with spinal cord transection and normal controls. 1991 , 114 (Pt 3), 1381-94	111
1825	Macrocytosis in multiple sclerosis. A study in 82 de novo Arab patients. 1991 , 54, 415-6	15
1824	No evidence of HTLV-I infection in French patients with multiple sclerosis using the polymerase chain reaction. 1991 , 44, 871-2	3
1823	Cognitive abnormalities in multiple sclerosis: a psychometric and MRI study. 1991 , 21, 59-68	113
1822	Multiple sclerosis, tropical spastic paraparesis and HTLV-1 infection in Afro-Caribbean patients in the United Kingdom. 1991 , 54, 689-94	27
1821	Radiological evidence of sinus infection in patients with multiple sclerosis. 1991 , 54, 925-6	2
1820	Biochemical changes within a multiple sclerosis plaque in vivo. 1991 , 54, 1004-6	19
1819	Childhood multiple sclerosis (MS): multimodal evoked potentials (EP) and magnetic resonance imaging (MRI) comparative study. 1991 , 22, 15-23	11
1818	The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority. 1991 , 54, 55-9	35
1817	Reactive lymphohistiocytosis with recurrence in the optic chiasm. 1991 , 11, 25-30	7
1816	The prevalence of cognitive impairment in a community survey of multiple sclerosis. 1991 , 30, 333-48	90
1815	Colocalization of lymphocytes bearing gamma delta T-cell receptor and heat shock protein hsp65+ oligodendrocytes in multiple sclerosis. 1991 , 88, 6452-6	267
1814	Paroxysmal kinesigenic choreoathetosis as presenting symptom of multiple sclerosis. 1991 , 54, 657-8	23
1813	The pineal gland in multiple sclerosis. 1991 , 61, 61-7	20
1812	Lower extremity motor evoked potentials in multiple sclerosis. 1991 , 48, 944-8	37
1811	Empirical support for psychological profiles observed in multiple sclerosis. 1991 , 48, 1150-4	19
1810	SPECT, MRI and cognitive functions in multiple sclerosis. 1991 , 54, 110-5	72

1809	Internal capsule plaque and tonic spasms in multiple sclerosis. 1991 , 48, 427-9	38
1808	Prolactin secretion in multiple sclerosis. 1991 , 61, 145-8	2
1807	The longstanding MS lesion. A quantitative MRI and electron microscopic study. 1991 , 114 (Pt 3), 1271-80	229
1806	The relationship between disability and memory dysfunction in multiple sclerosis. 1992 , 62, 17-34	42
1805	Responses of single spinal motoneurons to magnetic brain stimulation in healthy subjects and patients with multiple sclerosis. 1991 , 114 (Pt 1B), 643-62	103
1804	The pineal gland and the clinical course of multiple sclerosis. 1992 , 62, 65-74	8
1803	Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. 1992 , 161, 680-5	113
1802	Elevated neopterin levels in Guillain-Barré syndrome. Further evidence of immune activation. 1992 , 49, 1277-80	20
1801	. 1992 , 55, 524-524	
1800	Gadolinium-pentetic acid magnetic resonance imaging in patients with relapsing remitting multiple sclerosis. 1992 , 49, 687-9	30
1799	Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study. 1992 , 55, 869-76	131
1798	Multiple sclerosis in the Cambridge health district of east Anglia. 1992 , 55, 877-82	30
1797	A prospective study of physical trauma and multiple sclerosis.. 1992 , 55, 524-525	
1796	Defining prognosis in medical coma. 1992 , 55, 523-4	1
1795	Multiple lesions in cerebral white matter in two young adults with thoracic extramedullary tumours. 1992 , 55, 216-8	4
1794	Sleep disturbance, depression, and lesion site in patients with multiple sclerosis. 1992 , 49, 641-3	102
1793	The ocular manifestations of multiple sclerosis. 2. Abnormalities of eye movements. 1992 , 55, 863-8	38
1792	A predominantly cervical form of spinal muscular atrophy.. 1992 , 55, 524-524	

1791	High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. 1992 , 55, 450-3	138
1790	EDMUS, a European database for multiple sclerosis. 1992 , 55, 671-6	170
1789	Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis. 1992 , 67, 173-86	52
1788	Ventricular Size, Cognitive Function and Depression in Patients with Multiple Sclerosis. 1992 , 19, 352-356	20
1787	Lidocaine unmasks silent demyelinating lesions in multiple sclerosis. 1992 , 42, 2088-93	40
1786	Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature. 1992 , 31, 571-4	59
1785	Intrathecal immunoglobulin synthesis in multiple sclerosis: effect of corticosteroids and azathioprine. 1992 , 32, 349-53	2
1784	Demyelinating disease after neurologically complicated primary Epstein-Barr virus infection. 1992 , 42, 278-82	81
1783	Absence of lymphocytic alveolitis in patients with multiple sclerosis. 1992 , 102, 1303	2
1782	Assessment of different methods to detect increased autochthonous production of immunoglobulin G and oligoclonal immunoglobulins in multiple sclerosis. 1992 , 97, 858-60	5
1781	Respiratory function in multiple sclerosis. Utility of clinical assessment of respiratory muscle function. 1992 , 101, 479-84	76
1780	AIDS and multiple sclerosis: neural and mental features. 1992 , 85, 331-6	16
1779	Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. 1992 , 115 (Pt 4), 979-89	327
1778	A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. 1992 , 326, 581-8	921
1777	Severe periphlebitis, peripheral retinal ischemia, and preretinal neovascularization in patients with multiple sclerosis. 1992 , 113, 28-32	37
1776	Evaluating an abnormal urinary steroid profile. 1992 , 339, 941-2	38
1775	CORRECTION. 1992 , 339, 942	
1774	Evaluation of the visual system in multiple sclerosis: a comparative study of diagnostic tests. 1992 , 94, 191-5	22

1773	Genetic susceptibility to multiple sclerosis linked to myelin basic protein gene. 1992 , 340, 987-91	138
1772	HLAs and genes in Japanese patients with multiple sclerosis: evidence for increased frequencies of HLA-Cw3, HLA-DR2, and HLA-DQB1*0602. 1992 , 35, 116-24	23
1771	Psychiatric symptoms and mental changes as major features of multiple sclerosis. 1992 , 94 Suppl, S144-6	2
1770	Prevalence of HLA B7 in MS with symptomatic uveitis. 1992 , 339, 942	4
1769	Improvement in motor evoked potentials and clinical course post-steroid therapy in multiple sclerosis. 1992 , 108, 184-8	25
1768	Corticospinal conduction studied with magnetic double stimulation in the intact human. 1992 , 111, 180-8	88
1767	Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. 1992 , 112, 51-7	34
1766	Physiological study of the spinothalamic tract conduction in multiple sclerosis. 1992 , 107, 205-9	38
1765	P300 in multiple sclerosis: a preliminary report. 1992 , 12, 155-63	44
1764	Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. 1992 , 37, 169-76	20
1763	Intrathecal synthesis of soluble class I antigens in multiple sclerosis. 1992 , 36, 77-9	17
1762	Increased muscarinic cholinergic receptor density on CD4+ lymphocytes in progressive multiple sclerosis. 1992 , 36, 171-7	12
1761	In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. 1992 , 38, 27-33	196
1760	Frequency of T cells specific for myelin basic protein and myelin proteolipid protein in blood and cerebrospinal fluid in multiple sclerosis. 1992 , 38, 105-13	150
1759	Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. 1992 , 41, 29-34	264
1758	Experimental Therapies for Multiple Sclerosis: Historical Perspective. 1992 , 1-15	1
1757	Endogenous event-related potentials as indices of dementia in multiple sclerosis patients. 1992 , 82, 320-9	42
1756	Cortical somatosensory magnetic responses in multiple sclerosis. 1992 , 83, 192-200	24

- 1755 Pupillary light reflex latency in patients with multiple sclerosis. **1992**, 82, 213-9 21
- 1754 Macular dysfunction in multiple sclerosis revealed by steady-state flicker and pattern ERGs. **1992**, 82, 53-9 20
- 1753 [Immunosuppressive treatment in multiple sclerosis]. **1992**, 50, 295-301 1
- 1752 Is multiple sclerosis in Brazil and Asia alike?. **1992**, 50, 419-25 22
- 1751 Retinal nerve fibre layer atrophy in multiple sclerosis A reappraisal. **1992**, 12, 11-15
- 1750 Periodic Limb Movement Disorder is Associated with Normal Motor Conduction Latencies When Studied by Central Magnetic Stimulation—Successful Use of a New Technique. **1992**, 79, 325-36 4
- 1749 Pattern electroretinogram as a function of spatial frequency after retrobulbar optic neuritis. **1992**, 79, 325-36 4
- 1748 Differential diagnosis of HTLV-I-associated myelopathy and multiple sclerosis in Iranian patients. **1992**, 70, 1013-8 3
- 1747 Intrathecal versus systemic corticosteroids in the treatment of multiple sclerosis: results of a pilot study. **1992**, 239, 31-5 20
- 1746 Memory and naive CD4+ lymphocytes in multiple sclerosis. **1992**, 239, 437-40 28
- 1745 Hyperserotoninemia and antiserotonin antibodies in autism and other disorders. **1992**, 22, 33-45 41
- 1744 Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience. **1992**, 129, 31-55 20
- 1743 Cells of cerebrospinal fluid of multiple sclerosis patients secrete antibodies to myelin basic protein in vitro. **1992**, 35, 695-701 9
- 1742 In vivo magnetic resonance diffusion measurement in the brain of patients with multiple sclerosis. **1992**, 10, 7-12 150
- 1741 Abstracts-part II (Continue in Part III). **1992**, 1992, 274-432
- 1740 Automatic-voluntary dissociation: an unusual facial paresis in a patient with probable multiple sclerosis. **1992**, 242, 93-5 6
- 1739 Treatment of multiple sclerosis with mitoxantrone. **1992**, 242, 96-102 46
- 1738 Total lymphoid irradiation in chronic progressive multiple sclerosis. **1992**, 13, 131-4

1737	Interleukin-2 receptor expression on blood monocytes of patients with multiple sclerosis. 1992 , 13, 657-60	1
1736	An analysis of peripheral type benzodiazepine receptors on blood mononuclear cells during high dose steroid treatment of multiple sclerosis. 1992 , 13, 685-91	4
1735	Novel HLA-DR2-related haplotypes in Hong Kong Chinese implicate the DQB1*0602 allele in susceptibility to multiple sclerosis. 1992 , 19, 11-9	44
1734	Gd-DTPA-enhanced lesions in the brain of patients with acute optic neuritis. 1992 , 85, 141-6	15
1733	Neuropsychological assessment in MS: clinical, neurophysiological and neuroradiological relationships. 1992 , 86, 124-8	73
1732	Intravenous gamma globulin in progressive MS. 1992 , 86, 171-5	39
1731	Early onset MS under the age of 16: clinical and paraclinical features. 1992 , 86, 280-4	123
1730	CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. 1992 , 86, 291-7	44
1729	Correlation of magnetic resonance imaging and CSF findings in patients with acute monosymptomatic optic neuritis. 1992 , 86, 317-22	40
1728	Immunological and gadolinium-DTPA MRI evaluation of relapsing remitting multiple sclerosis. 1992 , 86, 342-5	11
1727	Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities. 1992 , 86, 354-8	42
1726	Abduction nystagmus in internuclear ophthalmoplegia. 1992 , 86, 365-70	3
1725	CSF and serum ganglioside antibody patterns in MS. 1992 , 86, 485-9	30
1724	HLA profiles of multiple sclerosis in Hokkaido, the northernmost island of Japan. 1992 , 86, 517-20	14
1723	Multimodal sensory and motor evoked potentials in a two-year follow-up study of MS patients with relapsing course. 1992 , 86, 15-8	20
1722	Optic neuritis in children with poor recovery of vision. 1992 , 20, 319-23	18
1721	Peripheral sensory abnormalities in patients with multiple sclerosis. 1992 , 15, 73-6	26
1720	Neuromuscular responses of patients with multiple sclerosis. 1992 , 15, 1123-32	138

1719	Lower motor neuron dysfunction in patients with multiple sclerosis. 1992 , 15, 1265-70		25
1718	Parkinsonism in multiple sclerosis. 1992 , 7, 380-2		25
1717	The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. 1992 , 48, 779-86		65
1716	beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. <i>Annals of Neurology</i> , 1992 , 31, 657-62	9.4	63
1715	Quantitation of T-cell receptor V beta chain expression on lymphocytes from blood, brain, and spinal fluid in patients with multiple sclerosis and other neurological diseases. <i>Annals of Neurology</i> , 1992 , 32, 24-30	9.4	28
1714	The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. <i>Annals of Neurology</i> , 1992 , 32, 123-30	9.4	120
1713	Multiple sclerosis in children: cerebral metabolic alterations monitored by localized proton magnetic resonance spectroscopy in vivo. <i>Annals of Neurology</i> , 1992 , 32, 140-50	9.4	103
1712	No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1992 , 32, 711-4	9.4	11
1711	Multiple sclerosis in 54 twinships: concordance rate is independent of zygoty. French Research Group on Multiple Sclerosis. <i>Annals of Neurology</i> , 1992 , 32, 724-7	9.4	86
1710	Criteria for diagnosing Parkinson's disease. <i>Annals of Neurology</i> , 1992 , 32 Suppl, S125-7	9.4	468
1709	Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. <i>Annals of Neurology</i> , 1993 , 33, 480-9	9.4	241
1708	Increased levels of circulating intercellular adhesion molecule-1 in multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. <i>Annals of Neurology</i> , 1993 , 33, 646-9	9.4	53
1707	Spinal fluid lymphocytes from a subgroup of multiple sclerosis patients respond to mycobacterial antigens. <i>Annals of Neurology</i> , 1993 , 34, 18-24	9.4	43
1706	The spectrum of immune responses to <i>Campylobacter jejuni</i> and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. <i>Annals of Neurology</i> , 1993 , 34, 136-44	9.4	134
1705	Adhesion molecule expression on cerebrospinal fluid T lymphocytes: evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls. <i>Annals of Neurology</i> , 1993 , 34, 155-61	9.4	104
1704	Significance of reactive Lyme serology in multiple sclerosis. <i>Annals of Neurology</i> , 1993 , 34, 745-7	9.4	30
1703	Spasmodic torticollis in multiple sclerosis: significance of an upper cervical spinal cord lesion. 1993 , 8, 234-6		7
1702	Abstracts-part VI (Continue in Part VII). 1993 , 1993, 301-350		1

1701	Quantitative cerebral magnetic resonance imaging during ACTH treatment of multiple sclerosis. 1993 , 11, 1147-53	3
1700	Chronic encephalitis and Eales disease. 1993 , 240, 299-301	8
1699	Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. 1993 , 240, 305-8	21
1698	Magnetic resonance imaging in patients with multiple sclerosis and spinal cord involvement: 28 cases. 1993 , 240, 41-5	23
1697	In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. 1993 , 240, 46-50	21
1696	Physiological assessment of aspects of autonomic function in patients with secondary progressive multiple sclerosis. 1993 , 240, 139-43	64
1695	Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study. 1993 , 240, 417-22	211
1694	Working memory impairment among persons with chronic progressive multiple sclerosis. 1994 , 241, 125-31	44
1693	Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis. 1994 , 241, 132-7	39
1692	Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing-remitting or chronic-progressive multiple sclerosis. 1993 , 241, 108-14	41
1691	Magnetic resonance imaging in tonic spasms of multiple sclerosis. 1993 , 241, 115-7	31
1690	Database for serial magnetic resonance imaging in multiple sclerosis. 1993 , 35, 362-6	5
1689	The callosal-septal interface lesion in multiple sclerosis: effect of sequence and imaging plane. 1993 , 35, 573-7	2
1688	Circulating CD3+ CD4+ CD8+ T lymphocytes in multiple sclerosis. 1993 , 13, 113-8	30
1687	Paroxysmal pruritus and multiple sclerosis. 1993 , 129, 597-8	25
1686	T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. 1993 , 37, 355-68	37
1685	HLA-DPB1 alleles correlate with risk for multiple sclerosis in Caucasoid and Cantonese patients lacking the high-risk DQB1*0602 allele. 1993 , 41, 31-6	20
1684	Intractable hiccups and sleep apnea syndrome in multiple sclerosis: report of two cases. 1993 , 88, 401-5	13

1683	Cytokine production by peripheral blood monocytes/macrophages in multiple sclerosis patients. 1993 , 87, 281-5	52
1682	Design, methods, and conduct of the Optic Neuritis Treatment Trial. 1993 , 14, 123-42	68
1681	Chronic granulomatous anterior uveitis associated with multiple sclerosis. 1993 , 231, 166-8	16
1680	An evaluation of the significance of areas of intense signal in the MR brain images of patients with multiple sclerosis. 1993 , 11, 311-7	5
1679	Red blood cell adenosine deaminase activity in multiple sclerosis. 1993 , 214, 97-101	3
1678	The measurement of fatigue: a new instrument. 1993 , 37, 753-62	382
1677	Sleep disturbance in chronic fatigue syndrome. 1993 , 37, 325-31	107
1676	Suppression of visual perception by transcranial magnetic stimulation--experimental findings in healthy subjects and patients with optic neuritis. 1993 , 86, 259-67	48
1675	Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. 1993 , 116 (Pt 5), 1077-94	224
1674	Auditory evoked potentials in multiple sclerosis: alpha responses are reduced in amplitude, but theta responses are not altered. 1993 , 73, 259-76	5
1673	Vitamin B12 and its relationship to age of onset of multiple sclerosis. 1993 , 71, 93-9	17
1672	Nocturnal melatonin secretion in multiple sclerosis patients with affective disorders. 1993 , 68, 227-40	31
1671	A longitudinal study of visual function in multiple sclerosis: With a note on the Cambridge Grating Test. 1993 , 13, 135-142	9
1670	Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. 1993 , 13, 333-40	91
1669	The influence of HLA-DR and -DQ alleles on progression to multiple sclerosis following a clinically isolated syndrome. 1993 , 37, 185-91	36
1668	Magnetic resonance imaging of spinal cord in multiple sclerosis by fluid-attenuated inversion recovery. 1993 , 341, 593-4	59
1667	Longstanding isolated cerebral systemic lupus erythematosus in an 8-year-old black girl. Resemblance with multiple sclerosis. 1993 , 95, 241-4	6
1666	Serum immune complexes in multiple sclerosis do not contain MBP epitopes. 1993 , 30, 365-8	3

1665	Long-latency reflexes, somatosensory evoked potentials and transcranial magnetic stimulation: relation of the three methods in multiple sclerosis. 1993 , 89, 235-41	26
1664	Absence of oligoclonally restricted immunoglobulins in tears from multiple sclerosis patients. 1993 , 44, 149-55	15
1663	Increased high affinity beta-adrenergic receptor densities and cyclic AMP responses of CD8 cells in multiple sclerosis. 1993 , 43, 1-7	45
1662	Susceptibility for multiple sclerosis is determined, in part, by inheritance of a 175-kb region of the TcR V beta chain locus and HLA class II genes. 1993 , 45, 53-60	150
1661	Interferon gamma- and interleukin-4-secreting cells in multiple sclerosis. 1993 , 46, 123-8	77
1660	Epitope specificity and V gene expression of cerebrospinal fluid T cells specific for intact versus cryptic epitopes of myelin basic protein. 1993 , 44, 57-67	11
1659	The germline repertoire of T cell receptor beta-chain genes in multiple sclerosis patients from Spain. 1993 , 47, 9-13	25
1658	Cardiovascular autonomic dysfunction in multiple sclerosis is likely related to brainstem lesions. 1993 , 120, 82-6	76
1657	Frontal lobe dysfunction in multiple sclerosis as assessed by means of Lurian tasks: effect of age at onset. 1993 , 115 Suppl, S42-50	15
1656	MRI and cognitive patterns in relapsing-remitting multiple sclerosis. 1993 , 115 Suppl, S59-65	10
1655	The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. 1993 , 115, 132-5	33
1654	Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. 1993 , 115, 230-3	32
1653	Decreased IL-3 production by peripheral blood mononuclear cells in patients with multiple sclerosis. 1993 , 118, 79-82	14
1652	Sympathetic skin response in multiple sclerosis. 1993 , 118, 88-91	39
1651	A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. 1993 , 120, 213-7	96
1650	4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. 1993 , 116, 220-6	46
1649	Psychopathological symptoms and magnetic resonance imaging findings in multiple sclerosis. 1993 , 33, 676-8	12
1648	Multiple sclerosis susceptibility: population and twin study of polymorphisms in the T-cell receptor beta and gamma genes region. French Group on Multiple Sclerosis. 1993 , 15, 67-73	8

- 1647 Evolutive patterns of the visual field in optic neuritis. **1993**, 13, 269-273
- 1646 Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. **1993**, 90, 923-7 126
- 1645 Visual evoked potentials in multiple sclerosis: frequency response shows reduced alpha amplitude. **1993**, 73, 235-58 3
- 1644 Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. **1993**, 116 (Pt 1), 117-34 477
- 1643 Multiple sclerosis: the role of the pineal gland in its timing of onset and risk of psychiatric illness. **1993**, 72, 95-106 23
- 1642 Multiple sclerosis: relationship between seasonal variations of relapse and age of onset. **1993**, 71, 147-57 13
- 1641 MS COSTAR: A Computerized Record for Use in Clinical Research in Multiple Sclerosis. **1993**, 7, 145-152
- 1640 Models of cognitive deficit and statistical hypotheses: multiple sclerosis, an example. **1993**, 15, 563-77 16
- 1639 Adhesion of cerebral endothelial cells to lymphocytes from patients with multiple sclerosis. **1993**, 14, 329-33 19
- 1638 A serial study of psychometric and magnetic resonance imaging changes in multiple sclerosis. **1993**, 116 (Pt 3), 569-602 67
- 1637 HLA class II susceptibility and resistance genes in patients with multiple sclerosis from northern Spain, by DNA-RFLP genotyping. **1993**, 56, 722-3 7
- 1636 Progressive spinal multiple sclerosis. **1993**, 13, 322-32 0
- 1635 Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. **1993**, 43, 655-61 2093
- 1634 [Immunosuppressive therapy of multiple sclerosis with mitoxantrone]. **1993**, 61, 410-7 5
- 1633 Nocturnal melatonin secretion in suicidal patients with multiple sclerosis. **1993**, 71, 173-82 17
- 1632 Reflex horizontal saccades in multiple sclerosis. **1993**, 13, 289-296 1
- 1631 The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. **1993**, 329, 1764-9 465
- 1630 Seizures due to multiple sclerosis: seven patients with MRI correlations. **1993**, 56, 1317-20 56

1629	Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. 1993 , 56, 169-74	38
1628	Brain magnetic resonance imaging in acute optic neuritis. Experience of the Optic Neuritis Study Group. 1993 , 50, 841-6	102
1627	The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. 1993 , 116 (Pt 1), 135-46	304
1626	Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. 1993 , 56, 1062-5	83
1625	Patterns of blood-brain barrier impairment and clinical features in multiple sclerosis. 1993 , 56, 356-60	23
1624	Beta-arrestin and arrestin are recognized by autoantibodies in sera from multiple sclerosis patients. 1993 , 90, 3241-5	47
1623	In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. 1993 , 43, 2080-7	89
1622	Detection of <i>Borrelia burgdorferi</i> antigens in cerebrospinal fluid. 1993 , 43, 1093-8	36
1621	Epidemiologic evidence for multiple sclerosis as an infection. 1993 , 6, 382-427	388
1620	Stability and determinants of psychosocial well-being in multiple sclerosis.. 1993 , 38, 11-26	67
1619	Memory dysfunction in multiple sclerosis: Its relation to working memory, semantic encoding, and implicit learning.. 1993 , 7, 364-374	117
1618	Involvement of cytokines in N-methyl-N'-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. 1993 , 33, 358-62	18
1617	Multiple Sclerosis Associated with Cerebral Mass Lesions on Computed Tomography. 1993 , 3, 256-259	
1616	Le malattie demielinizzanti: Inquadramento clinico. 1993 , 6, 21-24	
1615	Indagini neurofisiologiche nelle malattie demielinizzanti. 1993 , 6, 25-30	
1614	Neuroradiologia della sclerosi multipla: Tecnica di studio, semeiotica e diagnosi differenziata. 1993 , 6, 35-44	1
1613	Isoelectric focusing in an immobilized pH gradient for the detection of intrathecal IgG in cerebrospinal fluid: sensitivity and specificity for the diagnosis of multiple sclerosis. 1993 , 30 (Pt 5), 463-8	8
1612	Perils and pitfalls of magnetic resonance imaging in the diagnosis of multiple sclerosis. The Rochester-Toronto MRI Study Group. 1993 , 3, 81-8	8

1611	Cognitive Disturbances and Magnetic Resonance Imaging Findings in Multiple Sclerosis. 1993 , 3, 169-172	1
1610	HTLV-I Associated Myelopathy: An Endemic Disease of Canadian Aboriginals of the Northwest Pacific Coast. 1993 , 20, 302-306	14
1609	Chronisch-entzündliche Erkrankungen des zentralen Nervensystems. 1993 , 20, 96-101	
1608	Untersuchung kortikobulbärer Bahnen und peripherer Hirnnerven bei Normalpersonen und Patienten mit multipler Sklerose: Ergebnisse nach nichtinvasiver elektromagnetischer Reizung. 1993 , 24, 269-273	
1607	Brain stem magnetic resonance imaging and evoked potential studies of symptomatic multiple sclerosis patients. 1993 , 33, 232-7	25
1606	Soluble class I antigen secretion by peripheral blood lymphocytes in multiple sclerosis. 1993 , 33, 229-31	3
1605	Prediction of deficits in behavioral self-regulation among persons with multiple sclerosis. 1993 , 74, 1350-3	23
1604	Cognitive-linguistic assessment of individuals with multiple sclerosis. 1993 , 74, 637-43	26
1603	Social handicaps of multiple sclerosis and their relation to neurological alterations. 1994 , 75, 1223-7	18
1602	Laboratory Evaluations in HIV-1-Associated Cognitive/Motor Complex. 1994 , 17, 91-123	8
1601	[Increase of interleukin-2 soluble receptors in multiple sclerosis: preliminary study in 26 patients]. 1994 , 52, 216-20	2
1600	Multiple sclerosis and positive Lyme serology. 1994 , 52, 566-71	8
1599	Demyelinating and Neoplastic Diseases in Pregnancy. 1994 , 12, 509-526	12
1598	Alphanumeric Sequencing: A Report on a Brief Measure of Information Processing Used among Persons with Multiple Sclerosis. 1994 , 78, 883-887	8
1597	Electrodiagnostic abnormalities in patients with multiple sclerosis. 1994 , 75, 778-782	12
1596	A randomized trial of test result sequencing in patients with suspected multiple sclerosis. Rochester-Toronto MRI Study Group. 1994 , 51, 53-9	9
1595	Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial. 1994 , 57 Suppl, 11-4	23
1594	Serum cobalamin deficiency is uncommon in multiple sclerosis. 1994 , 51, 1110-4	34

1593	Propranolol in prophylaxis of migraine. 1994 , 51, 1181-2	
1592	Total lymphoid irradiation in multiple sclerosis. 1994 , 57, 154-63	20
1591	Cognitive functioning and depression in patients with chronic fatigue syndrome and multiple sclerosis. 1994 , 51, 705-10	123
1590	Magnetic resonance imaging in degenerative ataxic disorders. 1994 , 57, 51-7	59
1589	Multiple sclerosis as the cause of sudden 'pontine' deafness. 1994 , 33, 195-201	16
1588	The inter-rater reliability and construct validity of the Functional Independence Measure for multiple sclerosis subjects. 1994 , 8, 107-115	42
1587	Ultrastructure of multiple sclerosis. 1994 , 18, 3-13	127
1586	Multiple sclerosis lesions of the auditory pons are not silent. 1994 , 117 (Pt 5), 1127-41	30
1585	The relationship of pineal calcification to cerebral atrophy on CT scan in multiple sclerosis. 1994 , 76, 71-9	8
1584	Automatic and controlled information processing in multiple sclerosis. 1994 , 117 (Pt 5), 1115-26	103
1583	Some methodologic and sociodemographic issues in the epidemiology of multiple sclerosis. 1994 , 45, 261-276	
1582	The relationship between melatonin secretion and serum cholesterol in patients with multiple sclerosis. 1994 , 76, 81-6	8
1581	Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. 1994 , 179, 973-84	457
1580	A case-control study of chronic neuropsychiatric disease and organic solvent exposure in automobile assembly plant workers. 1994 , 51, 302-7	17
1579	Dysphagia and multiple sclerosis: a study and discussion of its nature and impact. 1994 , 8, 18-26	20
1578	The value of diagnostic information to patients with suspected multiple sclerosis. Rochester-Toronto MRI Study Group. 1994 , 51, 67-72	73
1577	Effect of diagnostic testing for multiple sclerosis on patient health perceptions. Rochester-Toronto MRI Study Group. 1994 , 51, 46-51	26
1576	Clinical diagnosis of multiple sclerosis. The impact of magnetic resonance imaging and ancillary testing. Rochester-Toronto Magnetic Resonance Study Group. 1994 , 51, 61-6	12

1575	Pelvic floor function in multiple sclerosis. 1994 , 35, 388-90	28
1574	The use of brain magnetic resonance imaging in multiple sclerosis. 1994 , 51, 505-16	32
1573	Serum homocysteine levels in multiple sclerosis. 1994 , 51, 1181	19
1572	Multiple sclerosis in black South Africans and Zimbabweans. 1994 , 57, 1064-9	37
1571	A placebo-controlled trial of isoprinosine in patients with multiple sclerosis. 1994 , 57, 164-8	18
1570	Dementia in two histologically confirmed cases of multiple sclerosis: one case with isolated dementia and one case associated with psychiatric symptoms. 1994 , 57, 353-9	29
1569	Benign form of multiple sclerosis: MRI evidence for less frequent and less inflammatory disease activity. 1994 , 57, 1070-2	25
1568	British Isles survey of multiple sclerosis in twins: MRI. 1994 , 57, 491-6	27
1567	No linkage or association between multiple sclerosis and the myelin basic protein gene in affected sibling pairs. 1994 , 57, 1191-4	23
1566	Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. 1994 , 44, 635-41	278
1565	The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. 1994 , 44, 1054-9	149
1564	Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. 1994 , 57 Suppl, 57-61	17
1563	Alphanumeric sequencing: a report on a brief measure of information processing used among persons with multiple sclerosis. 1994 , 78, 883-7	19
1562	The nature of memory impairments in multiple sclerosis: acquisition versus retrieval. 1994 , 16, 183-9	176
1561	Picture and motor sequencing in multiple sclerosis. 1994 , 16, 165-72	21
1560	HLA and prognosis in multiple sclerosis. 1994 , 241, 385-90	57
1559	Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up. 1994 , 241, 391-7	31
1558	Crohn's disease and multiple sclerosis: a single case report. 1994 , 15, 303-6	6

1557	Serial evoked potentials in multiple sclerosis bouts. Relation to steroid treatment. 1994 , 15, 333-40		18
1556	Multiple sclerosis: correlation of anxiety, physical impairment and cognitive dysfunction. 1994 , 15, 97-101		32
1555	TCRB-V gene usage in monozygotic twins discordant for multiple sclerosis. 1994 , 39, 281-5		1
1554	Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity. 1994 , 241, 500-10		5
1553	Multiple sclerosis and mitochondrial myopathy: an unusual combination of diseases. 1994 , 241, 511-6		15
1552	Prediction of outcome in multiple sclerosis based on multivariate models. 1994 , 241, 597-604		75
1551	The myelin basic protein gene is not a major susceptibility locus for multiple sclerosis in Italian patients. 1994 , 241, 615-9		17
1550	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. 1994 , 36, 382-7		47
1549	Human spumaretrovirus antibody reactivity in multiple sclerosis. 1994 , 241, 204-9		10
1548	Pregnancy and multiple sclerosis--a 3-year prospective study. 1994 , 241, 228-33		85
1547	Benign and secondary progressive multiple sclerosis: a preliminary quantitative MRI study. 1994 , 241, 246-51		43
1546	Cerebrospinal fluid concentrations of the complement MAC inhibitor CD59 in multiple sclerosis and patients with other neurological disorders. 1994 , 241, 557-60		14
1545	Correlation of spectroscopy and magnetization transfer imaging in the evaluation of demyelinating lesions and normal appearing white matter in multiple sclerosis. 1994 , 32, 285-93		87
1544	Conduction times of cortical projections to paravertebral muscles in controls and in patients with multiple sclerosis. 1994 , 17, 1348-9		11
1543	Genetic disorders that masquerade as multiple sclerosis. 1994 , 49, 149-69		30
1542	Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 62-7	9.4	298
1541	Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 76-82	9.4	173
1540	Leber's hereditary optic neuropathy mitochondrial DNA mutations in multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 109-12	9.4	126

1539	Myelin basic protein peptide specificity and T-cell receptor gene usage of HPRT mutant T-cell clones in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36, 734-40	9.4	24
1538	Natural history of multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36 Suppl, S6-11	9.4	228
1537	Trauma and multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36 Suppl, S33-7	9.4	17
1536	Clinical definition for multiple sclerosis treatment trials. <i>Annals of Neurology</i> , 1994 , 36 Suppl, S73-9	9.4	32
1535	Establishment and use of multiple sclerosis registers--EDMUS. <i>Annals of Neurology</i> , 1994 , 36 Suppl, S136-9	9.4	18
1534	Descriptive epidemiology of multiple sclerosis in Europe in the 1980s: a critical overview. <i>Annals of Neurology</i> , 1994 , 36 Suppl 2, S164-74	9.4	45
1533	Multiple sclerosis in Iceland, with observations on the alleged epidemic in the Faroe Islands. <i>Annals of Neurology</i> , 1994 , 36 Suppl 2, S175-9	9.4	29
1532	The epidemiology of multiple sclerosis: a general overview. <i>Annals of Neurology</i> , 1994 , 36 Suppl 2, S180-93	9.4	141
1531	Genetic epidemiology of multiple sclerosis: a survey. <i>Annals of Neurology</i> , 1994 , 36 Suppl 2, S194-203	9.4	27
1530	Use and misuse of statistics for epidemiological studies of multiple sclerosis. <i>Annals of Neurology</i> , 1994 , 36 Suppl 2, S218-30	9.4	20
1529	Short tau inversion recovery fast spin-echo (fast STIR) imaging of the spinal cord in multiple sclerosis. 1994 , 12, 983-9		25
1528	Magnetic resonance relaxation time mapping in multiple sclerosis: normal appearing white matter and the "invisible" lesion load. 1994 , 12, 33-42		106
1527	Abstracts-part X (Continue in Part XI). 1994 , 1994, 501-550		
1526	Diagnostic criteria for tuberculous meningitis and their validation. 1994 , 75, 149-52		90
1525	MRI correlates of disease course and activity in multiple sclerosis. 1994 , 2, 319-322		2
1524	Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. 1994 , 1, 55-63		61
1523	Diagnostic problems in "clinically definite" multiple sclerosis patients with normal CSF and multiple MRI abnormalities. 1994 , 1, 127-33		2
1522	Everyday memory impairment, neuroradiological findings and physical disability in multiple sclerosis. 1994 , 1, 159-63		5

1521	MHC-encoded TAP1 and TAP2 dimorphisms in multiple sclerosis. 1994 , 43, 129-32	34
1520	Serum antibodies from MS patients do not recognize HTLV-I, HIV-1, HIV-2 and SIV. 1994 , 102, 514-20	1
1519	Polymorphism of the tumour necrosis factor beta gene in multiple sclerosis and rheumatoid arthritis. 1994 , 21, 377-82	21
1518	The Ullanlinna Narcolepsy Scale: validation of a measure of symptoms in the narcoleptic syndrome. 1994 , 3, 52-59	97
1517	Simple dysphasic seizures as the sole manifestation of relapse in multiple sclerosis. 1994 , 35, 1342-5	27
1516	Panic attacks in a multiple sclerosis patient. 1994 , 35, 133-4	4
1515	No linkage between multiple sclerosis and the T cell receptor alpha chain locus. 1994 , 124, 32-7	11
1514	Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. 1994 , 125, 194-7	132
1513	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs. 1994 , 122, 6-14	81
1512	Cerebrovascular and neurological disorders associated with antiphospholipid antibodies in CSF and serum. 1994 , 122, 97-101	14
1511	Intrathecal synthesis of interleukin-10 (IL-10) in viral and inflammatory diseases of the central nervous system. 1994 , 126, 49-53	48
1510	Formulas for the quantitation of intrathecal IgG production. Their validity in the presence of blood-brain barrier damage and their utility in multiple sclerosis. 1994 , 121, 90-6	32
1509	Occurrence of oligoclonal IgM bands in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study. 1994 , 124, 215-9	32
1508	Expression of Fc epsilon R2/CD23 and p55 IL-2R/CD25 on peripheral blood macrophages/monocytes in multiple sclerosis. 1994 , 55, 127-33	4
1507	Presence of anti-CSL antibodies in the cerebrospinal fluid of patients: a sensitive and specific test in the diagnosis of multiple sclerosis. 1994 , 52, 175-82	13
1506	Tumor necrosis factor polymorphism in multiple sclerosis: no additional association independent of HLA. 1994 , 51, 93-9	53
1505	HLA and T-cell receptor polymorphisms in Belgian multiple sclerosis patients: no evidence for disease association with the T-cell receptor. 1994 , 52, 25-32	24
1504	Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy. 1994 , 52, 33-40	24

1503	V delta 1 gene usage, interleukin-2 receptors and adhesion molecules on gamma delta+ T cells in inflammatory diseases of the nervous system. 1994 , 49, 59-66	9
1502	Polyclonal and oligoclonal IgA synthesis in the cerebrospinal fluid of neurological patients: an immunoaffinity-mediated capillary blot study. 1994 , 49, 109-14	12
1501	In vitro intercellular adhesion molecule-1 expression on brain endothelial cells in multiple sclerosis. 1994 , 49, 181-7	15
1500	TAP 1 and TAP 2 transporter gene polymorphisms in multiple sclerosis: no evidence for disease association with TAP. 1994 , 54, 35-40	12
1499	The intrathecal synthesis of virus-specific oligoclonal IgG in multiple sclerosis. 1994 , 54, 75-80	103
1498	Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. 1994 , 117 (Pt 1), 49-58	475
1497	Antiphospholipid Antibody Syndrome Mimicking Multiple Sclerosis Clinically and by Magnetic Resonance Imaging. 1994 , 154, 917	29
1496	Depression, cognitive impairment and social stress in multiple sclerosis. 1994 , 38, 193-201	113
1495	Effect of orientation on spatiotemporal contrast sensitivity in multiple sclerosis. 1994 , 34, 123-36	2
1494	Cladribine in treatment of chronic progressive multiple sclerosis. 1994 , 344, 9-13	246
1493	Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. 1994 , 344, 298-301	168
1492	An early-onset case of multiple sclerosis with thalamic lesions on MRI. 1994 , 36, 431-4	2
1491	Pineal calcification and its relationship to the fatigue of multiple sclerosis. 1994 , 74, 95-103	10
1490	Sehnervenentzündung und Kontrastsehen. 1994 , 8, 212-216	0
1489	Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. 1994 , 57, 897-902	443
1488	A prevalence study of multiple sclerosis in the Crowsnest Pass region of southern Alberta. 1994 , 21, 262-5	11
1487	A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 1994 , 21, 266-70	42
1486	Relationship of nocturnal melatonin levels to duration and course of multiple sclerosis. 1994 , 75, 229-37	16

1485	Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological deficits, and treatment of the condition. 1994 , 117 (Pt 6), 1303-10	103
1484	SPECT data in a case of secondary Capgras delusion. 1994 , 27, 211-4	16
1483	Discriminating Multiple Sclerosis from other Diseases of Similar Presentation: Can a Formal Description Approach Help?. 1994 , 7, 37-45	6
1482	Event-related brain potential evidence for a verbal working memory deficit in multiple sclerosis. 1994 , 117 (Pt 2), 289-305	113
1481	Increased expression of high affinity IL-2 receptors and beta-adrenoceptors on peripheral blood mononuclear cells is associated with clinical and MRI activity in multiple sclerosis. 1994 , 117 (Pt 2), 307-15	55
1480	MRI of Multiple Sclerosis. Identification of Active Plaques: Contrast Dose Selection. 1994 , 7, 859-873	1
1479	Respiratory muscle function and exercise capacity in multiple sclerosis. 1994 , 7, 23-8	57
1478	Acute encephalopathy: diagnosis and outcome in patients at a regional neurological unit. 1994 ,	
1477	Distributional patterns of multiple sclerosis brain lesions. Magnetic resonance imaging--clinical correlation. 1994 , 4, 188-95	17
1476	A case with symptoms of vestibular neuronitis caused by an intramedullary lesion. 1995 , 109, 545-8	4
1475	Indications for Interferon Beta 1B Treatment in Multiple Sclerosis. 1995 , 22, 334-334	
1474	Screening for major depression in the early stages of multiple sclerosis. 1995 , 22, 228-31	66
1473	Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. 1995 , 35, 627-32	31
1472	Verbal abstraction deficit in multiple sclerosis.. 1995 , 9, 198-205	36
1471	Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. 1995 , 1, 82-7	26
1470	Optic neuritis: a population-based study in Olmsted County, Minnesota. 1995 , 45, 244-50	222
1469	Trigeminal neuralgia in multiple sclerosis. 1995 , 45, 1294-6	168
1468	Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. 1995 , 45, 1808-14	69

1467	Cardiovascular regulation in multiple sclerosis. 1995 , 1, 156-62	6
1466	A study of multiple sclerosis patients with magnetic resonance spectroscopic imaging. 1995 , 1, 25-31	9
1465	Case finding for epidemiological surveys of multiple sclerosis in United States communities. 1995 , 1, 48-55	10
1464	Depression before and after diagnosis of multiple sclerosis. 1995 , 1, 104-8	51
1463	Epidemiology of multiple sclerosis in Italy and in southern Europe. 1995 , 161, 60-70	24
1462	Epidemiologic strategies to detect an exogenous cause of MS. 1995 , 161, 93-9	8
1461	A brain MRI study of different types of chronic-progressive multiple sclerosis. 1995 , 91, 231-3	24
1460	Peripheral neuropathy in multiple sclerosis: a clinical and electrophysiologic study. 1995 , 91, 234-8	39
1459	Tumor necrosis factor alpha but not lymphotoxin is overproduced by blood mononuclear cells in multiple sclerosis. 1995 , 91, 276-9	24
1458	Leber's hereditary optic neuropathy associated with a disorder indistinguishable from multiple sclerosis in a male harbouring the mitochondrial DNA 11778 mutation. 1995 , 91, 326-9	67
1457	Central motor conduction as a measure of disease progression in early multiple sclerosis. 1995 , 1, 233-41	2
1456	Natural interferon-beta in chronic progressive multiple sclerosis: results after 2 years of treatment and 2 years of follow up. 1995 , 2, 139-41	1
1455	Central defects of autonomic function in secondary progressive multiple sclerosis: observations based on cardiovascular and growth hormone responses to clonidine. 1995 , 2, 163-9	1
1454	A prospective study of "undiagnosed" isolated myelopathy: I. Case selection and clinical features. 1995 , 2, 297-305	
1453	A prospective study of "undiagnosed" isolated myelopathy: II. Value of magnetic resonance imaging, evoked potentials and CSF analysis. 1995 , 2, 307-15	
1452	An investigation of HLA-encoded genetic susceptibility to multiple sclerosis in subjects of Asian Indian and Afro-Caribbean ethnic origin. 1995 , 45, 197-202	21
1451	Heat shock protein 70 gene polymorphisms and multiple sclerosis. 1995 , 46, 140-1	17
1450	Single strand conformation analysis of two genes contained within the first intron of the neurofibromatosis type I gene in patients with multiple sclerosis. 1995 , 21, 201-7	13

1449	Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 37, 30-40	9.4	249
1448	Elevated mast cell tryptase in cerebrospinal fluid of multiple sclerosis patients. <i>Annals of Neurology</i> , 1995 , 37, 63-6	9.4	157
1447	Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. <i>Annals of Neurology</i> , 1995 , 37, 82-8	9.4	250
1446	Decreased CD3-mediated interferon-gamma production in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 37, 546-9	9.4	13
1445	Reduced expression of peptide-loaded HLA class I molecules on multiple sclerosis lymphocytes. <i>Annals of Neurology</i> , 1995 , 38, 147-54	9.4	20
1444	Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. <i>Annals of Neurology</i> , 1995 , 38, 186-93	9.4	123
1443	Influx of nonactivated T lymphocytes into the cerebrospinal fluid during relapse of multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 38, 465-8	9.4	10
1442	Resolution-dependent estimates of lesion volumes in magnetic resonance imaging studies of the brain in multiple sclerosis. <i>Annals of Neurology</i> , 1995 , 38, 749-54	9.4	64
1441	Acute optic neuritis: myelin basic protein and proteolipid protein antibodies, affinity, and the HLA system. <i>Annals of Neurology</i> , 1995 , 38, 943-50	9.4	23
1440	Intrathecal immune activation in three patients with progressive myoclonic ataxia. 1995 , 10, 207-10		2
1439	Movement disorders in multiple sclerosis. 1995 , 10, 418-23		203
1438	Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter. 1995 , 33, 811-7		46
1437	Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. 1995 , 18, 1403-11		118
1436	Evidence for a missed signal to the CD8+ cells in CSF of multiple sclerosis patients. 1995 , 16, 479-85		1
1435	Acute and chronic pain syndromes in multiple sclerosis. A 5-year follow-up study. 1995 , 16, 629-32		67
1434	Paroxysmal dystonia and paroxysmal tremor in a young patient with multiple sclerosis. 1995 , 16, 315-9		8
1433	Lowering body temperature with a cooling suit as symptomatic treatment for thermosensitive multiple sclerosis patients. 1995 , 16, 533-9		21
1432	The clinical and paraclinical profile of optic neuritis: a prospective study. 1995 , 16, 167-76		12

1431	Erectile impotence in multiple sclerosis: a neurophysiological study. 1995 , 242, 123-6	44
1430	Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination. 1995 , 242, 143-6	39
1429	Discriminative power of visual evoked potential characteristics in multiple sclerosis. 1995 , 90, 247-57	8
1428	Cardiac autonomic function during sleep and wakefulness in multiple sclerosis. 1995 , 242, 639-43	19
1427	The Functional Limitations Profile may be a valid, reliable and sensitive measure of disability in multiple sclerosis. 1995 , 242, 650-7	11
1426	Susceptibility to multiple sclerosis and the immunoglobulin heavy chain variable region. 1995 , 242, 677-82	30
1425	Acute myelopathy of unknown aetiology: a clinical, neurophysiological and MRI study of short- and long-term prognostic factors. 1995 , 242, 497-503	25
1424	Subclinical autonomic disturbances in multiple sclerosis. 1995 , 242, 374-8	36
1423	Intravenous immunoglobulin treatment in the prevention of childbirth-associated acute exacerbations in multiple sclerosis: a pilot study. 1996 , 243, 25-8	53
1422	Sequence of the human homologue of a mitochondrially encoded murine transplantation antigen in patients with multiple sclerosis. 1995 , 242, 332-4	20
1421	Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission. 1995 , 242, 53-8	24
1420	HLA complement gene polymorphisms in multiple sclerosis. A study on 80 Italian patients. 1995 , 242, 64-8	12
1419	Neuroimaging in Multiple Sclerosis. 1995 , 13, 147-171	23
1418	Lilliputian and negative hallucinations in a patient with probable encephalomyelitis disseminata. 1995 , 28, 65-9	3
1417	HTLV-I associated myelopathy in patients from Brazil and Iran: neurological manifestations and cerebrospinal fluid findings. 1995 , 53, 213-7	6
1416	An evaluation of tumor necrosis factor microsatellite alleles in genetic susceptibility to multiple sclerosis. 1995 , 1, 181-5	32
1415	Aseptic meningitis: an unusual presentation of multiple sclerosis. 1995 , 35, 240-1	3
1414	Fulminant form of multiple sclerosis simulating brain tumor: a case with parkinsonian features and pathologic study. 1995 , 53, 503-8	17

1413	[Multiple sclerosis: clinical analysis and development of 214 cases]. 1995 , 53, 203-7	8
1412	[Abnormalities of pattern reversal evoked visual potential in patients with defined multiple sclerosis]. 1995 , 53, 743-8	2
1411	The Natural History of Multiple Sclerosis. 1995 , 13, 119-146	174
1410	Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. 1995 , 58, 300-6	86
1409	IL-3-LA production by mononuclear cells of patients with multiple sclerosis: effect of treatment with intravenous immunoglobulins. 1995 , 24, 765-73	2
1408	Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. 1995 , 58, 577-81	38
1407	Introduction of integrated care pathways for patients with multiple sclerosis in an inpatient neurorehabilitation setting. 1995 , 17, 443-8	24
1406	Clinical Research: Pattern Reversal Visual Evoked Potentials: Influence of age, Gender and Check Size in the Diagnosis of Multiple Sclerosis. 1995 , 15, 83-91	4
1405	Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. 1995 , 118 (Pt 1), 253-61	293
1404	Reducing heterogeneity in chronic fatigue syndrome: a comparison with depression and multiple sclerosis. 1995 , 21, 1204-10	47
1403	Brainstem multiple sclerosis in an 11-year-old child presenting as acute disseminated encephalomyelitis. 1995 , 10, 476-80	7
1402	Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. 1995 , 58, 31-7	50
1401	Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin-echo images. 1995 , 45, 1684-90	267
1400	Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis. 1995 , 58, 360-2	30
1399	Mistletoe. 1995 , 58, 6	6
1398	Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. 1995 , 58, 638-9	29
1397	Multiple sclerosis in island populations: prevalence in the Bailiwicks of Guernsey and Jersey. 1995 , 58, 22-6	18
1396	Bilateral simultaneous optic neuropathy in adults: clinical, imaging, serological, and genetic studies. 1995 , 58, 70-4	32

1395	The benefit of inpatient neurorehabilitation in multiple sclerosis. 1995 , 9, 198-203	31
1394	Multiple sclerosis progression in a natural history study: predictive value of cerebrospinal fluid free kappa light chains. 1995 , 1, 150-5	43
1393	A new treatment of spasticity with repetitive magnetic stimulation in multiple sclerosis. 1995 , 58, 254-5	20
1392	The Brief Repeatable Battery of Neuropsychological Tests for Multiple Sclerosis: a preliminary serial study. 1995 , 1, 165-9	101
1391	Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. 1995 , 1, 173-80	17
1390	The T-cell receptor beta locus and susceptibility to multiple sclerosis. 1995 , 45, 1859-63	37
1389	Multiple sclerosis in Spain. 1995 , 45, 202	9
1388	Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. 1995 , 45, 1956-61	281
1387	Association between trigeminal neuralgia and multiple sclerosis: role of magnetic resonance imaging. 1995 , 59, 253-9	70
1386	Magnetisation transfer ratios and transverse magnetisation decay curves in optic neuritis: correlation with clinical findings and electrophysiology. 1995 , 59, 487-92	88
1385	Intra- and inter-observer agreement of brain MRI lesion volume measurements in multiple sclerosis. A comparison of techniques. 1995 , 118 (Pt 6), 1593-600	97
1384	Reply from the Author. 1995 , 45, 2300-2301	2
1383	Sural neuropathy. 1995 , 45, 2301	6
1382	Signal intensity on MRI of basal ganglia in multiple sclerosis. 1995 , 59, 306-8	34
1381	A prevalence survey of multiple sclerosis in Sussex. 1995 , 58, 27-30	26
1380	Multiple sclerosis: it epidemiological, genetic, and health care impact. 1995 , 49, 563-9	21
1379	Demographic, Clinical, and Cognitive Characteristics of Multiple Sclerosis Patients Who Continue to Work. 1995 , 9, 167-173	31
1378	Cognitive impairment in early-onset multiple sclerosis. Pattern, predictors, and impact on everyday life in a 4-year follow-up. 1995 , 52, 168-72	284

1377	Chickenpox and multiple sclerosis: a case report. 1995 , 58, 637-8	6
1376	A neurological disease cluster at a manufacturing plant. 1995 , 50, 190-5	6
1375	Multiple sclerosis in the north Cambridgeshire districts of East Anglia. 1995 , 59, 71-6	23
1374	Psychological Predictors of Depression in Multiple Sclerosis. 1995 , 9, 15-23	19
1373	Supplement: treatment for Parkinson's disease. 1995 , 45, 2301-2	
1372	Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. 1995 , 118 (Pt 6), 1583-92	338
1371	Is the frequency of multiple sclerosis increasing in Mexico?. 1995 , 59, 528-30	33
1370	Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. 1995 , 58, 38-43	110
1369	Attention related performance in two cognitively different subgroups of patients with multiple sclerosis. 1995 , 59, 77-82	91
1368	Onset symptoms of multiple sclerosis. 1995 , 58, 253-4	30
1367	Surveying multiple sclerosis in the United Kingdom. 1995 , 58, 2-6	41
1366	Soluble E-selectin in the serum and cerebrospinal fluid of patients with multiple sclerosis and human T-lymphotropic virus type 1-associated myelopathy. 1995 , 45, 1914-8	13
1365	Telling your patient he/she has multiple sclerosis. 1995 , 71, 449-52	4
1364	Reply from the Supplement Editors. 1995 , 45, 2301.3-2302	1
1363	Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. 1995 , 45, 1268-76	1563
1362	Diagnostic value of paraclinical tests in multiple sclerosis: relative sensitivities and specificities for reclassification according to the Poser committee criteria. 1995 , 59, 152-9	56
1361	In vitro cytokine, sCD23 and IgG secretion in multiple sclerosis. 1995 , 61, 1-5	4
1360	Myelin oligodendrocyte glycoprotein (MOG) gene polymorphisms and multiple sclerosis: no evidence of disease association with MOG. 1995 , 61, 117-22	27

1359	Cerebrospinal fluid free kappa light chains versus IgG findings in neurological disorders: qualitative and quantitative measurements. 1995 , 62, 19-25	26
1358	Increased activity of hypothalamic corticotropin-releasing hormone neurons in multiple sclerosis. 1995 , 62, 27-33	61
1357	Interferon-gamma induces T lymphocyte proliferation in multiple sclerosis via a Ca(2+)-dependent mechanism. 1995 , 62, 169-76	11
1356	The immune profile of multiple sclerosis: T-lymphocyte effects predominate over all other factors in cyclophosphamide-treated patients. 1995 , 63, 133-42	10
1355	Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. 1995 , 63, 143-7	66
1354	Genetic susceptibility to multiple sclerosis in a Shanghai Chinese population. The role of the HLA class II genes. 1995 , 42, 203-8	18
1353	Pediatric multiple sclerosis report of 14 cases. 1995 , 17, 9-12	35
1352	Lymphocyte ultrastructure in patients with multiple sclerosis. 1995 , 49, 300-3	3
1351	Eye problems in children with multiple sclerosis. 1995 , 12, 207-12	18
1350	Optic neuritis in children: recurrence and subsequent development of multiple sclerosis. 1995 , 13, 293-5	29
1349	Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. 1995 , 129, 223-7	111
1348	A longitudinal study of the T cell activation marker CD26 in chronic progressive multiple sclerosis. 1995 , 130, 178-82	28
1347	Characterization of humoral and cellular immunity in the central nervous system of HAM/TSP. 1995 , 130, 183-9	13
1346	Genetic susceptibility to multiple sclerosis may be linked to polymorphism of the myelin basic protein gene. 1995 , 131, 96-8	6
1345	Multiple sclerosis in Arabs in Jordan. 1995 , 131, 144-9	34
1344	Utility of auditory P300 in detection of presenile dementia. 1995 , 131, 150-5	23
1343	Cobalt-55 positron emission tomography in relapsing-progressive multiple sclerosis. 1995 , 132, 139-45	27
1342	Glial fibrillary acidic protein in CSF of multiple sclerosis patients: relation to neurological deficit. 1995 , 133, 61-5	82

1341	Brain MRI correlates of cognitive impairment in primary and secondary progressive multiple sclerosis. 1995 , 132, 222-7	150
1340	Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment (SEFCI). 1995 , 45, 718-23	138
1339	Multiple sclerosis and the HLA-D region: linkage and association studies. 1995 , 58, 183-90	58
1338	Increased levels of soluble vascular cell adhesion molecule-1 (VCAM-1) in the cerebrospinal fluid and sera of patients with multiple sclerosis and human T lymphotropic virus type-1-associated myelopathy. 1995 , 59, 35-40	47
1337	Indirect evidence for nitric oxide involvement in multiple sclerosis by characterization of circulating antibodies directed against conjugated S-nitrosocysteine. 1995 , 60, 117-24	82
1336	MRI in the investigation of patients with myelopathy thought to be due to multiple sclerosis. 1995 , 37, 384-7	16
1335	Relationship Between Lower Urinary Tract Abnormalities and Disease-Related Parameters in Multiple Sclerosis. 1995 , 154, 169-173	110
1334	Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis. 1995 , 21, 231-9	9
1333	A new approach to affective symptoms in relapsing-remitting multiple sclerosis. 1995 , 36, 390-5	42
1332	Epilepsia partialis continua in multiple sclerosis. 1995 , 345, 658-9	12
1331	Long time echo stir sequence magnetic resonance imaging of optic nerves in optic neuritis. 1995 , 19, 155-63	5
1330	Epidemiology of multiple sclerosis. 1996 , 14, 291-308	145
1329	Urodynamics and multiple sclerosis. 1996 , 23, 475-81	57
1328	The diagnosis of multiple sclerosis. 1996 , 14, 27-43	16
1327	Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. 1996 , 4, 87-96	117
1326	La sclérose en plaques. 1996 , 7, 125-131	
1325	Serum IgG to brain microvascular endothelial cells in multiple sclerosis. 1996 , 143, 107-13	14
1324	Brain and spinal cord MR in benign multiple sclerosis: a follow-up study. 1996 , 143, 143-9	33

1323	High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. Comparison with biochemical changes in demyelinating plaques. 1996 , 144, 182-90	64
1322	Regulation of disease susceptibility: decreased prevalence of IgE-mediated allergic disease in patients with multiple sclerosis. 1996 , 97, 1402-8	74
1321	In vitro TNF-alpha, IL-2 and IFN-gamma production as markers of relapses in multiple sclerosis. 1996 , 98, 286-90	31
1320	Epidemiology of multiple sclerosis in Arabs in Jordan: a comparative study between Jordanians and Palestinians. 1996 , 135, 162-7	26
1319	The clinical significance of a single abnormal immunoglobulin band in cerebrospinal fluid electrophoresis. 1996 , 136, 159-61	14
1318	Lymphocyte subsets in multiple sclerosis A study with two-colour fluorescence analysis. 1996 , 139, 71-77	16
1317	Characterization of the mitochondrial DNA in patients with multiple sclerosis. 1996 , 140, 75-84	42
1316	Chronic progressive myelopathy: diagnostic analysis of cases with and without sensory involvement. 1996 , 142, 153-6	8
1315	Language functions in incipient cognitive decline in multiple sclerosis. 1996 , 141, 79-86	52
1314	Involvement of the limbic system in multiple sclerosis patients with depressive disorders. 1996 , 39, 970-5	69
1313	A study of oligoclonal band negative multiple sclerosis. 1996 , 60, 27-30	104
1312	Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. 1996 , 46, 368-72	66
1311	Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. 1996 , 46, 1607-12	173
1310	Multiphasic disseminated encephalomyelitis mimicking multiple sclerosis. 1996 , 18, 412-4	29
1309	Improvement of amplitude variability of motor evoked potentials in multiple sclerosis patients and in healthy subjects. 1996 , 101, 404-411	25
1308	Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: predominant intrathecal release of vascular cell adhesion molecule-1. 1996 , 64, 185-91	46
1307	Circulating L-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques. 1996 , 65, 61-5	30
1306	Circulating antibodies directed against conjugated fatty acids in sera of patients with multiple sclerosis. 1996 , 65, 75-81	33

1305	No genetic linkage between multiple sclerosis and the interferon alpha/beta locus. 1996 , 65, 163-5	10
1304	A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis. 1996 , 66, 49-55	17
1303	Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. 1996 , 66, 57-64	53
1302	Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. 1996 , 66, 115-23	49
1301	Immunologic response to acute psychological stress in MS patients and controls. 1996 , 68, 85-94	32
1300	The temporal frequency response function of pattern ERG and VEP: changes in optic neuritis. 1996 , 100, 428-435	10
1299	Brief Papers. 1996 , 32, 193-273	2
1298	Primary CNS demyelinating diseases in childhood: multiple sclerosis. 1996 , 12, 149-54	10
1297	Treatment of refractory urge urinary incontinence with sacral spinal nerve stimulation in multiple sclerosis patients. 1996 , 348, 717-9	92
1296	Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. 1996 , 347, 1728-30	281
1295	T cell vaccination: clinical application in autoimmune diseases. 1996 , 74, 653-62	5
1294	Expiratory training in multiple sclerosis. 1996 , 77, 909-12	69
1293	Multiple sclerosis. 1996 , 42, 1-55	7
1292	Drug therapy in multiple sclerosis: a study of Nova Scotia senior citizens. 1996 , 18, 303-18; discussion 302	10
1291	Elevated serum levels of interleukin-12 in chronic progressive multiple sclerosis. 1996 , 70, 87-90	103
1290	A study of human T-cell lines generated from multiple sclerosis patients and controls by stimulation with peptides of myelin basic protein. 1996 , 70, 65-74	13
1289	Increased Fas antigen on T cells in multiple sclerosis. 1996 , 71, 125-9	60
1288	Multifocal white matter lesions. 1996 , 17, 251-64	3

1287	The pattern of production of cytokine mRNAs is markedly altered at the onset of multiple sclerosis. 1996 , 147, 435-41	23
1286	Progressive visual loss: an unusual presentation of multiple sclerosis. 1996 , 3, 264-7	7
1285	Health-Related Quality of Life in People with Multiple Sclerosis Undergoing Inpatient Rehabilitation. 1996 , 10, 185-194	2
1284	Magnetisation transfer ratios of contrast-enhancing and nonenhancing lesions in multiple sclerosis. 1996 , 38, 115-9	43
1283	Long echo time STIR sequence MRI of optic nerves in optic neuritis. 1996 , 38, 66-9	24
1282	Cortical plaques visualised by fluid-attenuated inversion recovery imaging in relapsing multiple sclerosis. 1996 , 38 Suppl 1, S10-3	35
1281	High-dose contrast-enhanced MRI in multiple sclerosis. 1996 , 38 Suppl 1, S5-9	3
1280	Depression and multiple sclerosis. 1996 , 46, 628-32	425
1279	Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test. 1996 , 19, 30-4	24
1278	Copolymer-1. 1996 , 6, 319-331	9
1277	A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. 1996 , 60, 572-5	48
1276	Magnetic Resonance Imaging of White Matter Disease. 1996 ,	
1275	Antibody response in seropositive multiple sclerosis patients vaccinated with attenuated live varicella zoster virus. 1996 , 7, 303-6	2
1274	[Genetic aspects in multiple sclerosis. II: HLA system]. 1996 , 54, 439-50	1
1273	[Tropical spastic paraparesis: a necessary redefinition]. 1996 , 54, 131-5	2
1272	Failure to Detect Measles Virus Rna, by Reverse Transcription-Polymerase Chain Reaction, in Peripheral Blood Leucocytes of Patients with Multiple Sclerosis. 1996 , 1, 204-206	10
1271	Magnetic Resonance Imaging of Epilepsy in Multiple Sclerosis: A Case Control Study. Implications for Treatment Trials with 4-Aminopyridine. 1996 , 1, 213-217	31
1270	Clinical and Magnetic Resonance Imaging Predictors of Disability in Primary and Secondary Progressive Multiple Sclerosis. 1996 , 1, 218-222	67

- 1269 Human T Lymphotropic Virus Type I (Htlv-I)-Specific T Helper Cell Responses from Htlv-I Seronegative Patients with Chronic Myelopathy and Ms in Japan. **1996**, 1, 200-203
- 1268 Identification of peptides specific for cerebrospinal fluid antibodies in multiple sclerosis by using phage libraries. **1996**, 93, 11063-7 58
- 1267 Acute Unilateral Papillitis versus Retrobulbar Neuritis: Relation to Multiple Sclerosis. **1996**, 1, 223-227 6
- 1266 The evolutionary relationship among Caucasian MS patients and controls. **1996**, 1, 288-95 3
- 1265 Interferon alpha-2a treatment of relapsing-remitting multiple sclerosis: disease activity resumes after stopping treatment. **1996**, 47, 123-9 46
- 1264 Paradoxical heat sensation in patients with multiple sclerosis. Evidence for a supraspinal integration of temperature sensation. **1996**, 119 (Pt 5), 1729-36 61
- 1263 A Comparison of the Sensitivity of Different Sequences in Identifying Plaques in Multiple Sclerosis. **1996**, 9, 521-528 2
- 1262 Measurement of health-related quality of life in multiple sclerosis patients. **1996**, 23, 99-103 77
- 1261 Serum oligoclonal IgG is a common and persistent finding in multiple sclerosis, and has a systemic source. **1996**, 89, 187-93 19
- 1260 Cerebrospinal fluid from multiple sclerosis patients inactivates neuronal Na⁺ current. **1996**, 119 (Pt 2), 457-63 22
- 1259 Assessing somatization disorder in the chronic fatigue syndrome. **1996**, 58, 50-7 60
- 1258 The occurrence of multiple sclerosis in the Hutterites of North America. **1996**, 23, 291-5 8
- 1257 Clinical and radiologic correlates of a novel T lymphocyte gamma-interferon-activated Ca²⁺ influx in patients with relapsing-remitting multiple sclerosis. **1996**, 46, 1416-21 16
- 1256 CAMPATH-IH in multiple sclerosis. **1996**, 1, 357-65 52
- 1255 Primary progressive multiple sclerosis: a distinct syndrome?. **1996**, 2, 137-41 24
- 1254 A program to facilitate retention of employment among persons with multiple sclerosis. **1996**, 7, 37-46 5
- 1253 Long term recombinant interferon alpha treatment in MS with special emphasis to side effects. **1996**, 1, 366-71 17
- 1252 Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: design of a randomised, placebo-controlled, double blind trial in Norway. **1996**, 1, 372-5 6

1251	Patterns of cognitive impairment in relapsing-remitting multiple sclerosis and their relationship to neuropathology on magnetic resonance images.. 1996 , 10, 176-193	38
1250	Expansion of a recurrent V beta 5.3+ T-cell population in newly diagnosed and untreated HLA-DR2 multiple sclerosis patients. 1996 , 93, 12461-6	55
1249	The treatment of chronic progressive multiple sclerosis with cladribine. 1996 , 93, 1716-20	177
1248	Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. 1996 , 41, 2493-8	75
1247	Validation of the NES2 in patients with neurologic disorders. 1996 , 18, 441-8	21
1246	Personality dimensions in the chronic fatigue syndrome: a comparison with multiple sclerosis and depression. 1996 , 30, 9-20	70
1245	Serial position and temporal cue effects in multiple sclerosis: two subtypes of defective memory mechanisms. 1996 , 34, 853-62	21
1244	Drug therapy for acquired pendular nystagmus in multiple sclerosis. 1997 , 244, 9-16	89
1243	Symptomatic cerebral microangiopathy preceding initial manifestation of ulcerative colitis. 1996 , 41, 1807-10	9
1242	Long time echo STIR sequence magnetic resonance imaging of optic nerves in optic neuritis. 1996 , 17, 35-42	8
1241	Sexual function in multiple sclerosis. A 5-year follow-up study. 1996 , 17, 67-9	24
1240	Increased expression of V beta 1.2 T cells in the cerebrospinal fluid of patients with multiple sclerosis. 1996 , 17, 441-2	
1239	Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI. 1996 , 17, 325-32	8
1238	Neuroimmunological findings in Guillain Barré syndrome, multiple sclerosis, and idiopathic polyneuropathies. 1996 , 28, 279-84	1
1237	Tumour necrosis factor alpha is elevated in serum and cerebrospinal fluid in multiple sclerosis and inflammatory neuropathies. 1996 , 243, 165-70	22
1236	Preface to the special issue: Management of voiding, bowel and sexual dysfunction in multiple sclerosis: Towards a holistic approach. 1996 , 14, 3-6	1
1235	Bowel dysfunction in multiple sclerosis. 1996 , 14, 33-39	4
1234	Sexual dysfunction in male multiple sclerosis patients in relation to clinical findings. 1996 , 3, 462-466	10

1233	Evaluation of interleukin 10 and interferon- β in the cerebrospinal fluid and serum of patients with multiple sclerosis. 1996 , 3, 544-547	3
1232	The cerebrospinal fluid in multiple sclerosis. Quantitative assessment of intrathecal immunoglobulin synthesis by empirical formulae. 1996 , 3, 548-559	12
1231	Blood-brain barrier impairment in acute optic neuritis evaluated by Gadolinium-DTPA enhanced MRI and CSF studies. 1996 , 3, 560-566	6
1230	Motor-evoked potentials from multiple target muscles in multiple sclerosis and cervical myelopathy. 1996 , 3, 567-573	4
1229	Clinical uro-neurophysiological investigation in multiple sclerosis. 1996 , 3, 574-580	18
1228	Serum carnitine and disabling fatigue in multiple sclerosis. 1996 , 50, 323-5	7
1227	Higher cerebral dysfunction in a case with atypical multiple sclerosis with concentric lesions. 1996 , 50, 41-4	5
1226	The expression of the endothelial cell antigen CD34 in demyelinating disease. 1996 , 22, 101-107	6
1225	Paroxysmal convergence spasm in multiple sclerosis. 1996 , 94, 35-7	18
1224	Visual form agnosia in multiple sclerosis. 1996 , 94, 38-44	14
1223	Blood-CSF barrier integrity in multiple sclerosis. 1996 , 94, 404-10	20
1222	Mitochondrial DNA mutations in multiple sclerosis patients with severe optic involvement. 1996 , 94, 167-71	57
1221	Cerebrospinal fluid myelin basic protein-like material in acute monosymptomatic optic neuritis. 1996 , 94, 303-9	7
1220	Cerebral metabolism in a case of multiple sclerosis with acute mental disorder. 1996 , 94, 310-3	16
1219	Growth hormone deficiency and hypogonadism in a patient with multiple sclerosis. 1996 , 44, 117-9	4
1218	Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. 1996 , 6, 580-4	46
1217	A case of parkinsonism associated with multiple sclerosis. 1996 , 11, 460-1	25
1216	Reply. 1996 , 11, 461-461	1

1215	Parkinsonism due to Binswanger's subcortical arteriosclerotic encephalopathy. 1996 , 11, 461-2		17
1214	Apparent diffusion coefficients in benign and secondary progressive multiple sclerosis by nuclear magnetic resonance. 1996 , 36, 393-400		166
1213	Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. 1996 , 36, 632-6		209
1212	Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. <i>Annals of Neurology</i> , 1996 , 39, 6-16	9.4	387
1211	Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). <i>Annals of Neurology</i> , 1996 , 39, 285-94	9.4	2075
1210	Impact of aerobic training on fitness and quality of life in multiple sclerosis. <i>Annals of Neurology</i> , 1996 , 39, 432-41	9.4	488
1209	Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. <i>Annals of Neurology</i> , 1996 , 40, 569-74	9.4	254
1208	MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR V beta CDR2 peptides: comparison with myelin basic protein-specific T cells. 1996 , 45, 838-51		15
1207	Decline of muscle fiber conduction velocity during short-term high-dose methylprednisolone therapy. 1996 , 19, 100-2		11
1206	PCR typing of DNA fragments of the two short tandem repeat (STR) systems upstream of the human myelin basic protein (MBP) gene in Danes and Greenland Eskimos. 1996 , 78, 139-56		3
1205	Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. 1996 , 14, 495-505		169
1204	A comparison of two neurologic scoring instruments for multiple sclerosis. 1996 , 243, 209-13		17
1203	Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study. 1996 , 243, 214-24		93
1202	Pathological yawning as a symptom of multiple sclerosis. 1996 , 243, 300-1		21
1201	Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair. 1996 , 243, 667-70		5
1200	A spinal cord MRI study of benign and secondary progressive multiple sclerosis. 1996 , 243, 502-5		108
1199	Patterns of disease activity in multiple sclerosis patients: a study with quantitative gadolinium-enhanced brain MRI and cytokine measurement in different clinical subgroups. 1996 , 243, 536-42		31
1198	Disturbances of ano-rectal function in multiple sclerosis. 1996 , 243, 445-51		61

1197	Quality of life in multiple sclerosis: the disability and impact profile (DIP). 1996 , 243, 469-74	67
1196	CD4 subsets (CD45RA/RO) exhibit differences in proliferative responses, IL-2 and gamma-interferon production during intravenous methylprednisolone treatment of multiple sclerosis. 1996 , 243, 475-81	7
1195	Impaired stretch reflex and joint torque modulation during spastic gait in multiple sclerosis patients. 1996 , 243, 566-74	74
1194	A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. 1996 , 13, 464-8	572
1193	A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. 1996 , 13, 477-80	181
1192	Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. 1996 , 2, 1109-15	159
1191	Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. 1996 , 47, 1469-76	392
1190	A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. 1996 , 60, 339-41	52
1189	Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. 1996 , 2, 222-6	118
1188	MRI dynamics of brain and spinal cord in progressive multiple sclerosis. 1996 , 60, 15-9	130
1187	Prevalence of multiple sclerosis in Rochdale. 1996 , 61, 415-7	17
1186	Screening for cognitive dysfunction in multiple sclerosis. 1996 , 53, 980-4	64
1185	Evaluation of formulae for CSF IgG synthesis using data obtained from two methods: importance of receiver operator characteristic curve analysis. 1996 , 49, 24-8	5
1184	Evidence for a complex role of HLA class II genotypes in susceptibility to multiple sclerosis in Iceland. 1996 , 46, 1107-11	29
1183	Interferon-gamma activated calcium influx in peripheral blood lymphocytes from patients with primary and secondary progressive multiple sclerosis. 1996 , 61, 515-7	2
1182	Alexia without agraphia in multiple sclerosis. 1996 , 61, 528	9
1181	Clinical and Immunological Effects of Cooling in Multiple Sclerosis. 1996 , 10, 9-15	13
1180	Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. 1996 , 2, 227-32	76

1179	Multiple sclerosis with onset at 35 months of age. 1996 , 35, 209-12	3
1178	Spinal cord MRI in multiple sclerosis with multicoil arrays: a comparison between fast spin echo and fast FLAIR. 1996 , 61, 632-5	27
1177	Comparison between multiple sclerosis in India and the United States: a case-control study. 1996 , 46, 385-7	33
1176	Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment. 1996 , 46, 632-5	61
1175	Physiotherapy in chronic multiple sclerosis: a controlled trial. 1996 , 10, 195-204	29
1174	The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. 1996 , 53, 642-9	292
1173	Effects of Electrically Stimulated Exercise Training on Muscle Function in Multiple Sclerosis. 1996 , 10, 143-151	
1172	Variation between observers in classifying multiple sclerosis. 1996 , 61, 418	1
1171	Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial. 1996 , 53, 1270-5	81
1170	More immunotherapy for multiple sclerosis. 1996 , 61, 239-41	11
1169	Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. 1996 , 119 (Pt 3), 701-8	542
1168	Retinal venous sheathing and the blood-retinal barrier in multiple sclerosis. 1996 , 114, 34-9	39
1167	Outcomes-based research in neurorehabilitation: the need for multidisciplinary team involvement. 1996 , 18, 106-10	9
1166	Adolescent conduct disorder, depression, and central nervous system demyelination in magnetic resonance imaging:A report with two cases. 1996 , 50, 419-421	0
1165	Multiple sclerosis in south Cambridgeshire: incidence and prevalence based on a district register. 1996 , 50, 274-9	18
1164	Further validation of constructs from the selective reminding test. 1996 , 18, 52-5	6
1163	Problem solving by patients with multiple sclerosis: comparison of performance on the Wisconsin and California Card Sorting Tests. 1996 , 2, 134-40	72
1162	Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. 1996 , 46, 1639-43	58

1161	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. 1996 , 1, 339-42	22
1160	Providing a neuropsychology service for people with multiple sclerosis in an interdisciplinary rehabilitation unit. 1996 , 18, 348-53	6
1159	Resolution of left hemisphere cognitive dysfunction in multiple sclerosis with magnetic resonance correlates: a case report. 1996 , 1, 17-26	13
1158	Qualitative assessment of intrathecal IgG synthesis by isoelectric focusing and immunodetection: interlaboratory reproducibility and interobserver agreement. 1996 , 56, 135-43	51
1157	Psychosocial impact of illness intrusiveness moderated by age in multiple sclerosis. 1996 , 1, 179-191	46
1156	Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. 1996 , 46, 373-8	161
1155	Plasma exchange combined with azathioprine in multiple sclerosis using serial gadolinium-enhanced MRI to monitor disease activity: a randomized single-masked cross-over pilot study. 1996 , 46, 1620-5	32
1154	Magnetoencephalographic Findings In Patients With Multiple Sclerosis. 1996 , 41, 308-309	
1153	Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease. 1996 , 60, 20-6	43
1152	The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. 1996 , 53, 185-8	106
1151	Multiple sclerosis in Italy. A reappraisal of incidence and prevalence in Ferrara. 1996 , 53, 793-8	52
1150	Auditory evoked potentials in multiple sclerosis: correlation with magnetic resonance imaging. 1996 , 7, 245-78	5
1149	A Quantitative Study of Olfaction in Multiple Sclerosis. 1996 , 10, 97-99	3
1148	Preliminary clinical observations on a new trigeminal reflex: the trigemino-cervical reflex. 1996 , 46, 479-85	53
1147	Clinical concordance in sibling pairs with multiple sclerosis. 1996 , 47, 347-52	69
1146	Soluble intercellular adhesion molecule-1 in serum and cerebrospinal fluid of clinically active relapsing-remitting multiple sclerosis: correlation with Gd-DTPA magnetic resonance imaging-enhancement and cerebrospinal fluid findings. 1996 , 47, 1535-41	34
1145	T-cell subpopulations in the cerebrospinal fluid and peripheral blood of patients with multiple sclerosis: a follow-up study. 1996 , 47, 1542-5	5
1144	Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. 1996 , 53, 753-7	87

1143	Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. 1996 , 119 (Pt 1), 225-37	227
1142	Functional coupling between the central-autonomic and the cognitive systems is enhanced in states after optic neuritis and early multiple sclerosis. 1996 , 86, 87-93	3
1141	Quantitative assessment of MRI lesion load in multiple sclerosis. A comparison of conventional spin-echo with fast fluid-attenuated inversion recovery. 1996 , 119 (Pt 4), 1349-55	147
1140	A comparison of clinical and laboratory measures of spasticity. 1996 , 1, 296-301	38
1139	Retinal and cortical evoked responses to chromatic contrast stimuli. Specific losses in both eyes of patients with multiple sclerosis and unilateral optic neuritis. 1996 , 119 (Pt 3), 723-40	92
1138	Heterogeneity of hypothalamic-pituitary-adrenal system response to a combined dexamethasone-CRH test in multiple sclerosis. 1996 , 104, 31-7	46
1137	Selective impairment of auditory processing in chronic fatigue syndrome: a comparison with multiple sclerosis and healthy controls. 1996 , 83, 51-62	37
1136	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 8-1996. A 28-year-old woman with the rapid development of a major personality change and global aphasia. 1996 , 334, 715-20	5
1135	Proton MR spectroscopy and MR imaging in acute and chronic multiple sclerosis--ringlike appearances in acute plaques. 1996 , 37, 278-87	15
1134	Energy cost of exercise in multiple sclerosis patients with low degree of disability. 1996 , 2, 161-7	35
1133	Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. 1996 , 119 (Pt 3), 709-14	132
1132	Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. 1996 , 119 (Pt 2), 449-55	173
1131	Pregnancy and multiple sclerosis. 1997 , 72, 977-89	59
1130	Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. 1997 , 3, 1-7	40
1129	Neuropsychological aspects of multiple sclerosis: a quantitative review. 1997 , 19, 810-24	69
1128	Ethical issues in multiple sclerosis. 1997 , 17, 227-34	5
1127	Severe irreversible optic neuritis following Mantoux tuberculin skin test in a child with multiple sclerosis--a case report. 1997 , 28, 338-40	4
1126	Selective versus sustained attention: A continuous performance test revisited. 1997 , 11, 18-33	14

1125	Positron emission tomography, magnetic resonance imaging and proton NMR spectroscopy of white matter in multiple sclerosis. 1997 , 3, 8-17	77
1124	Long-lasting depression of soleus motoneurons excitability following repetitive magnetic stimuli of the spinal cord in multiple sclerosis patients. 1997 , 3, 18-30	36
1123	Impairment of central and peripheral myelin in mitochondrial diseases. 1997 , 2, 267-78	10
1122	Bilateral acute optic neuritis: prospective clinical, MRI, CSF, neurophysiological and HLA findings. 1997 , 17, 175-183	7
1121	A double-blind, cross-over trial of intravenous immunoglobulin G in multiple sclerosis: preliminary results. 1997 , 3, 145-8	23
1120	The effects of fatigue on neuropsychological performance in patients with chronic fatigue syndrome, multiple sclerosis, and depression. 1997 , 4, 145-53	84
1119	Pathological association and dissociation of functional systems in multiple sclerosis and Huntington's disease. 1997 , 19, 63-76	5
1118	Hemiparesis and homonymous hemianopia as the presenting sign of multiple sclerosis. 1997 , 17, 63-68	
1117	Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. 1997 , 48, 1557-65	72
1116	Identification of a Val 145 Ile substitution in the human myelin oligodendrocyte glycoprotein: lack of association with multiple sclerosis. The Réseau de Recherche Clinique INSERM sur la Susceptibilité Génétique à la Sclérose en Plaques. 1997 , 3, 377-81	17
1115	The influence of slice orientation on brain MRI lesion load measurement in multiple sclerosis. 1997 , 3, 382-4	0
1114	MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. 1997 , 3, 221-5	26
1113	Risk factors for developing multiple sclerosis after childhood optic neuritis. 1997 , 49, 1413-8	145
1112	Risks of multiple sclerosis in relatives of patients in Flanders, Belgium. 1997 , 62, 329-33	70
1111	Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. 1997 , 54, 531-3	252
1110	Interferon-gamma induced increases in intracellular calcium in T lymphocytes from patients with multiple sclerosis precede clinical exacerbations and detection of active lesions on MRI. 1997 , 63, 339-45	6
1109	Serum angiotensin-converting enzyme in multiple sclerosis. 1997 , 54, 1012-5	45
1108	Failure of intravenous immunoglobulin to arrest progression of multiple sclerosis: a clinical and MRI based study. 1997 , 3, 370-6	19

1107	Transitional progressive multiple sclerosis: a clinical and imaging study. 1997 , 63, 396-8	28
1106	Cerebrospinal fluid analysis differentiates between relapsing-remitting and secondary progressive multiple sclerosis. 1997 , 63, 446-51	13
1105	Survey of the distribution of lesion size in multiple sclerosis: implication for the measurement of total lesion load. 1997 , 63, 452-5	20
1104	Age at immigration to England of Asian and Caribbean immigrants and the risk of developing multiple sclerosis. 1997 , 63, 565-8	101
1103	Multiple sclerosis lesion detection in the brain: a comparison of fast fluid-attenuated inversion recovery and conventional T2-weighted dual spin echo. 1997 , 49, 364-70	102
1102	Open label gabapentin treatment for pain in multiple sclerosis. 1997 , 3, 250-3	87
1101	The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. 1997 , 54, 1475-80	56
1100	Genetic epidemiology of multiple sclerosis. 1997 , 19, 99-106	43
1099	IFN-beta 1b treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months. 1997 , 90, 135-44	12
1098	Executive function in multiple sclerosis. The role of frontal lobe pathology. 1997 , 120 (Pt 1), 15-26	204
1097	¹ H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. 1997 , 63, 736-42	161
1096	Therapeutic effects of alternating current pulsed electromagnetic fields in multiple sclerosis. 1997 , 3, 365-86	13
1095	Spasm of the near reflex: case report and review of the literature. 1997 , 17, 149-152	4
1094	Side-to-side differences in visual event-related potentials but not VEP in patients with multiple sclerosis: A report of three cases. 1997 , 17, 107-111	
1093	Pelvic floor rehabilitation is effective in patients with multiple sclerosis. 1997 , 11, 211-9	60
1092	Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. 1997 , 54, 1116-21	184
1091	Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. 1997 , 48, 1446-8	70
1090	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. 1997 , 49, 351-7	205

1089	Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. 1997 , 54, 1018-25	176
1088	Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. 1997 , 54, 731-6	60
1087	Treatment effects of monthly intravenous immunoglobulin on patients with relapsing-remitting multiple sclerosis: further analyses of the Austrian Immunoglobulin in MS study. 1997 , 3, 137-41	22
1086	Subclinical multisystemic autoimmunity presenting as a progressive myelopathy. 1997 , 6, 675-7	5
1085	A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. 1997 , 7, 78-80	28
1084	Sensitivity and reproducibility of fast-FLAIR, FSE, and TGSE sequences for the MRI assessment of brain lesion load in multiple sclerosis: a preliminary study. 1997 , 7, 98-102	15
1083	[Optic nerve neuritis after 50 years of age: symptom of a previously undiagnosed multiple sclerosis]. 1997 , 211, 28-31	1
1082	Brain microvascular endothelial cells and leukocytes derived from patients with multiple sclerosis exhibit increased adhesion capacity. 1997 , 8, 629-33	43
1081	Coping with a diagnosis of multiple sclerosis.. 1997 , 29, 249-256	11
1080	Respiratory dysfunction in multiple sclerosis: a prospective analysis of 60 patients. 1997 , 10, 139-45	58
1079	Executive functions in multiple sclerosis: An analysis of temporal ordering, semantic encoding, and planning abilities.. 1997 , 11, 535-544	111
1078	The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. 1997 , 49, 1404-13	318
1077	Interscanner variation in brain MRI lesion load measurements in MS: implications for clinical trials. 1997 , 49, 371-7	67
1076	Clozapine treatment of psychosis associated with multiple sclerosis. 1997 , 42, 90-1	22
1075	Letters to the Editor. 1997 , 51, 133-136	
1074	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. 1997 , 120 (Pt 11), 2059-69	832
1073	Verbal learning in amnesic anterior communicating artery aneurysm patients and in patients with multiple sclerosis. 1997 , 4, 89-98	17
1072	Increased in vitro induced CD4+ and CD8+ T cell IFN-gamma and CD4+ T cell IL-10 production in stable relapsing multiple sclerosis. 1997 , 90, 187-202	18

1071	Prescribing recommendations for interferon-Beta in multiple sclerosis. 1997 , 8, 102-12	12
1070	Depression, coping and level of neurological impairment in multiple sclerosis. 1997 , 3, 254-8	105
1069	Isolated cranial nerve palsies in multiple sclerosis. 1997 , 63, 682-5	57
1068	The question of disproportionate impairments in visual and auditory information processing in multiple sclerosis. 1997 , 19, 34-42	68
1067	Double-blind study of pulsing magnetic field effects on multiple sclerosis. 1997 , 3, 21-9	32
1066	Working memory impairment in early multiple sclerosis. Evidence from an event-related potential study of patients with clinically isolated myelopathy. 1997 , 120 (Pt 11), 2039-58	90
1065	Coping with general and disease-related stressors by patients with multiple sclerosis: relationships to psychological distress. 1997 , 3, 191-6	38
1064	Rational clinical immunotherapy for multiple sclerosis. 1997 , 72, 765-80	11
1063	Pregnancy and Multiple Sclerosis. 1997 , 72, 977-989	71
1062	Raised serum nitrate and nitrite levels in patients with multiple sclerosis. 1997 , 145, 77-81	87
1061	Multiple sclerosis in the Turkish- and Greek-speaking communities of Cyprus. A United Nations (UNHCR) Bicomunal Project. 1997 , 145, 163-8	21
1060	Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. 1997 , 147, 135-44	53
1059	Interleukin-12 and tumor necrosis factor-alpha levels in cerebrospinal fluid of multiple sclerosis patients. 1997 , 147, 145-50	44
1058	Binocular saccadic eye movements in multiple sclerosis. 1997 , 148, 53-65	32
1057	Activity levels of a beta1,6 N-acetylglucosaminyltransferase in lymphomonocytes from multiple sclerosis patients. 1997 , 151, 177-83	15
1056	Tumor necrosis factor alpha and its receptors in relapsing-remitting multiple sclerosis. 1997 , 152, 51-61	44
1055	The effects of high-dose intravenous methylprednisolone on event-related potentials in patients with multiple sclerosis. 1997 , 152, 147-53	41
1054	Epidemiology and prognosis of acute myelitis in Southern Finland. 1997 , 152, 140-6	5

1053	Changes in nitrite and nitrate (NO ₂ -/NO ₃ -) levels in cerebrospinal fluid of patients with multiple sclerosis. 1997 , 153, 32-4	53
1052	Acute myelitis associated with hyperIgEemia and atopic dermatitis. 1997 , 148, 199-203	60
1051	Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis. 1997 , 149, 87-93	25
1050	Menstrually related worsening of symptoms in multiple sclerosis. 1997 , 149, 95-7	75
1049	Depression and multiple sclerosis. 1997 , 12, 425	1
1048	Multiple sclerosis in childhood: clinical features of 149 cases. 1997 , 3, 43-6	239
1047	Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles. 1997 , 61, 454-7	87
1046	[Diagnostic importance of middle latency auditory evoked potentials (MLAEP) in multiple sclerosis]. 1997 , 27, 293-9	1
1045	Childhood multiple sclerosis treated with plasmapheresis. 1997 , 17, 83-7	37
1044	The varicella zoster virus: a pilot trial of a potential therapeutic agent in multiple sclerosis. 1997 , 50, 63-8	20
1043	Comparison of a generic to disease-targeted health-related quality-of-life measures for multiple sclerosis. 1997 , 50, 557-69	118
1042	Gliotoxicity, reverse transcriptase activity and retroviral RNA in monocyte/macrophage culture supernatants from patients with multiple sclerosis. 1997 , 413, 477-85	33
1041	Multiple sclerosis: myelin basic protein induced mRNA expression of proinflammatory cytokines in mononuclear cells is suppressed by interferon- β in vitro. 1997 , 4, 460-467	4
1040	Misdiagnosis of multiple sclerosis and beta-interferon. 1997 , 349, 1916	33
1039	Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis. 1997 , 349, 1587-90	79
1038	Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. 1997 , 349, 589-93	318
1037	High levels of cerebrospinal fluid IgM binding to myelin basic protein are associated with early benign course in multiple sclerosis. 1997 , 77, 128-33	16
1036	HLA-DR and -DQ associations with multiple sclerosis in Turkey. 1997 , 55, 59-65	77

1035	Genomewide scan of multiple sclerosis in Finnish multiplex families. 1997 , 61, 1379-87	267
1034	TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. 1997 , 72, 149-53	195
1033	Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease. 1997 , 75, 59-68	29
1032	Increased perforin expression in multiple sclerosis patients during exacerbation of disease in peripheral blood lymphocytes. 1997 , 74, 198-204	20
1031	Detection of the soluble form of the Fas molecule in patients with multiple sclerosis and human T-lymphotropic virus type I-associated myelopathy. 1997 , 75, 141-6	45
1030	Results of a phase I clinical trial of a T-cell receptor peptide vaccine in patients with multiple sclerosis. I. Analysis of T-cell receptor utilization in CSF cell populations. 1997 , 76, 15-28	39
1029	Results of a phase I clinical trial of a T-cell receptor vaccine in patients with multiple sclerosis. II. Comparative analysis of TCR utilization in CSF T-cell populations before and after vaccination with a TCRV beta 6 CDR2 peptide. 1997 , 76, 29-38	51
1028	Detection of CSF-specific oligoclonal antibodies to recombinant JC virus VP1 in patients with progressive multifocal leukoencephalopathy. 1997 , 76, 100-4	30
1027	Occurrence and clinical relevance of an interleukin-4 gene polymorphism in patients with multiple sclerosis. 1997 , 76, 189-92	87
1026	Effects of beta-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study. 1997 , 79, 76-83	37
1025	Cytokine secretion and nitric oxide production by mononuclear cells of patients with multiple sclerosis. 1997 , 80, 76-86	48
1024	Cytokine mRNA expression in CSF and peripheral blood mononuclear cells in multiple sclerosis: detection by RT-PCR without in vitro stimulation. 1997 , 80, 137-42	27
1023	Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis. 1997 , 80, 172-8	64
1022	Comparison of psychophysical and evoked potential methods in the detection of visual deficits in multiple sclerosis. 1997 , 104, 82-90	8
1021	Soluble HLA class I and class II molecule levels in serum and cerebrospinal fluid of multiple sclerosis patients. 1997 , 54, 54-62	30
1020	The CCR5 deletion mutation fails to protect against multiple sclerosis. 1997 , 58, 52-9	100
1019	Minimal surface: a useful paradigm to describe the deeper part of the corpus callosum?. 1997 , 44, 117-24	10
1018	Rationale for early treatment with interferon beta-1a in relapsing-remitting multiple sclerosis. 1997 , 19, 868-82	13

1017	Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. 1997 , 2, 279-82	18
1016	Autobiographical memory in multiple sclerosis. 1997 , 3, 246-251	23
1015	Responding to reported clusters of common diseases: the case of multiple sclerosis. 1997 , 88, 277-9	2
1014	Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. 1997 , 2, 283-90	19
1013	[Magnetic resonance in HTL-I associated myelopathy. Leukoencephalopathy and spinal cord atrophy]. 1997 , 55, 728-36	13
1012	Strength, skeletal muscle composition, and enzyme activity in multiple sclerosis. 1997 , 83, 1998-2004	181
1011	The HLA-DQ(alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR(alpha 1*01, beta 1*1501) heterodimer. 1997 , 50, 15-22	37
1010	Cytokines and soluble IL-4 in patients with acute optic neuritis and multiple sclerosis. 1997 , 4, 59-67	21
1009	Fatigue in multiple sclerosis is not due to sleep apnoea. 1997 , 4, 72-8	17
1008	Fulminant inflammatory demyelination: long-term course and magnetic resonance imaging findings. 1997 , 4, 162-70	0
1007	Micturition disorders in multiple sclerosis patients: neurological, neurourodynamic and magnetic resonance findings. 1997 , 4, 259-265	4
1006	Hypermetabolism in multiple sclerosis patients. 1997 , 4, 342-347	1
1005	Autoantigen-induced IL-13 mRNA expression is increased in blood mononuclear cells in myasthenia gravis and multiple sclerosis. 1997 , 4, 468-475	
1004	Assessment of MRI criteria for abnormal brain MRI in acute monosymptomatic optic neuritis. Comparison to findings in healthy persons. 1997 , 4, 561-566	1
1003	Multiple sclerosis and exposure to house pets during childhood and adolescence: a case-control study. 1997 , 4, 572-575	2
1002	Cerebrospinal fluid lactate and glutamine are reduced in multiple sclerosis. 1997 , 95, 9-12	38
1001	Optic neuritis progressing to multiple sclerosis. 1997 , 95, 85-9	15
1000	Multiple sclerosis in India: a case-control study of environmental exposures. 1997 , 95, 90-5	30

999	Serum sAPO-1/Fas levels in multiple sclerosis. 1997 , 95, 208-10	21
998	Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone. 1997 , 95, 275-9	6
997	Absence of seven human herpesviruses, including HHV-6, by polymerase chain reaction in CSF and blood from patients with multiple sclerosis and optic neuritis. 1997 , 95, 280-3	85
996	Sensitivity of delayed gadolinium-enhanced MRI in multiple sclerosis. 1997 , 95, 331-4	23
995	Evaluation of myocardial muscle functional parameters in patients with multiple sclerosis. 1997 , 95, 335-7	11
994	Expression of endogenous retroviruses in blood mononuclear cells and brain tissue from multiple sclerosis patients. 1997 , 169, 38-44	11
993	Human T-cell lymphotropic virus tax and Epstein-Barr virus DNA in peripheral blood of multiple sclerosis patients during acute attack. 1997 , 169, 79-85	18
992	Early recognition of postural disorders in multiple sclerosis through movement analysis: a modeling study. 1997 , 44, 1029-38	42
991	Physical activity in chronic fatigue syndrome: assessment and its role in fatigue. 1997 , 31, 661-73	173
990	The genetic analysis of multiple sclerosis. 1997 , 13, 234-9	60
989	A replicated prospective investigation of life stress, coping, and depressive symptoms in multiple sclerosis. 1997 , 20, 433-45	91
988	Identification of Beck Depression Inventory items related to multiple sclerosis. 1997 , 20, 407-14	89
987	Correlation between interferon production and clinical disease activity in patients with multiple sclerosis. 1997 , 17, 293-300	34
986	Left arm monoballism as a relapse in multiple sclerosis. 1997 , 12, 1091-2	9
985	Inhibition of the progression of multiple sclerosis by linomide is associated with upregulation of CD4+/CD45RA+ cells and downregulation of CD4+/CD45RO+ cells. 1997 , 85, 202-9	13
984	Objective and subjective cognitive dysfunction and quality of life in multiple sclerosis. 1997 , 3, 187-195	1
983	Orthostatic hypotension in a case with multiple sclerosis. 1997 , 7, 163-5	29
982	Helplessness, self-efficacy, cognitive distortions, and depression in multiple sclerosis and spinal cord injury. 1997 , 19, 287-94	108

981	Sympathetic vasoconstrictor responses in multiple sclerosis with thermo-regulatory dysfunction. 1997 , 7, 13-6	10
980	Autonomic involvement in multiple sclerosis: a pupillometric study. 1997 , 7, 315-9	24
979	Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. 1997 , 244, 153-9	212
978	Immunological monitoring of azathioprine treatment in multiple sclerosis patients. 1997 , 244, 167-74	17
977	Prevalence of multiple sclerosis in the province of Teruel, Spain. 1997 , 244, 182-5	32
976	Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. 1997 , 244, 266-70	148
975	Anti-nuclear antibodies and the optic-spinal form of multiple sclerosis. 1997 , 244, 483-8	15
974	Familial Mediterranean fever and multiple sclerosis. 1997 , 244, 510-4	31
973	Facial palsy in multiple sclerosis. 1997 , 244, 631-3	33
972	Prevalence and incidence of multiple sclerosis in the city of Monreale, Italy. 1998 , 245, 40-3	23
971	[Attitude of patients with multiple sclerosis to illness information]. 1997 , 68, 963-6	7
970	Magnetisation transfer ratio measurement in the cervical spinal cord: a preliminary study in multiple sclerosis. 1997 , 39, 441-5	36
969	Four-year follow-up of a case of acute multiple sclerosis of the Marburg type. 1997 , 18, 163-6	15
968	Pudendal nerve somatosensory evoked potentials in probable multiple sclerosis. 1997 , 18, 289-91	3
967	Dystonia as an isolated symptom of multiple sclerosis?. 1997 , 18, 301-2	3
966	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. 1997 , 15, 155-62	40
965	Soluble adhesion molecules (sVCAM-1 and sICAM-1) in cerebrospinal fluid and serum correlate with MRI activity in multiple sclerosis. <i>Annals of Neurology</i> , 1997 , 41, 326-33	9-4 83
964	Genetic predisposition to multiple sclerosis as revealed by immunoprinting. <i>Annals of Neurology</i> , 1997 , 41, 341-52	9-4 93

963	Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. <i>Annals of Neurology</i> , 1997 , 41, 669-74	9.4	133
962	The impact of inpatient rehabilitation on progressive multiple sclerosis. <i>Annals of Neurology</i> , 1997 , 42, 236-44	9.4	185
961	Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. <i>Annals of Neurology</i> , 1997 , 42, 783-93	9.4	367
960	Application of the Poser criteria in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1997 , 42, 982-3	9.4	14
959	Analysis of action tremor and impaired control of movement velocity in multiple sclerosis during visually guided wrist-tracking tasks. 1997 , 12, 992-9		51
958	Remitting parkinsonism as a symptom of multiple sclerosis and the associated magnetic resonance imaging findings. 1997 , 12, 1090-1		19
957	The detection of intrathecal synthesis of anti-herpes simplex IgG antibodies: comparison between an antigen-mediated immunoblotting technique and antibody index calculations. European Union Concerted Action on Virus Meningitis and Encephalitis. 1997 , 53, 324-31		28
956	Autonomic evaluation by means of standard tests and power spectral analysis in multiple sclerosis. 1997 , 20, 809-14		20
955	Central motor drive is increased during voluntary muscle contractions in multiple sclerosis. 1997 , 20, 1213-8		26
954	Frequency-dependent conduction delay of motor-evoked potentials in multiple sclerosis. 1997 , 20, 1264-74		12
953	Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis. 1998 , 64, 339-46		37
952	Analysis of allelic association between D6S461 marker and multiple sclerosis in Ashkenazi and Iraqi Jewish patients. 1998 , 11, 265-9		6
951	Neuropsychological aspects of multiple sclerosis. 1998 , 8, 43-77		152
950	Transverse myelitis. Comparison with spinal cord presentations of multiple sclerosis. 1998 , 50, 429-33		77
949	Epilepsy in patients with multiple sclerosis: radiological-clinical correlations. 1998 , 39, 893-6		52
948	HLA-DP-associated susceptibility to the optico-spinal form of multiple sclerosis in the Japanese. 1998 , 52, 179-82		47
947	Molecular analysis of HLA class I (HLA-A and -B) and HLA class II (HLA-DRB1) genes in Japanese patients with multiple sclerosis (Western type and Asian type). 1998 , 52, 539-42		35
946	Sexual dysfunction in men with multiple sclerosis--a comprehensive pilot-study into etiology. 1998 , 10, 233-7		18

945	The prevalence of multiple sclerosis in the Hungarian city of Szeged. 1998 , 97, 315-9		17
944	Space-time clustering of multiple sclerosis cases around birth. 1998 , 97, 351-8		9
943	Effect of high-dose methylprednisolone administration on immune functions in multiple sclerosis patients. 1998 , 97, 359-65		36
942	Pulsed methylprednisolone induces a reversible impairment of memory in patients with relapsing-remitting multiple sclerosis. 1998 , 97, 366-9		41
941	Intrathecal synthesis of free immunoglobulin light chains in multiple sclerosis. 1998 , 98, 161-5		31
940	Is the mitochondrial DNA involved in determining susceptibility to multiple sclerosis?. 1998 , 98, 232-7		32
939	Multiple sclerosis in M̃totes, central Spain. 1998 , 98, 238-42		40
938	An epidemiological study of multiple sclerosis in central Sardinia, Italy. 1998 , 98, 391-4		23
937	A single subtype of Epstein-Barr virus in members of multiple sclerosis clusters. 1998 , 98, 395-9		35
936	Cortical and subcortical influences on clustering and switching in the performance of verbal fluency tasks. 1998 , 36, 295-304		165
935	Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II. 1998 , 91, 73-81		27
934	No evidence for elevated numbers of mononuclear cells expressing MCP-1 and RANTES mRNA in blood and CSF in multiple sclerosis. 1998 , 91, 108-12		17
933	B7-1 (CD80), B7-2 (CD86), interleukin-12 and transforming growth factor-beta mRNA expression in CSF and peripheral blood mononuclear cells from multiple sclerosis patients. 1998 , 91, 198-203		18
932	HLA-DRB1 and tumor necrosis factor gene polymorphisms in Japanese patients with multiple sclerosis. 1998 , 92, 109-12		36
931	Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. 1998 , 92, 113-21		195
930	Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 15-24	9.4	42
929	Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 116-20	9.4	66
928	Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 332-9	9.4	142

927	Clinical demographics of multiplex families with multiple sclerosis. Multiple Sclerosis Genetics Group. <i>Annals of Neurology</i> , 1998 , 43, 530-4	9.4	31
926	Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 43, 809-14	9.4	283
925	Multiple sclerosis: the increased frequency of the ICAM-1 exon 6 gene point mutation genetic type K469. <i>Annals of Neurology</i> , 1998 , 44, 70-5	9.4	85
924	Infrequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from multiple sclerosis patients. <i>Annals of Neurology</i> , 1998 , 44, 391-4	9.4	46
923	A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. <i>Annals of Neurology</i> , 1998 , 44, 629-34	9.4	115
922	Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. <i>Annals of Neurology</i> , 1998 , 44, 980-3	9.4	116
921	Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. 1998 , 28, 3329-35		95
920	Urological dysfunctions and upper urinary tract involvement in multiple sclerosis patients. 1998 , 17, 89-98		72
919	Autonomic evaluation by means of standard tests and power spectral analysis in multiple sclerosis. 1998 , 21, 678-80		0
918	Walking and fatigue in multiple sclerosis: the role of the corticospinal system. 1998 , 21, 1068-70		49
917	Abstracts (Continue in Part IX). 1998 , 1998, 401-450		
916	Implementation and evaluation of a new pulse sequence for rapid acquisition of double inversion recovery images for simultaneous suppression of white matter and CSF. 1998 , 8, 544-7		48
915	Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. 1998 , 245, 153-8		63
914	The soluble 60-kDa tumour necrosis factor receptor: no difference found between patients with relapsing-remitting multiple sclerosis and controls: increasing levels are associated with the recovery from Guillain-Barré syndrome. 1998 , 245, 803-8		11
913	Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. 1998 , 12, 89-94		84
912	[Bilateral simultaneous acute amaurosis in neuritis nervi optici. Initial manifestation of encephalomyelitis disseminata]. 1998 , 95, 344-7		3
911	[Intravenous immunoglobulins in therapy of intermittent multiple sclerosis. An update]. 1998 , 69, 361-5		1
910	Affective disorders and multiple sclerosis: a controlled study on 65 Italian patients. 1998 , 19, 171-5		12

909	Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. 1998 , 5, 35-48	58
908	Quantitative techniques for lesion load measurement in multiple sclerosis: an assessment of the global threshold technique after non uniformity and histogram matching corrections. 1998 , 5, 55-60	8
907	Influence of IFN-beta1b (Betaferon) on cytokine mRNA profiles in blood mononuclear cells and plasma levels of soluble VCAM-1 in multiple sclerosis. 1998 , 5, 265-275	21
906	Neuropsychological, neuroradiological and clinical findings in multiple sclerosis. A 3 year follow-up study. 1998 , 5, 283-286	26
905	Absence of linkage with the neuronal nitric oxide synthase (NOS1) gene in 41 multiplex Swedish MS families. 1998 , 5, 393-396	14
904	Intracerebral malignant lymphoma in a patient with long-standing multiple sclerosis. 1998 , 5, 507-510	
903	Correlation between symptom fatigue and muscular fatigue in multiple sclerosis. 1998 , 5, 579-585	31
902	Interleukin-12 and perforin mRNA expression is augmented in blood mononuclear cells in multiple sclerosis. 1998 , 47, 582-90	29
901	A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 1998 , 111, 186-92	15
900	IL-15 mRNA expression is up-regulated in blood and cerebrospinal fluid mononuclear cells in multiple sclerosis (MS). 1998 , 111, 193-7	50
899	Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b). 1998 , 113, 96-9	63
898	Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behçt patients. 1998 , 113, 100-4	43
897	Cytokine autoantibodies in multiple sclerosis, aseptic meningitis and stroke. 1998 , 28, 295-9	21
896	Brain MRI lesion volume measurement reproducibility is not dependent on the disease burden in patients with multiple sclerosis. 1998 , 16, 1185-9	3
895	Natural history of cognitive dysfunction in multiple sclerosis: a 4-year longitudinal study. 1998 , 19, S388-S391	1
894	Relation of cognitive impairment and depression to quality of life in multiple sclerosis patients. 1998 , 19, S392-S398	3
893	Active versus passive exploration of virtual environments modulates spatial memory in MS patients: a yoked control study. 1998 , 19, S424-S430	11
892	Computer-assisted memory retraining of patients with multiple sclerosis. 1998 , 19, S431-S438	31

891	Effects of an anti-IL-10 monoclonal antibody on rIFNbeta-1b-mediated immune modulation. Relevance to multiple sclerosis. 1998 , 81, 109-15	9
890	CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis. No differences from normal individuals and no relation to HLA-DR2. 1998 , 81, 168-72	22
889	Corticosteroids induce expression of transforming-growth-factor-beta1 mRNA in peripheral blood mononuclear cells of patients with multiple sclerosis. 1998 , 84, 1-6	17
888	Detection of skewed T-cell receptor V-beta gene usage in the peripheral blood of patients with multiple sclerosis. 1998 , 85, 22-32	28
887	Multiple sclerosis: the frequency of allelic forms of tumor necrosis factor and lymphotoxin-alpha. 1998 , 84, 198-206	74
886	Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients. 1998 , 84, 213-7	8
885	Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerebrospinal fluid cells in multiple sclerosis. 1998 , 84, 179-87	39
884	Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. 1998 , 85, 122-30	90
883	Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis. 1998 , 86, 13-9	58
882	ELI-spot of Th-1 cytokine secreting PBMC's in multiple sclerosis: correlation with MRI lesions. 1998 , 85, 212-9	25
881	Raised CSF levels of soluble adhesion molecules across the clinical spectrum of multiple sclerosis. 1998 , 85, 186-92	32
880	Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. 1998 , 88, 9-12	27
879	Cerebrospinal fluid thrombomodulin and sVCAM-1 in different clinical stages of multiple sclerosis patients. 1998 , 87, 88-93	7
878	Mechanism of gammadelta T cell-induced human oligodendrocyte cytotoxicity: relevance to multiple sclerosis. 1998 , 87, 49-61	48
877	Elevated serum levels of IFN-gamma, IL-4 and TNF-alpha/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage. 1998 , 87, 27-32	91
876	HLA associations with multiple sclerosis in the Canary Islands. 1998 , 87, 130-5	55
875	Intercellular adhesion molecule-1 in cerebrospinal fluid--the evaluation of blood-derived and brain-derived fractions in neurological diseases. 1998 , 87, 156-61	30
874	Soluble ICAM-1, demyelination, and inflammation in multiple sclerosis and acute optic neuritis. 1998 , 88, 120-7	5

873	Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. 1998 , 89, 198-205	54
872	Neuromodulation: urodynamic effects of sacral (S3) spinal nerve stimulation in patients with detrusor instability or detrusor hyperflexia. 1998 , 92, 141-50	42
871	Impaired VEP after photostress response in multiple sclerosis patients previously affected by optic neuritis. 1998 , 108, 73-9	18
870	Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. 1998 , 39, 1024-8	38
869	Presence of donor-specific DNA in plasma of kidney and liver-transplant recipients. 1998 , 351, 1329-30	220
868	A urinary marker for multiple sclerosis. 1998 , 351, 1330	6
867	Randomised double-blind placebo-controlled study of interferon β 1a in relapsing/remitting multiple sclerosis. 1998 , 352, 1498-1504	1700
866	Placebo-controlled multicentre randomised trial of interferon β 1b in treatment of secondary progressive multiple sclerosis. 1998 , 352, 1491-1497	837
865	HLA-DP: a class II restriction molecule involved in epitope spreading during the development of multiple sclerosis. 1998 , 59, 15-24	39
864	[Multiple sclerosis and antiphospholipid antibodies: study of 62 consecutive patients]. 1998 , 19, 635-9	21
863	Detection of a gliotoxic activity in the cerebrospinal fluid from multiple sclerosis patients. 1998 , 245, 49-52	13
862	Cerebrospinal fluid levels of alpha-tocopherol in patients with multiple sclerosis. 1998 , 249, 65-7	29
861	Lack of evidence for Marek's disease virus genomic sequences in leukocyte DNA from multiple sclerosis patients in Germany. 1998 , 250, 138-40	5
860	Serum interleukin-12 levels in patients with multiple sclerosis. 1998 , 251, 129-32	17
859	Insulin-like growth factor system in serum and cerebrospinal fluid in patients with multiple sclerosis. 1998 , 257, 168-70	20
858	Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. 1998 , 55, 66-72	183
857	Neuropsychological Similarities and Differences Among Huntington's Disease, Multiple Sclerosis, and Cortical Dementia. 1998 , 13, 721-735	3
856	Anticorps sériques circulants dirigés contre des antigènes modifiés par le NO dans les affections neurologiques et rhumatismales. 1998 , 13, 209-217	1

855	Interhemispheric inhibition in patients with multiple sclerosis. 1998 , 109, 230-7	56
854	The nature of fatigue in multiple sclerosis. 1998 , 45, 33-8	139
853	The persistence of fatigue in chronic fatigue syndrome and multiple sclerosis: development of a model. 1998 , 45, 507-17	191
852	Rater reliability of Fahn's tremor rating scale in patients with multiple sclerosis. 1998 , 79, 1076-9	62
851	Extended outpatient rehabilitation: its influence on symptom frequency, fatigue, and functional status for persons with progressive multiple sclerosis. 1998 , 79, 141-6	93
850	Susceptibility to relapsing-progressive multiple sclerosis is associated with inheritance of genes linked to the variable region of the TcR beta locus: use of affected family-based controls. 1998 , 62, 373-85	40
849	Serum levels of macrophage-derived protein MRP-8/14 are elevated in active multiple sclerosis. 1998 , 247, 195-7	30
848	Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group. 1998 , 65, 460-6	78
847	Correlates of coping style in patients with multiple sclerosis. 1998 , 4, 440-3	27
846	Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders (Belgium). 1998 , 64, 444-50	41
845	Subclinical saccadic adduction slowing in patients with monosymptomatic unilateral optic neuritis predicts the development of multiple sclerosis. 1998 , 20, 203-209	
844	Economic evaluation of multiple sclerosis in the UK, Germany and France. 1998 , 13, 607-22	56
843	Acquisition and storage deficits in multiple sclerosis. 1998 , 20, 376-90	140
842	Prevalence of multiple sclerosis in the sanitary district of Calatayud, Northern Spain: is Spain a zone of high risk for this disease?. 1998 , 17, 258-64	26
841	Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. 1998 , 21, 748-52	53
840	Memory Dysfunction in Fatiguing Illness: Examining Interference and Distraction in Short-term Memory. 1998 , 3, 269-285	19
839	Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. 1998 , 20, 373-82	116
838	Awareness of remembering achieved through automatic and conscious processes in multiple sclerosis. 1998 , 38, 183-201	21

837	Immunologic parameters in chronic fatigue syndrome, major depression, and multiple sclerosis. 1998 , 105, 43S-49S	40
836	Choosing drug therapy for multiple sclerosis. An update. 1998 , 56, 555-69	12
835	Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients. 1998 , 4, 174-7	6
834	Reduced prevalence of allergic disease in patients with multiple sclerosis is associated with enhanced IL-12 production. 1998 , 102, 428-35	31
833	Sensory impairments in spinal multiple sclerosis: a combined clinical, magnetic resonance imaging and somatosensory evoked potential study. 1998 , 100, 199-204	19
832	Cerebrospinal fluid complement activation in neurological diseases. 1998 , 154, 173-81	17
831	Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. 1998 , 154, 194-9	124
830	A gliotoxic factor and multiple sclerosis. 1998 , 154, 209-21	18
829	Elevated serum levels of soluble E- and L-selectin in patients with human T-cell lymphotropic virus type I-associated myelopathy. 1998 , 155, 76-9	5
828	Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group. 1998 , 155, 44-9	35
827	Longitudinal follow-up of cardiovascular reflex tests in multiple sclerosis. 1998 , 155, 50-4	26
826	Multiple sclerosis with mite antigen-specific IgE. 1998 , 157, 138-42	12
825	Unusual association of multiple sclerosis and tomaculous neuropathy. 1998 , 157, 217-22	10
824	Modulation of ICAM-1, VCAM-1 and HLA-DR by cytokines and steroids on HUVECs and human brain endothelial cells. 1998 , 157, 117-21	23
823	Intrathecal activation of the complement system and disability in multiple sclerosis. 1998 , 157, 168-74	67
822	Apolipoprotein E and multiple sclerosis: a biochemical and genetic investigation. 1998 , 158, 180-6	37
821	A one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetization transfer lesion loads. 1998 , 158, 203-8	21
820	The significance of oligoclonal bands in multiple sclerosis in Japan: relevance of immunogenetic backgrounds. 1998 , 158, 209-14	46

819	Incidence of optic neuritis in Stockholm, Sweden 1990-1995: I. Age, sex, birth and ethnic-group related patterns. 1998 , 159, 107-14	38
818	The effects of 4-aminopyridine on motor evoked potentials in multiple sclerosis. 1998 , 159, 102-6	36
817	A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis. 1998 , 159, 94-101	9
816	Multiple sclerosis presenting as acute disseminated encephalomyelitis. 1998 , 160, 100-1	4
815	Fatigue in multiple sclerosis: interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. 1998 , 160, 164-70	141
814	Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. 1998 , 339, 285-91	1137
813	Cerebrospinal fluid measures of disease activity in patients with multiple sclerosis. 1998 , 4, 475-9	37
812	Predictors for Employment Status in People With Multiple Sclerosis: A 10-Year Longitudinal Observational Study. 2018 , 99, 1483-1490	9
811	Smoking Cessation and the Reduction of Disability Progression in Multiple Sclerosis: A Cohort Study. 2018 , 20, 589-595	14
810	Physical activity is associated with a decreased multiple sclerosis risk: The EnvIMS study. 2018 , 24, 150-157	27
809	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. 2018 , 24, 301-312	55
808	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. 2018 , 24, 472-480	19
807	Pediatric-onset multiple sclerosis and other acquired demyelinating syndromes of the central nervous system in Denmark during 1977-2015: A nationwide population-based incidence study. 2018 , 24, 1077-1086	30
806	Fatigue after a first attack of suspected multiple sclerosis. 2018 , 24, 974-981	8
805	BICAMS in the Argentine population: Relationship with clinical and sociodemographic variables. 2018 , 25, 424-433	8
804	Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile. 2018 , 24, 1317-1327	30
803	Diffusion tensor imaging in multiple sclerosis at different final outcomes. 2018 , 137, 165-173	12
802	Low clinical conversion rate in clinically isolated syndrome patients - diagnostic benefit of McDonald 2010 criteria?. 2018 , 25, 247-e9	8

801	Analysis of NOD-like receptor NLRP1 in multiple sclerosis families. 2018 , 70, 205-207	10
800	Investigating multiple sclerosis genetic susceptibility on the founder population of east-central Sardinia via association and linkage analysis of immune-related loci. 2018 , 24, 1815-1824	6
799	Role of Demographic and Clinical Factors in Cognitive Functioning of Persons with Relapsing-Remitting and Progressive Multiple Sclerosis. 2018 , 24, 139-146	3
798	Psychiatric morbidity develops after onset of pediatric multiple sclerosis: A Danish nationwide population-based study. 2018 , 19, 30-34	5
797	A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland. 2018 , 265, 108-114	7
796	Changes in disability in people with multiple sclerosis: a 10-year prospective study. 2018 , 265, 119-126	44
795	Trials of Licenced RRMS DMTs in Progressive MS. 2018 , 207-232	
794	Progressive Forms of Multiple Sclerosis: Distinct Entity or Age-Dependent Phenomena. 2018 , 36, 163-171	28
793	Gray matter atrophy patterns in multiple sclerosis: A 10-year source-based morphometry study. 2018 , 17, 444-451	41
792	Consistent increase in the prevalence and female ratio of multiple sclerosis over 15 years in northern Japan. 2018 , 25, 334-339	21
791	Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. 2018 , 24, 481-490	10
790	Multiple Sclerosis: Diagnosis and Differential Diagnosis. 2018 , 55, S1-S9	13
789	Model Systems to Define Remyelination Therapies. 2018 ,	
788	Information provision for people with multiple sclerosis. 2018 , 10, CD008757	20
787	Palliative care interventions for people with multiple sclerosis. 2018 ,	78
786	A Pilot Investigation of Natural Killer Cell Function and Phenotypes in Stable and Active Multiple Sclerosis Patients. 2018 , 05,	
785	Immune System Dysregulation and Autoimmunity in Schizophrenia: IgGs from Sera of Patients with Several Catalytic Activities. 2018 ,	3
784	2. Dataset. 2018 , 9-70	

783	Influence of functioning and contextual factors on activity-related travel behaviour in Multiple Sclerosis. 2018 , 11, 100-109	1
782	TPP2 mutation associated with sterile brain inflammation mimicking MS. 2018 , 4, e285	5
781	A Systematic Assessment of Prevalence, Incidence and Regional Distribution of Multiple Sclerosis in Bavaria From 2006 to 2015. 2018 , 9, 871	25
780	Association Between Multiple Sclerosis and Risk of Female Sexual Dysfunction: A Systematic Review and Meta-Analysis. 2018 , 15, 1716-1727	12
779	Multiple sclerosis. 2018 , 4, 43	372
778	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. 2018 , 4, 2055217318819535	10
777	Genetic Association and Altered Gene Expression of in Multiple Sclerosis Patients. 2018 , 6,	6
776	Should Spinal MRI Be Routinely Performed in Patients With Clinically Isolated Optic Neuritis?. 2018 , 38, 502-510	1
775	Vitamin D for the management of multiple sclerosis. 2018 , 9, CD008422	48
774	Multiple Sclerosis: A Global Concern with Multiple Challenges in an Era of Advanced Therapeutic Complex Molecules and Biological Medicines. 2018 , 6,	10
773	The Role of Information Processing Speed in Clinical and Social Support Variables of Patients with Multiple Sclerosis. 2018 , 14, 472-477	17
772	Prevalence of Cognitive Impairment in Newly Diagnosed Relapsing-Remitting Multiple Sclerosis. 2018 , 20, 153-157	18
771	[Care pathway diversity of patients with multiple sclerosis between French regions]. 2018 , 66, 385-394	2
770	Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1. 2018 , 18, 143	8
769	Present Drug Therapy of Demyelinating Disorders. 2018 , 13, 25-42	
768	Effect of Rehabilitation on Fatigue Level in Patients with Multiple Sclerosis. 2018 , 24, 5761-5770	1
767	The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. 2018 , 48, 1861-1871	12
766	Comorbidities Are Associated with Altered Health Services Use in Multiple Sclerosis: A Prospective Cohort Study. 2018 , 51, 1-10	14

765	Multiple sclerosis biomarkers: Helping the diagnosis?. 2018 , 174, 364-371	5
764	The Sound of Jacqueline du Pr: Revisiting her Medical and Musical History. 2018 , 4, 2055217318775756	
763	Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis. 2018 , 8, 8169	18
762	Determination of Care Burden of Caregivers of Patients with Multiple Sclerosis in Turkey. 2018 , 2018, 7205046	8
761	Acute Visual Deficits. 2018 , 281-302	
760	Sensory Function and Chronic Pain in Multiple Sclerosis. 2018 , 2018, 1924174	7
759	2017 McDonald diagnostic criteria: A review of the evidence. 2018 , 24, 48-54	28
758	Prevalence of Multiple Sclerosis in Iceland. 2018 , 51, 50-56	7
757	Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies. 2018 , 4, 2055217318783347	13
756	Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study. 2018 , 25, 1425-1431	24
755	Neuroepidemiology in Latin America. 2018 , 105-127	
754	Effects of exercise training on cytokines and adipokines in multiple Sclerosis: A systematic review. 2018 , 24, 91-100	27
753	Factors associated with perceived need for mental health care in multiple sclerosis. 2018 , 25, 179-185	8
752	Neurofilaments and 10-year follow-up in multiple sclerosis. 2018 , 24, 1301-1307	42
751	Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients With a Typical Clinically Isolated Syndrome. 2018 , 75, 1392-1398	57
750	Transient impairment of olfactory threshold in acute multiple sclerosis relapse. 2018 , 23, 74-77	15
749	The Vaccination Model in Psychoneuroimmunology Research: A Review. 2018 , 1781, 309-326	6
748	Current Perspectives in the MRI Diagnosis of Multiple Sclerosis: The 2016 Revised MRI Criteria. 2018 , 48, 686-692	

747	Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response. 2018 , 138, 447-453	2
746	Clinical trials in multiple sclerosis: milestones. 2018 , 11, 1756286418785499	7
745	Establishing the diagnosis of multiple sclerosis in Croatian patients with clinically isolated syndrome: 2010 versus 2017 McDonald criteria. 2018 , 25, 99-103	17
744	Applicability of McDonald 2010 and Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS) 2016 Magnetic Resonance Imaging Criteria for the Diagnosis of Multiple Sclerosis in Sri Lanka. 2018 , 14, 339-344	1
743	Obstetric anesthesia/analgesia does not affect disease course in multiple sclerosis: 10-year retrospective cohort study. 2018 , 8, e01082	7
742	There is no benefit in the use of postnatal intravenous immunoglobulin for the prevention of relapses of multiple sclerosis: findings from a systematic review and meta-analysis. 2018 , 76, 361-366	11
741	Blood Mononuclear Cell Mitochondrial Respiratory Chain Complex IV Activity Is Decreased in Multiple Sclerosis Patients: Effects of Interferon Treatment. 2018 , 7,	15
740	Common variation near IRF6 is associated with IFN- γ -induced liver injury in multiple sclerosis. 2018 , 50, 1081-1085	28
739	ANN Classification of MS Subgroups with Diffusion Limited Aggregation. 2018 , 121-136	4
738	Cladribine: mechanisms and mysteries in multiple sclerosis. 2018 , 89, 1266-1271	29
737	Infectious agents and different course of multiple sclerosis: a systematic review. 2018 , 118, 361-377	13
736	Natural Course of Clinically Isolated Syndrome: A Longitudinal Analysis Using a Markov Model. 2018 , 8, 10857	4
735	Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015. 2018 , 18, 15	23
734	Prodromal symptoms of multiple sclerosis in primary care. <i>Annals of Neurology</i> , 2018 , 83, 1162-1173	9-4 62
733	Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management. 2018 , 1-20	0
732	Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara. 2018 , 51, 158-165	6
731	Open study with (-)-OSU6162 in multiple sclerosis-related fatigue. 2018 , 138, 482-489	7
730	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. 2018 , 91, e1130-e1134	20

729	[Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017]. 2018 , 89, 1344-1354	8
728	The association of fatigue, pain, depression and anxiety with work and activity impairment in immune mediated inflammatory diseases. 2018 , 13, e0198975	30
727	Multiple sclerosis. 2018 , 148, 723-730	13
726	Linkage analysis and whole exome sequencing identify a novel candidate gene in a Dutch multiple sclerosis family. 2019 , 25, 909-917	10
725	Infections seem to be more frequent before onset of pediatric multiple sclerosis: A Danish nationwide nested case-control study. 2019 , 25, 783-791	6
724	High neurofilament levels are associated with clinically definite multiple sclerosis in children and adults with clinically isolated syndrome. 2019 , 25, 958-967	18
723	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. 2019 , 25, 1444-1451	25
722	Five years before multiple sclerosis onset: Phenotyping the prodrome. 2019 , 25, 1092-1101	35
721	Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study. 2019 , 10, 1666	10
720	Altered individual behavioral and EEG parameters are related to the EDSS score in relapsing-remitting multiple sclerosis patients. 2019 , 14, e0219594	4
719	Drug Treatment of Clinically Isolated Syndrome. 2019 , 33, 659-676	6
718	Performances comparatives des tests immunologiques du liquide cphalo-rachidien dans le diagnostic de la sclrose en plaques. 2019 , 2019, 71-80	0
717	Enhancing research quality of studies on VEMPs in central neurological disorders: a scoping review. 2019 , 122, 1186-1206	6
716	Emotional outcomes in clinically isolated syndrome and early phase multiple sclerosis: a systematic review and meta-analysis. 2019 , 124, 109761	7
715	Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. 2019 , 35, 119-127	13
714	Prevalence of multiple sclerosis in Goiãia, Goiã, Brazil. 2019 , 77, 352-356	2
713	Patients With Epileptic Seizures and Multiple Sclerosis in a Multiple Sclerosis Center in Southern Germany Between 2003-2015. 2019 , 10, 613	10
712	Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. 2019 , 93, e968-e974	17

711	Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. 2019 , 8,	11
710	Transcranial Magnetic Stimulation as a Potential Biomarker in Multiple Sclerosis: A Systematic Review with Recommendations for Future Research. 2019 , 2019, 6430596	13
709	Validation of the multiple sclerosis diagnosis in the Norwegian Patient Registry. 2019 , 9, e01422	10
708	Transcranial direct current stimulation (tDCS) for improving fatigue, motor function, and pain in people with multiple sclerosis. 2019 ,	1
707	Short-term prediction of secondary progression in a sliding window: A test of a predicting algorithm in a validation cohort.. 2019 , 5, 2055217319875466	0
706	NLRX1 inhibits the early stages of CNS inflammation and prevents the onset of spontaneous autoimmunity. 2019 , 17, e3000451	13
705	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. 2019 , 365,	309
704	Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. 2019 , 18, 269-285	407
703	Measuring of job satisfaction: the use of quality of work life factors. 2019 , 26, 871-892	31
702	High performance of cerebrospinal fluid immunoglobulin G analysis for diagnosis of multiple sclerosis. 2019 , 266, 902-909	
701	Conversion of clinically isolated syndrome to multiple sclerosis: a prospective multi-center study in Eastern India. 2019 , 5, 2055217319849721	2
700	Multiple sclerosis and stroke: a systematic review and meta-analysis. 2019 , 19, 139	20
699	Differential Diagnosis of Pediatric Multiple Sclerosis. 2019 , 6,	2
698	Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients. 2019 , 55,	6
697	Multiple sclerosis prevalence and incidence in San Vicente del Raspeig, Spain. 2019 , 33, 78-81	4
696	Exome sequencing in multiple sclerosis families identifies 12 candidate genes and nominates biological pathways for the genesis of disease. 2019 , 15, e1008180	26
695	The electrophysiological assessment of visual function in Multiple Sclerosis. 2019 , 4, 90-96	14
694	Familial multiple sclerosis patients have a shorter delay in diagnosis than sporadic cases. 2019 , 32, 97-102	8

- 693 Long-term disability progression of pediatric-onset multiple sclerosis. **2019**, 92, e2764-e2773 37
- 692 Association study of G+2044A (R130Q) polymorphism in IL-13 gene with risk of developing Multiple Sclerosis in Iranian population. **2019**, 15, 100392
- 691 K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. **2019**, 8, 17
- 690 Epilepsy in Multiple Sclerosis and Other Acquired Demyelinating Diseases. **2019**, 749-756
- 689 "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. **2019**, 92, e2527-e2537
- 688 Worsening of disability caused by relapses in multiple sclerosis: A different approach. **2019**, 32, 1-8 20
- 687 Impact of the McDonald Criteria 2017 on Early Diagnosis of Relapsing-Remitting Multiple Sclerosis. **2019**, 10, 188 25
- 686 High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis. **2019**, 17, 51 7
- 685 Socioeconomic status and disability progression in multiple sclerosis: A multinational study. **2019**, 92, e1497-e1506 30
- 684 Pediatric Multiple Sclerosis in Rio de Janeiro: Secondary Progression and Disability. **2019**, 94, 48-54
- 683 A Survey of Assistive Technologies for Assessment and Rehabilitation of Motor Impairments in Multiple Sclerosis. **2019**, 3, 6 10
- 682 Diagnosis of Multiple Sclerosis. **2019**,
- 681 Economic burden of multiple sclerosis in France estimated from a regional medical registry and national sick fund claims. **2019**, 36, 101396 9
- 680 Palliative care interventions for people with multiple sclerosis. **2019**, 10, CD012936 3
- 679 Actualisation des aspects cliniques et des critères diagnostiques de la sclérose en plaques. **2019**, 10, 118-125
- 678 Interventions for preventing falls in people with multiple sclerosis. **2019**, 11, CD012475 20
- 677 The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. **2019**, 2019, 1409069 13
- 676 Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis. **2019**, 5, 2055217319885987 3

675	Interferon β 1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland. 2019 , 11, 8177	1
674	Molecular biomarkers in multiple sclerosis. 2019 , 16, 272	75
673	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 - continuity and change. 2019 , 32, 327-337	17
672	Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry. 2019 , 25, 1641-1652	53
671	How common is truly benign MS in a UK population?. 2019 , 90, 522-528	13
670	Shedding light on the link between early life sun exposure and risk of multiple sclerosis: results from the EnvIMS Study. 2019 , 48, 1073-1082	4
669	A single nucleotide polymorphism in the metabotropic glutamate receptor 7 gene is associated with multiple sclerosis in Iranian population. 2019 , 28, 189-192	3
668	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. 2019 , 321, 175-187	172
667	Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. 2019 , 92, e733-e741	30
666	Blood lead levels and multiple sclerosis: A case-control study. 2019 , 27, 151-155	10
665	Peripapillary retinal nerve fibre layer as measured by optical coherence tomography is a prognostic biomarker not only for physical but also for cognitive disability progression in multiple sclerosis. 2019 , 25, 196-203	40
664	Change of olfactory function as a marker of inflammatory activity and disability progression in MS. 2019 , 25, 267-274	17
663	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. 2019 , 25, 565-573	4
662	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. 2019 , 25, 591-600	9
661	Biomarkers in Multiple Sclerosis. 2019 , 9,	34
660	Employment and multiple sclerosis: A meta-analytic review of psychological correlates. 2019 , 24, 38-51	32
659	Smelling multiple sclerosis: Different qualities of olfactory function reflect either inflammatory activity or neurodegeneration. 2020 , 26, 57-68	12
658	Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria. 2020 , 26, 69-78	24

657	Prevalence of multiple sclerosis in Sardinia: A systematic cross-sectional multi-source survey. 2020 , 26, 372-380	17
656	Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. 2020 , 26, 924-935	4
655	Reproductive history of the Danish multiple sclerosis population: A register-based study. 2020 , 26, 902-911	8
654	Periventricular magnetisation transfer ratio abnormalities in multiple sclerosis improve after alemtuzumab. 2020 , 26, 1093-1101	5
653	Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. 2020 , 267, 3489-3498	39
652	Risk of cancer among multiple sclerosis patients, siblings, and population controls: A prospective cohort study. 2020 , 26, 1569-1580	14
651	Clinical and MRI efficacy of sc IFN β 1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS. 2020 , 267, 64-75	1
650	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. 2020 , 26, 1658-1669	18
649	The multiple sclerosis gut microbiota: A systematic review. 2020 , 37, 101427	50
648	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. 2020 , 26, 1372-1380	16
647	Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. 2020 , 26, 1682-1690	14
646	The rate of neuropsychological assessments in multiple sclerosis has increased-A retrospective study in a Finnish Central Hospital. 2020 , 141, 156-161	2
645	Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. 2020 , 37, 101459	25
644	Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?. 2020 , 39, 101931	2
643	No evidence of disease activity status in patients treated with early vs. delayed subcutaneous interferon β 1a. 2019 , 39, 101891	1
642	To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis. 2019 , 39, 101908	8
641	Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. 2020 , 37, 101431	3
640	Multiple sclerosis prevalence in 2000 and 2010 in Western Finland. 2020 , 141, 311-318	5

639	Social phobia in immune-mediated inflammatory diseases. 2020 , 128, 109890	3
638	EBNA-1 titer gradient in families with multiple sclerosis indicates a genetic contribution. 2020 , 7,	3
637	Overview of Differences and Similarities of Published Mixed Treatment Comparisons on Pharmaceutical Interventions for Multiple Sclerosis. 2020 , 9, 335-358	2
636	Secular trends in disease modifying treatment and expenditure in multiple sclerosis: A longitudinal population study in the north of Ireland. 2020 , 45, 102444	1
635	Association of Pregnancy With the Onset of Clinically Isolated Syndrome. 2020 , 77, 1496-1503	11
634	Validity and reliability of the Greek version of the neurogenic bladder symptom score (NBSS) questionnaire in a sample of Greek patients with multiple sclerosis. 2021 , 39, 2697-2702	3
633	Ten-year disease progression in multiple sclerosis: walking declines more rapidly than arm and hand function. 2020 , 45, 102343	2
632	Genetic determinants of the humoral immune response in MS. 2020 , 7,	3
631	The Role of Autoimmunity-Related Gene in the B Cell Receptor-Mediated HLA Class II Pathway. 2020 , 205, 945-956	5
630	New insights into the socio-economic aspects of multiple sclerosis in a cohort of Polish patients. 2021 , 28, 99-106	0
629	Long-term drug treatment in multiple sclerosis: safety success and concerns. 2020 , 19, 1121-1142	5
628	Parity and disability progression in relapsing-remitting multiple sclerosis. 2020 , 267, 3753-3762	6
627	Regional differences in the association of cytomegalovirus seropositivity and multiple sclerosis: A systematic review and meta-analysis. 2020 , 45, 102393	3
626	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. 2020 , 143, 2637-2652	22
625	Reduced IB-β Protein Levels in Peripheral Blood Cells of Patients with Multiple Sclerosis-A Possible Cause of Constitutive NF-β Activation. 2020 , 9,	0
624	Long-term effect of first-line injectable multiple sclerosis treatments: Input of a time-dependent propensity score. 2020 , 29, 1680-1688	
623	Familial aggregation of multiple sclerosis: Results from the national registry of the disease in Saudi Arabia. 2020 , 6, 2055217320960499	3
622	IgG Index Revisited: Diagnostic Utility and Prognostic Value in Multiple Sclerosis. 2020 , 11, 1799	5

621	Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients. 2020 , 10, 14651		2
620	Predictive factors and early biomarkers of response in multiple sclerosis patients treated with natalizumab. 2020 , 10, 14244		5
619	Long-term effects of latitude, ambient temperature, and ultraviolet radiation on the incidence of multiple sclerosis in two cohorts of US women. 2020 , 4, e0105		5
618	Phenome-wide examination of comorbidity burden and multiple sclerosis disease severity. 2020 , 7,		9
617	Toxoplasma gondii and multiple sclerosis: a population-based case-control study. 2020 , 10, 18855		4
616	The CSF Profile Linked to Cortical Damage Predicts Multiple Sclerosis Activity. <i>Annals of Neurology</i> , 2020 , 88, 562-573	9-4	22
615	Dietary interventions for multiple sclerosis-related outcomes. 2020 , 5, CD004192		6
614	A Polymorphism Within the Gene Is Associated With a Higher Relapse Number in Male Patients of Multiple Sclerosis. 2020 , 11, 771		2
613	High incidence and prevalence of MS in Mjfe and Romsdal County, Norway, 1950-2018. 2020 , 7,		5
612	Neurophysiological impairments in multiple sclerosis-Central and peripheral motor pathways. 2020 , 142, 401-417		11
611	Can multiple sclerosis be cured? A case of highly active relapsing multiple sclerosis treated with autologous hematopoietic stem-cell transplantation 13 years ago. 2020 , 44, 102253		1
610	Long-term MS secondary progression: Derivation and validation of a clinical risk score. 2020 , 194, 105792		1
609	Association of Individual-Level Factors With Visual Outcomes in Optic Neuritis: Secondary Analysis of a Randomized Clinical Trial. 2020 , 3, e204339		2
608	An overview of lipidomic analysis in different human matrices of multiple sclerosis. 2020 , 44, 102189		7
607	Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis. 2020 ,		0
606	Changes in multiple sclerosis epidemiology in Finland over five decades. 2020 , 142, 200-209		3
605	Siponimod for multiple sclerosis. 2020 ,		1
604	Epidemiology of pediatric multiple sclerosis: A systematic literature review and meta-analysis. 2020 , 44, 102260		15

603	Conversion of clinically isolated syndrome to multiple sclerosis: a prospective study. 2020 , 44, 102262	4
602	Eligibility and implementation of disease-modifying therapy for primary progressive multiple sclerosis in a UK cohort. 2020 , 42, 102056	
601	Comorbidity is associated with disease activity in MS: Findings from the CombiRx trial. 2020 , 95, e446-e456	11
600	Epidemiology of multiple sclerosis in Central Europe, update from Hungary. 2020 , 10, e01598	4
599	The Effectiveness of Group-based Cognitive Hypnotherapy on the Psychological Well-being of Patients with Multiple Sclerosis: A Randomized Clinical Trial. 2020 , 62, 364-379	2
598	Serum levels of Homocysteine, Vitamin B12 and Folate in Patients with Multiple Sclerosis: an Updated Meta-Analysis. 2020 , 17, 751-761	13
597	Factors associated with relapses in relapsing-remitting multiple sclerosis: A systematic review and meta-analysis. 2020 , 99, e20885	12
596	The retirement rate due to multiple sclerosis has decreased since 1995- A retrospective study in a Finnish central hospital. 2020 , 45, 102360	3
595	Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity. 2020 , 267, 3518-3527	7
594	Diet quality is not associated with late-onset multiple sclerosis risk- A Danish Cohort Study. 2020 , 40, 101968	4
593	The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. 2020 , 6, 2055217319901291	7
592	Brain atrophy and employment in multiple sclerosis patients: a 10-year follow-up study. 2020 , 6, 2055217320902481	
591	White Matter Diseases. 2020 ,	1
590	The Rare Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. 2020 , 9,	
589	Incidence and prevalence of multiple sclerosis in persian gulf area: A systematic review and meta-analysis. 2020 , 40, 101959	11
588	Interrogation of the Multiple Sclerosis Prodrome Using High-Dimensional Health Data. 2020 , 54, 140-147	5
587	Application of the 2017 McDonald criteria in a Chinese population with clinically isolated syndrome. 2020 , 13, 1756286419898083	2
586	The importance of considering differences in study and patient characteristics before undertaking indirect treatment comparisons: a case study of siponimod for secondary progressive multiple sclerosis. 2020 , 36, 1145-1156	4

- 585 The relationship between executive functions and fluid intelligence in multiple sclerosis. **2020**, 15, e0231868 5
- 584 Application of the 2017 McDonald criteria for the diagnosis of multiple sclerosis after a first demyelinating event in patients from Argentina. **2020**, 41, 102043 2
- 583 Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort. **2021**, 27, 729-741 3
- 582 Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. **2021**, 27, 61-70 9
- 581 First-ever treatment in multiple sclerosis. **2021**, 177, 93-99
- 580 The course of multiple sclerosis rewritten: a Norwegian population-based study on disease demographics and progression. **2021**, 268, 1330-1341 8
- 579 Iron Heterogeneity in Early Active Multiple Sclerosis Lesions. *Annals of Neurology*, **2021**, 89, 498-510 9.4 9
- 578 MR Diffusion Properties of Cervical Spinal Cord as a Predictor of Progression to Multiple Sclerosis in Patients with Clinically Isolated Syndrome. **2021**, 31, 108-114 0
- 577 The epidemiology of primary headaches in patients with multiple sclerosis. **2021**, 11, e01830 2
- 576 Increased frequency of canine distemper virus-specific antibodies in multiple sclerosis. **2021**, 11, e01920 3
- 575 A case report of late-onset atypical Hemolytic Uremic Syndrome during interferon beta in multiple sclerosis: Open issues in literature review. **2021**, 11, e01930 2
- 574 Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. **2021**, 47, 102591 3
- 573 Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis. **2021**, 96, e111-e120 11
- 572 The Danish Multiple Sclerosis Registry. **2021**, 11, e01921 15
- 571 Activity limitations and participation restrictions in people with multiple sclerosis: a detailed 10-year perspective. **2021**, 43, 406-413 5
- 570 The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia. **2021**, 7, 2055217321989767 0
- 569 Electrophysiology in neuro-ophthalmology. **2021**, 178, 79-96 0
- 568 Cumulative effects of therapies on disability in relapsing multiple sclerosis. **2021**, 27, 1760-1770 3

567	Evolution of the Diagnostic Criteria in Multiple Sclerosis. 2021 , 75-87	
566	Risk factors for relapse in relapsing remitting multiple sclerosis. 2021 , 17, S34-S36	
565	Is multiple sclerosis overdiagnosed?. 2021 , 47, 102721	0
564	Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. 2021 , 55, 224-231	0
563	Herpesvirus Antibodies, Vitamin D and Short-Chain Fatty Acids: Their Correlation with Cell Subsets in Multiple Sclerosis Patients and Healthy Controls. 2021 , 10,	3
562	Systematic Review of Studies on Telomere Length in Patients with Multiple Sclerosis. 2021 , 12, 1272-1286	3
561	B3 agonists or anticholinergics in the treatment of the lower urinary tract dysfunction in patients with multiple sclerosis?-A randomized study. 2021 , 39, 3049-3056	1
560	Brain atrophy and clinical characteristics predicting SDMT performance in multiple sclerosis: A 10-year follow-up study. 2021 , 7, 2055217321992394	1
559	References. 2021 , 1000-1023	
558	An enrichment strategy for clinical trials in SPMS. 2021 , 27, 1884-1893	1
557	Blood Trace Element Status in Multiple Sclerosis: a Systematic Review and Meta-analysis. 2022 , 200, 13-26	1
556	Defining Benign/Burnt-Out MS and Discontinuing Disease-Modifying Therapies. 2021 , 8,	3
555	Epidemiology and clinical features of demyelinating disorders in India. 2021 , 9, 266-273	0
554	Main Role of Antibodies in Demyelination and Axonal Damage in Multiple Sclerosis. 2021 , 1	2
553	Comorbidity in multiple sclerosis patients from Nordland County, Norway - validated data from the Norwegian Patient Registry. 2021 , 48, 102691	4
552	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. 2021 , 27, 913-921	7
551	Pregnancy-Related and Perinatal Outcomes in Women With Multiple Sclerosis: A Nationwide Danish Cross-sectional Study. 2021 , 11, 280-290	2
550	Rituximab for people with multiple sclerosis.	78

549	Cognitive Issues in Pediatric Multiple Sclerosis. 2021 , 11,	1
548	Is the cochleovestibular nerve function affected in patients with hemifacial spasm?. 2021 , 1	
547	Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. 2021 , 49, 102695	4
546	Seasonal patterns of relapse and disability in Danish MS patients: A population-based cohort study. 2021 , 49, 102739	1
545	Detection of Dysbiosis and Increased Intestinal Permeability in Brazilian Patients with Relapsing-Remitting Multiple Sclerosis. 2021 , 18,	6
544	Defining the disease course of TNFblockers-associated Multiple Sclerosis. 2021 , 353, 577525	3
543	Deciphering Multiple Sclerosis Progression. 2021 , 12, 608491	7
542	Integrative biochemical, proteomics and metabolomics cerebrospinal fluid biomarkers predict clinical conversion to multiple sclerosis. 2021 , 3, fcab084	7
541	Definitions of primary-progressive multiple sclerosis trajectories by rate of clinical disability progression. 2021 , 50, 102814	
540	Does multiple sclerosis increase the risk of preeclampsia? A systematic review and meta-analysis. 2021 , 40, 180-185	0
539	Clinical and radiological activity of secondary progressive multiple sclerosis in a population-based cohort. 2021 , 28, 2238-2248	2
538	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. 2021 , 97, e403-e413	2
537	Genes and environment in multiple sclerosis: Impact of temporal changes in the sex ratio on recurrence risks. 2021 , 13524585211020221	1
536	Determinants of disability development in patients with multiple sclerosis. 2021 , 79, 489-496	0
535	The multiple sclerosis prodrome. 2021 , 17, 515-521	10
534	Disease-modifying therapies for T1 hypointense lesions (Black Holes) volume in patients with multiple sclerosis: Protocol for a systematic review and meta-analysis.	
533	Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome. 2021 , 8,	5
532	Cognitive Dysfunction in Multiple Sclerosis: Educational Level as a Protective Factor. 2021 , 13, 335-342	2

531	Beyond McDonald: updated perspectives on MRI diagnosis of multiple sclerosis. 2021 , 21, 895-911		0
530	Temporal trends in the incidence and prevalence of Multiple Sclerosis in the Northwest of Spain. 2021 , 52, 102979		0
529	Spinal Fluid Myeloid Microvesicles Predict Disease Course in Multiple Sclerosis. <i>Annals of Neurology</i> , 2021 , 90, 253-265	9.4	2
528	Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions. 2021 , 14, 183		2
527	Magnetic Resonance Imaging Correlates of Multiple Sclerosis Immunopathological Patterns. <i>Annals of Neurology</i> , 2021 , 90, 440-454	9.4	3
526	Optic neuritis classification in 2021. 2021 , 11206721211028050		1
525	Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County. 2021 , 144, 680-686		1
524	Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg Test as Clinical Trial Outcomes in Relapsing-Remitting Multiple Sclerosis. 2021 , 97, e1560-e1570		4
523	Toxoplasma gondii and multiple sclerosis: A systematic review and meta-analysis. 2021 , 28, 4251-4257		1
522	Intrinsic and Extrinsic Cell Apoptotic Pathways in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Systematic Review. 2021 , 34, 380-391		
521	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. 2021 , 53, 103012		3
520	Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum. 2021 , 97, e1334-e1342		2
519	Volume changes of thalamus, hippocampus and cerebellum are associated with specific CSF profile in MS. 2021 , 13524585211031786		1
518	Childhood pet ownership and multiple sclerosis: A systematic review and meta-analysis. 2021 , 53, 103046		
517	Relapses add to permanent disability in relapsing multiple sclerosis patients. 2021 , 53, 103029		1
516	Genetic susceptibility to multiple sclerosis in African Americans. 2021 , 16, e0254945		0
515	End of life in multiple sclerosis: Disability, causes and place of death among cases diagnosed from 1981 to 2010 in Pirkanmaa hospital district in Western Finland. 2021 , 54, 103139		0
514	Performance of highly cited multiple sclerosis publications in the Science Citation Index expanded: A scientometric analysis. 2021 , 54, 103112		2

513	Oral pulsed therapy of relapsing multiple sclerosis with cladribine tablets - expert opinion on issues in clinical practice. 2021 , 54, 103075	0
512	Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors. 2021 , 1	1
511	Erhalt der Arbeitsfähigkeit von Patienten mit Multipler Sklerose in Österreich. 1	
510	The Effectiveness of Statins as Potential Therapy for Multiple Sclerosis: A Systematic Review of Randomized Controlled trials. 2021 , 13, e18092	0
509	Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. 2021 , 54, 103107	2
508	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. 2021 , 97, e1641-e1652	6
507	Multiple sclerosis epidemiology in Asia and Oceania; A systematic review and meta-analysis. 2021 , 54, 103119	6
506	Results of analytic and epidemiologic research of external risk factors for multiple sclerosis among moscow population. 1998 , XXX, 25-27	
505	Apparent changes in the epidemiology and severity of multiple sclerosis. 2021 , 17, 676-688	6
504	Natural history of relapsing remitting multiple sclerosis in a long-lasting cohort from a tertiary MS centre in Portugal. 2021 , 54, 103091	0
503	Serum GFAP and NFL levels in benign relapsing-remitting multiple sclerosis. 2021 , 56, 103280	1
502	Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. 2021 , 7, 2055217321990852	1
501	Clinical Trial Design in Neuroimmunology. 2021 , 43-57	
500	Noninvasive Electrophysiology. 2021 , 251-265	
499	Cannabinoids for multiple sclerosis.	1
498	Interferon beta for primary progressive multiple sclerosis.	3
497	Memory rehabilitation for people with multiple sclerosis. 2021 , 10, CD008754	3
496	Multiple Sclerosis: Critical Review of the Evidence for each Question. 221-233	3

495	Predicting Clinical Course. 163-180	1
494	Multiple Sclerosis and Autoimmune Encephalomyelitis. 2007 , 373-404	1
493	The Natural History of Multiple Sclerosis. 1992 , 17-45	20
492	In Vivo and in Vitro Abnormal IgG Regulation in Multiple Sclerosis. 1989 , 205-218	1
491	Magnetic Resonance Imaging in Demyelination. 1989 , 259-272	2
490	Multiple Sclerosis. 1990 , 321-341	2
489	Statistical and Epidemiological Considerations. 1990 , 29-51	1
488	Human Cerebrospinal Fluid Immunology. 1989 , 179-226	6
487	Cognitive Dysfunction in Multiple Sclerosis. 1994 , 781-788	1
486	Free Light Chains of Immunoglobulins in Multiple Sclerosis: A Putative Index of the Intrathecal Humoral Immune Response. 1987 , 187-200	1
485	Multifractal Analysis with L2 Norm Denoising Technique: Modelling of MS Subgroups Classification. 2019 , 257-269	2
484	Predicting Clinically Definite Multiple Sclerosis from Onset Using SVM. 2012 , 116-123	1
483	Correlation between structural brain lesions and emotional and cognitive function in patients with multiple sclerosis: an MRI study. 1991 , 123-124	2
482	Neuropsychologische Befunde und Therapieoptionen bei Multipler Sklerose. 2001 , 251-270	1
481	Klinische Symptomatik und natürlicher Krankheitsverlauf der Multiplen Sklerose. 2001 , 67-79	1
480	Tuberculous Radiculomyelopathy and Myelitic Tuberculomas. 2000 , 27-42	2
479	Neurological Disorders Associated with HTLV-1. 1990 , 99-119	3
478	Multiple Sklerose bei Kindern – Die Rolle serieller Magnetresonanztomographie-Untersuchungen für die Frühdiagnose. 1990 , 296-298	1

477	Multiple Sclerosis, Neuromyelitis Optica, Concentric Sclerosis, and Schilder's Diffuse Sclerosis. 1989 , 179-205	2
476	Multiple Sclerosis. 1995 , 296-313	2
475	Chemokine receptors on mononuclear phagocytes in the central nervous system of patients with multiple sclerosis. 2002 , 193-211	1
474	Früherkennung und Diagnostik der Multiplen Sklerose. 2016 , 23-54	1
473	Update on management and genetics of multiple sclerosis. 1997 , 50, 167-72	2
472	Overview of Treatment Trials: Early Baseline Clinical and MRI Data of the PROMiSe Trial. 2002 , 47-61	1
471	Compact Manual for Multiple Sclerosis Registration in Clinical Research. 1986 , 85-93	1
470	A Systematic Review and Mixed Treatment Comparison of Pharmaceutical Interventions for Multiple Sclerosis. 2020 , 9, 359-374	6
469	Multiple Sclerosis. 2003 , 677-706	1
468	Increased Levels of TGF β in Cerebrospinal Fluid of Multiple Sclerosis Patients. 1997 , 311-316	1
467	Clinically Isolated Syndromes. 2010 , 206-218	1
466	The Peculiar Difficulties of Therapeutic Trials for Multiple Sclerosis. 1990 , 8, 119-141	7
465	Neuroimaging in Multiple Sclerosis. 1984 , 2, 759-777	18
464	NEUROLOGIC DISEASE IN SJOGREN'S SYNDROME: MONONUCLEAR INFLAMMATORY VASCULOPATHY AFFECTING CENTRAL/PERIPHERAL NERVOUS SYSTEM AND MUSCLE: A Clinical Review and Update of Immunopathogenesis. 1993 , 19, 869-908	94
463	Conduction studies in multiple sclerosis. 1-7	1
462	Multiple Sclerosis. 2004 , 188-222	1
461	Multiple sclerosis and age at infection with common viruses. 2001 , 12, 301-6	103
460	Body cooling may not improve somatosensory pathway function in multiple sclerosis. 1997 , 76, 191-6	7

- 459 The role of spouse responses to disability and family environment in multiple sclerosis. **1999**, 78, 525-32 46
- 458 A 12-week, open trial of donepezil hydrochloride in patients with multiple sclerosis and associated cognitive impairments. **2000**, 20, 350-6 69
- 457 A new computer-assisted method for the quantification of enhancing lesions in multiple sclerosis. **1997**, 21, 145-51 31
- 456 Relationship Between Lower Urinary Tract Abnormalities and Disease-Related Parameters in Multiple Sclerosis. **1995**, 169-173 1
- 455 MULTIPLE SCLEROSIS AND THE UROLOGIST. **1999**, 743-757 4
- 454 Quantitation of lower physical activity in persons with multiple sclerosis. **1997**, 29, 517-23 150
- 453 Successful Treatment of Intracerebral Hydatid Cysts with Albendazole. **1992**, 31, 571-574 2
- 452 Pathogenesis, diagnosis, and treatment of acute disseminated encephalomyelitis. **1999**, 12, 395-401 59
- 451 Moderating effects of coping on the relationship between stress and the development of new brain lesions in multiple sclerosis. **2002**, 64, 803-9 48
- 450 Systematic Review of Studies on Telomere Lengths in Patients with Multiple Sclerosis. 1
- 449 Genetic Susceptibility to Multiple Sclerosis: Interactions between Conserved Extended Haplotypes of the MHC and other Susceptibility Regions. 1
- 448 Alterations in levels of CD28-/CD8+ suppressor cell precursor and CD45RO+/CD4+ memory T lymphocytes in the peripheral blood of multiple sclerosis patients. **1995**, 2, 249-52 75
- 447 A new cell enzyme-linked immunosorbent assay demonstrates gamma interferon suppression by beta interferon in multiple sclerosis. **1999**, 6, 415-9 10
- 446 Similar humoral and cellular immunological reactivities to human herpesvirus 6 in patients with multiple sclerosis and controls. **1999**, 6, 545-9 45
- 445 Detection of JC virus in cerebrospinal fluid (CSF) samples from patients with progressive multifocal leukoencephalopathy but not in CSF samples from patients with herpes simplex encephalitis, enteroviral meningitis, or multiple sclerosis. **1998**, 36, 1137-8 21
- 444 Adolescent-onset Krabbe disease with an initial diagnosis of multiple sclerosis and a novel mutation. **2015**, 2015, 6
- 443 Breast feeding and multiple sclerosis. **1994**, 308, 1411-2 39
- 442 "Abnormal" illness behaviour in chronic fatigue syndrome and multiple sclerosis. **1995**, 311, 15-8 23

441	Making the diagnosis of multiple sclerosis. 2001 , 71 Suppl 2, ii3-8	8
440	Expression of chemokines in the CSF and correlation with clinical disease activity in patients with multiple sclerosis. 2002 , 72, 498-502	84
439	Spinal fluid lymphocytes responsive to autologous and allogeneic cells in multiple sclerosis and control individuals. 1984 , 74, 1307-17	25
438	Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. 1991 , 87, 949-54	583
437	Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. 1993 , 92, 2602-8	245
436	Myelin basic protein-specific T lymphocyte repertoire in multiple sclerosis. Complexity of the response and dominance of nested epitopes due to recruitment of multiple T cell clones. 1993 , 92, 2633-43	116
435	Natural killer type 2 bias in remission of multiple sclerosis. 2001 , 107, R23-9	91
434	Comparative analysis of antibody and cell-mediated autoimmunity to transaldolase and myelin basic protein in patients with multiple sclerosis. 1997 , 99, 1238-50	51
433	Diversity and plasticity of self recognition during the development of multiple sclerosis. 1997 , 99, 1682-90	133
432	Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. 2005 , 115, 187-94	188
431	Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. 1998 , 102, 1045-50	247
430	Neuropsychiatric Status of Patients with Chronic Fatigue Syndrome: An Overview. 1994 , 10, 513-522	10
429	Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation. 1998 , 92, 3505-3514	6
428	Attention in multiple sclerosis: correlates of impairment on the WAIS-R Digit Span Test. 1995 , 2, 139-144	9
427	Phases and Phenotypes of Multiple Sclerosis. 2019 , 25, 636-654	15
426	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. 2021 , 96, e482-e490	6
425	Magnetization transfer imaging of patients with definite MS and negative conventional MRI. 1999 , 52, 845-8	46
424	Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. 1999 , 52, 1626-32	497

423	Familial factors influence disability in MS multiplex families. French Multiple Sclerosis Genetics Group. 1999 , 52, 1632-6	58
422	Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b. 1999 , 52, 1636-9	41
421	Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. 1999 , 52, 1893-5	24
420	Pulmonary oedema with multiple sclerosis. 2002 , 95, 401-2	6
419	Spinal Cord Injury Pain Classification: History, Current Trends, and Commentary. 2007 , 13, 1-19	14
418	Interaction of * and in a Population-based Case-control Study of Multiple Sclerosis. 2013 , 1, 10-17	1
417	Vitamin D and Risk of Multiple Sclerosis: A Mendelian Randomization Study. 2015 , 12, e1001866	252
416	Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. 2008 , 3, e3490	83
415	IL2RA/CD25 gene polymorphisms: uneven association with multiple sclerosis (MS) and type 1 diabetes (T1D). 2009 , 4, e4137	55
414	Lipoic acid attenuates inflammation via cAMP and protein kinase A signaling. 2010 , 5, e13058	65
413	DRB1*03:01 haplotypes: differential contribution to multiple sclerosis risk and specific association with the presence of intrathecal IgM bands. 2012 , 7, e31018	10
412	Genome-wide association study of multiple sclerosis confirms a novel locus at 5p13.1. 2012 , 7, e36140	41
411	Geographical variations in sex ratio trends over time in multiple sclerosis. 2012 , 7, e48078	139
410	Systematic review and meta-analysis of the sero-epidemiological association between Epstein Barr virus and multiple sclerosis. 2013 , 8, e61110	74
409	Fine mapping and functional analysis of the multiple sclerosis risk gene CD6. 2013 , 8, e62376	15
408	Multiple sclerosis incidence associated with the soil lead and arsenic concentrations in Taiwan. 2013 , 8, e65911	23
407	Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica. 2013 , 8, e72919	70
406	Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. 2013 , 8, e82325	23

405	High nationwide incidence of multiple sclerosis in Sweden. 2014 , 9, e108599	41
404	Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study. 2015 , 10, e0132033	40
403	Lesion Activity on Brain MRI in a Chinese Population with Unilateral Optic Neuritis. 2015 , 10, e0141005	2
402	The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. 2016 , 11, e0152347	22
401	The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retrospective Study. 2016 , 11, e0157721	3
400	Month of birth and level of insolation as risk factors for multiple sclerosis in Poland. 2017 , 12, e0175156	2
399	Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. 2018 , 13, e0190043	14
398	Generational changes in multiple sclerosis phenotype in North African immigrants in France: A population-based observational study. 2018 , 13, e0194115	7
397	GAS6 signaling tempers Th17 development in patients with multiple sclerosis and helminth infection. 2020 , 16, e1009176	4
396	Multiple sclerosis or multiphasic disseminated encephalomyelitis? A new question about an old problem. Case report. 1996 , 54, 505-9	4
395	Multiple sclerosis in Brazil. Analysis of cerebrospinal fluid by standard methods. 1999 , 57, 927-31	4
394	[Development of the Brazilian version of the Multiple Sclerosis Functional Composite Measure (MSFC-BCTRIMS): pilot study]. 2004 , 62, 363-9	8
393	[Oligoclonal IgG bands in the cerebrospinal fluid of portuguese patients with multiple sclerosis: negative results indicate benign disease]. 2005 , 63, 375-9	14
392	Description and characteristics of 81 patients attending the Reference Center for Multiple Sclerosis of the coastal region of the state of Sã Paulo-Brazil. 2005 , 63, 741-4	8
391	Cytokines and intrathecal IgG synthesis in multiple sclerosis patients during clinical remission. 2005 , 63, 914-9	21
390	Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients. 2006 , 64, 51-4	4
389	Attention impairment associated with relapsing-remitting multiple sclerosis patients with mild incapacity. 2007 , 65, 262-7	8
388	Immunomodulator therapy migration in relapsing remitting multiple sclerosis: a study of 152 cases. 2008 , 66, 11-4	8

387	Contribui� do Mismatch Negativity na avalia� cognitiva de indiv�os portadores de esclerose mltipla. 2006 , 72, 800-807	5
386	Chemokines in the cerebrospinal fluid of patients with active and stable relapsing-remitting multiple sclerosis. 2006 , 39, 441-5	11
385	[Issues of the current terminology in multiple sclerosis]. 2018 , 118, 121-127	2
384	[Registry-based comparison of multiple sclerosis epidemiology trend data in 1999 and 2019: the case of Yaroslavl]. 2020 , 120, 48-53	2
383	Serum total antioxidant capacity in patients with multiple sclerosis. 2011 , 11, 33-6	26
382	Frequency of Multiple Sclerosis (MS) Among Relatives of MS Patients in Hamadan Society, Iran. 2016 , 3,	4
381	Web search behavior and information needs of people with multiple sclerosis: focus group study and analysis of online postings. 2014 , 3, e12	37
380	Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study. 2018 , 7, e15	17
379	[Magnetic resonance findings in the brain of patients with multiple sclerosis without oligoclonal bands in the cerebrospinal fluid]. 2003 , 131, 31-5	2
378	[Clinical characteristics and neurophysiologic findings in patients with multiple sclerosis without oligoclonal IgG in cerebrospinal fluid]. 2003 , 131, 122-6	5
377	A unique case of a 70-hour decompression sickness latency. 2018 , 69, 350-353	1
376	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. 2020 , 41, 1001-1008	30
375	Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation. 2017 , 21, 1-352	21
374	Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. 2020 , 10,	15
373	Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. 2020 , 22,	17
372	[Systematic review and meta-analysis of randomized controlled trials of Chinese herbal medicine in treatment of multiple sclerosis]. 2012 , 10, 141-53	10
371	Neuropsychiatric Problems in Patients With Multiple Sclerosis. 2002 , 32, 128-132	3
370	Uveitis associated with multiple sclerosis: complications and visual prognosis. 2014 , 7, 1010-3	9

- 369 Evoked potential tests in clinical diagnosis. **2013**, 133, 960-5 7
- 368 Multiple sclerosis in India: An overview. **2015**, 18, S2-5 12
- 367 Evolving Landscape of Multiple Sclerosis in India: Challenges in the Management. **2018**, 21, 107-115 2
- 366 Early-Onset Multiple Sclerosis: Reports of 300 Patients from Iran. **2018**, 13, 137-140 3
- 365 The value of oligoclonal bands in neurobrucellosis. **1991**, 11, 411-3 3
- 364 A Review of Geoepidemiological Differences of Multiple Sclerosis in Iran and Other Middle East Countries. **2014**, 2, 7
- 363 [Antioxidant use as dietary therapy in patients with multiple sclerosis]. **2015**, 15, e6065 5
- 362 Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community. **2011**, 13, 65-74 17
- 361 Information processing and magnetic resonance imaging indices of brain pathology in multiple sclerosis. **2012**, 14, 84-91 7
- 360 Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010. **2012**, 14, 105-14 16
- 359 Fatigue and Comorbidities in Multiple Sclerosis. **2016**, 18, 96-104 27
- 358 Clinical presentation and diagnosis of multiple sclerosis. **2020**, 20, 380-383 16
- 357 Correlation between the clinical disability and T1 hypointense lesions' volume in cerebral magnetic resonance imaging of multiple sclerosis patients: A systematic review and meta-analysis. **2021**, 27, 1268-1280 3
- 356 Multiple Sclerosis. **2000**, 686-703
- 355 Management of Multiple Sclerosis. **2000**, 10, 4-11
- 354 Biological backlink in multiple sclerosis treatment. **2000**, XXXII, 13-16
- 353 Emotional disturbances in patients with different clinical variations of multiple sclerosis and their correlation with MRT findings. **2000**, XXXII, 10-13
- 352 Anxiety as one of the factors determining the rate of multiple sclerosis progressing. **2000**, XXXII, 5-9

351 Multiple Sclerosis. **2001**, 235-248

1

350 Sonderformen der Multiplen Sklerose. **2001**, 81-90

349 Epilepsie und Multiple Sklerose. **2001**, 211-214

348 Neuritis nervi optici und Multiple Sklerose. **2001**, 135-147

0

347 Multiple Sclerosis: Ethics, Outcome Variables and Clinical Scales. **2001**, 359-370

346 Adaptaõ Transcultural e Validaõ da Escala de Impacto de Esclerose Múltipla. **2011**, 19, 433-440

2

345 Peculiarities of frustrational tolerance and anticipational activity in patients with multiple sclerosis. **2001**, XXXIII, 16-20

344 Multiple Sclerosis. **2001**, 411-424

343 Magnetic resonance imaging in the diagnosis of multiple sclerosis cerebral foci. **2001**, XXXIII, 78-83

342 Treatment of neuropathic pain for multiple sclerosis.

341 Erkrankungen, die zu einer organischen psychischen Störung führen können. **2002**, 281-456

340 [Magnetic resonance imaging in the diagnosis and understanding of the nature of pathologic changes in multiple sclerosis]. **2002**, 130, 226-31

339 Disorders Affecting Motor Neurons. **2002**, 581-651

338 Multiple Sclerosis, Diagnosis. **2003**, 244-253

337 Neuroimmunology. **2003**, 477-501

336 Multiple Sklerose. **2003**, 1443-1446

335 Geschichte der Entmarkungskrankheiten. **2003**, 133-148

334 Epidemiologie und Genetik. **2003**, 205-219

333 Azathioprine treatment for multiple sclerosis.

332 Ergänzende Untersuchungen. **2003**, 241-260

331 Klinische Diagnose und Verlauf der multiplen Sklerose. **2003**, 220-240

330 Diagnosis and differential diagnosis. **2003**, 55-102

329 Pharmacovigilance des vaccins contre l'hépatite B. **2003**, 187, 1489-1500

328 Diagnosis of multiple sclerosis: comparison of the Poser criteria and the new McDonald criteria. **2003**, 061120065753028

327 Multiple sclerosis in Nord-Trøndelag County, Norway: a prevalence and incidence study. **2003**, 061120065753027

326 Neuroepidemiology: Fundamental Considerations. **2004**, 2-22

325 Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment. **2004**, 15-25

324 Multiple Sclerosis. **2004**, 142-170

323 Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol. **2004**, 129-133

322 Early Treatment in Multiple Sclerosis with Intravenous Immunoglobulin: Rationale and Study Design. **2004**, 119-128

321 [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis]. **2004**, 132, 209-13

2

320 Promoting Health through a Self-help Care Model for the Management of Multiple Sclerosis. **2005**, 195-208

319 Differential Diagnosis of Surgical Disorders of the Spine. **2005**, 33-60

318 References. **2005**, 251-324

317 Clinical Trials in Neuro-Ophthalmology. **2006**, 125-145

316 Multiple Sklerose. **2006**, 1105-1137

315 References. **2006**, 811-946

314 A case of childhood relapsing/remitting multiple sclerosis and interferon β treatment in a Korean patient. **2007**, 50, 580

313 Use of magnetic resonance imaging in clinical management of multiple sclerosis. **2007**, 761-771

o

312 Interferon beta for secondary progressive multiple sclerosis.

311 Neuroimmunology. **2009**, 517-542

310 Early MRI in optic neuritis: The risk for disability. **2010**, 2010, 140-141

309 Radiology of the Orbit and Visual Pathways - Pages 391-400. **2010**, 391-400

308 Symptômes, formes, évolution. **2010**, 11-20

307 Management of Aggressive Multiple Sclerosis: Options and Challenges. **2010**, 35, 304-315

306 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis. 1

305 Non-tumoral Neurology. **2011**, 51-74

304 Multiple Sklerose. **2011**, 1219-1257

303 Imaging Preparation for Surgery. **2011**, 477-494

302 MS: Clinical Features, Symptom Management, and Diagnosis. **2011**, 89-110

301 Neurologic Complications. **2011**, 861-891.e5

300 Acute Therapies and Disease-Modifying Therapies for Multiple Sclerosis. **2012**, 273-291

299 Cannabinoids for multiple sclerosis.

298 Multiple Sklerose und andere autoimmune ZNS-Erkrankungen. **2012**, 1-114

- 297 Interferon treatment of multiple sclerosis. **2012**, 24, 38-43
- 296 Diagnosing Multiple Sclerosis. **2012**, 15-27 1
- 295 Acquired Disorders Affecting the White Matter. **2012**, 1052-1061
- 294 Current Treatments for Progressive Multiple Sclerosis: Disease-Modifying Therapies. **2013**, 187-219
- 293 What Is Disease Progression?. **2013**, 11-30
- 292 Treatment of neuropathic pain for multiple sclerosis.
- 291 Betaferon – MRI-Daten. **2013**, 69-77
- 290 Betaferon – Klinische Evidenz. **2013**, 53-67
- 289 Patient Reported Frequency of Lupus Flare: Associations with Foundation Makeup and Sunscreen Use. **2014**, 04, 344-354
- 288 Biomarkers for Phase Switches in Multiple Sclerosis. **2014**, 1-22
- 287 Tumor necrosis factor-alpha polymorphism and susceptibility to multiple sclerosis in the Iranian population. **2015**, 17, e18247
- 286 Numerical classification of multiple sclerosis. **1984**, 327-332
- 285 Uhthoff-Phänomen bei nicht demyelinisierenden Erkrankungen – Vaskul bedingte passagere Leitungsverzögerung im N. opticus. **1985**, 215-220
- 284 Die spontane –Burst–Aktivität peripherer Blutmonozyten (MO) von MS-Patienten – Ein Parameter für die aktuelle Aktivität des entzündlichen ZNS-Prozesses?. **1985**, 737-739
- 283 Klinische und labordiagnostische Beobachtungen bei familiärer MS. **1985**, 728-732
- 282 HLA Markers and Course of Disease in Multiple Sclerosis. **1986**, 315-321
- 281 Multiple Sclerosis: A Two Stage Process?. **1986**, 225-229
- 280 Magnetic Resonance Imaging in Multiple Sclerosis: The Experience at UCB. **1987**, 11-14

- 279 Humoral Immunity in Multiple Sclerosis Cerebrospinal Fluid: Role of the Blood-Brain Barrier Integrity in the Detection of Intrathecally Synthesized Immunoglobulins. **1987**, 259-265
- 278 Fine Analysis of Cytolytic and Natural Killer T Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis and other Neurological Diseases Patients. **1987**, 323-336
- 277 Efficacy of Intrathecally Administered Natural Human Fibroblast Interferon as Treatment of Multiple Sclerosis. **1987**, 525-529
- 276 Multiple Sklerose im Kindesalter. Literaturübersicht und eigene Beobachtungen. **1987**, 72-79
- 275 Analysis of Immune Complexes in Multiple Sclerosis. **1987**, 129-137
- 274 Lymphocyte Subpopulations as Markers of Disease Activity in Multiple Sclerosis*. **1988**, 35-42
- 273 Failure to Detect Anti-HTLV-III Antibodies in Serum and CSF of 84 Neurological Patients. **1988**, 193-195
- 272 Die Rolle der Kernspintomographie bei der diagnostischen Abklärung isolierter Optikusneuritiden. **1988**, 126-129
- 271 Immunotherapy in Multiple Sclerosis: Arguments for Early Treatment. **1988**, 141-146
- 270 Serial Evoked Potentials and Disease Progression in Multiple Sclerosis. **1988**, 208-213
- 269 Multiple sclerosis CNS infection. **1988**, 122-151
- 268 Immunosuppression with Azathioprine in Multiple Sclerosis. **1988**, 162-171
- 267 Loss of Reliability and Sensitivity of Agarose Isoelectric Focusing and Quantitative Formulae in the Detection of Intrathecally Synthesized IgG in the Presence of Blood-Brain Barrier Damage. **1988**, 32-34
- 266 Detection of HLA Class II Restriction Fragment Length Polymorphisms in Multiple Sclerosis Using Pooled DNA Samples. **1988**, 55-63
- 265 Long-Term Hyperbaric Oxygen in Chronic Progressive Multiple Sclerosis: A Placebo-Controlled Double-Blind Randomized Study with Evoked Potential Evaluation. **1988**, 221-224
- 264 Contribution of Magnetic Resonance Imaging in the Assessment of Multiple Sclerosis. **1988**, 205-207
- 263 Zur Situation der psychologischen Betreuung MS-Kranker: Ergebnis einer Befragung von 847 Patienten. **1989**, 611-614
- 262 Visuell evozierte Potentiale im Krankheitsverlauf bei der multiplen Sklerose. **1989**, 592-594

- 261 Mumpsenzephalomyelitis sine Parotitis versus Enzephalomyelitis disseminata â Differentialdiagnostische Überlegungen anhand einer klinischen und kernspintomographischen Fallstudie. **1989**, 662-665
- 260 Magnetic Resonance Imaging in Isolated Optic Neuritis. **1989**, 401-403
- 259 Entmarkungserkrankungen. **1989**, 292-316
- 258 MRT-kontrollierte Verlaufskontrollen der Encephalomyelitis disseminata im Zweijahresvergleich. **1989**, 619-620
- 257 On the Intrathecal Synthesis of Immunoglobulins: Detection of BSF-2/IL-6 in CSF. **1990**, 33-39 1
- 256 Disease Duration, Relapse rate and Clinical Course in Multiple Sclerosis: Relation to IgG Production within the Blood Brain Barrier. **1990**, 23-31
- 255 Quantitative Analysis of Multiple Sclerosis by Means of MRI. **1990**, 290-293
- 254 Visual evoked potentials in clinical neurology. **1990**, 161-204
- 253 Läsionsmuster zerebraler Herde bei multipler Sklerose und subkortikaler arteriosklerotischer Enzephalopathie (SAE). Ein Vergleich von CCT- und MRT-Befunden. **1991**, 69-70
- 252 Onset and duration of blood-brain barrier breakdown in multiple sclerosis. **1991**, 125-126
- 251 Zur diagnostischen Wertigkeit der somatosensibel evozierten Potentiale nach Trigemiusstimulation bei Encephalomyelitis disseminata. **1991**, 116-117
- 250 Sind epileptische Anfälle ein wenn auch seltenes Symptom der Encephalomyelitis disseminata?. **1991**, 59-60
- 249 Immunzytochemische Analyse von Immunglobulin enthaltenden Zellen im Liquor cerebrospinalis bei Encephalomyelitis disseminata. **1991**, 173-174
- 248 Correlation of Somatosensory Evoked Potential Abnormalities with Brain and Cervical Cord Magnetic Resonance Imaging in Multiple Sclerosis. **1991**, 516-525
- 247 Gadolinium enhancement of new MRI lesions in progressive multiple sclerosis. **1991**, 127-128
- 246 Zur klinischen Differenzierbarkeit von multipler Sklerose und M. Binswanger. **1991**, 71-72
- 245 Motorisch und somatosensibel evozierte Potentiale bei multipler Sklerose. **1991**, 127-128
- 244 Extrapiramidal-motorische Störungen bei multipler Sklerose. **1991**, 55-56

243 Der diagnostische Stellenwert der bildgebenden Verfahren bei der multiplen Sklerose. **1991**, 89-93

242 Treatment of Multiple Sclerosis with Copolymer I. **1992**, 173-198

2

241 Multiple Coenthesien bei Encephalomyelitis disseminata. **1992**, 572-574

240 Clinical Biochemistry of the Central Nervous System. **1994**, 560-580

239 Angewandte Medizinpsychologie bei chronischen Erkrankungen am Beispiel der Multiplen Sklerose. **1995**, 587-600

1

238 Indikationen und Dosierungsschemata. **1995**, 85-155

237 Intravenöse und intrathekale Behandlung der schubförmig verlaufenden Multiplen Sklerose mit natürlichem Interferon-Beta. **1995**, 721-724

236 Assessment and Treatment of Multiple Sclerosis. **1995**, 389-429

0

235 Strategies to Delay the Onset of Clinically Definite Multiple Sclerosis in Patients with Monosymptomatic Presentations of Optic Neuritis, Brainstem Syndromes or Myelopathy. **1996**, 201-221

234 Quality assurance and sample handling in cerebrospinal fluid investigation. **1996**, 133-141

233 Conclusions. **1996**, 143-147

232 The Emergence of Multiple Sclerosis as a "treatable" Condition; An Historical Perspective. **1996**, 351-360

231 Magnetic Resonance Imaging of Patients with Isolated Idiopathic Optic Neuritis, Brainstem Syndromes and Myelopathy. **1996**, 187-200

230 Die Wertigkeit der somatosensorisch, visuell und akustisch evozierten Potentiale sowie der transkraniellen Magnetstimulation in der Diagnostik der multiplen Sklerose (MS). **1996**, 487-498

229 Treatment of Multiple Sclerosis with Methotrexate. **1996**, 251-287

2

228 Treatment of Multiple Sclerosis with Copolymer 1. **1996**, 289-312

227 Paraparesia espática tropical: uma redefinição necessária. **1996**, 54, 535-535

226 Quality Assurance and Sample Handling in CSF Investigation. **1997**, 433-441

- 225 Clinical Trials of Multiple Sclerosis. **1997**, 517-526
- 224 Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms). **1997**, XXIX, 55-58
- 223 Genomic Screening in Multiple Sclerosis. **1999**, 116-129
- 222 Molekulare Aspekte der Behandlung der Multiplen Sklerose. **1999**, 411-449
- 221 Multiple Sklerose. **1999**, 1127-1160
- 220 Levels of platelet-activating factor in cerebrospinal fluid and plasma of patients with relapsing-remitting multiple sclerosis. **1999**, 49-57
- 219 New Viruses and Diseases of the Human Central Nervous System. **1999**, 505-519
- 218 Sleep Disorders Associated with Multiple Sclerosis. **1999**,
- 217 Antibodies to Acinetobacter and Pseudomonas Bacteria in Multiple Sclerosis Patients. **2015**, 87-96
- 216 Antibodies to Acinetobacter Peptide Sequences Resembling Myelin and Neurofilaments in Multiple Sclerosis Patients. **2015**, 97-107
- 215 Poser Criteria, for Multiple Sclerosis. **2015**, 1-2
- 214 Magnetresonanztomografie. **2015**, 137-175
- 213 Multiple Sclerosis: Diagnosis and Treatment. **2016**, 105-122
- 212 Differential Diagnosis between Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. **2016**, 34, 290-296 1
- 211 Diagnostic positif de la sclérose en plaques. **2017**, 79-111
- 210 [A current view on the MRI diagnosis of multiple sclerosis: an update of 2016 revised MRI criteria]. **2017**, 117, 66-73 1
- 209 [Primary progressive multiple sclerosis: current issues of timely diagnosis]. **2017**, 117, 35-40 1
- 208 A Clinical Case Report of Multiple Sclerosis Treated with Only Hominis Placental Pharmacopuncture. **2017**, 38, 289-300 1

- 207 Effects of Psychiatric Comorbidity in Immune-Mediated Inflammatory Disease: Protocol for a Prospective Study (Preprint).
- 206 General Introduction: What Is Progressive Multiple Sclerosis?. **2018**, 1-29
- 205 Encyclopedia of Ophthalmology. **2018**, 1408-1408
- 204 Pathologie de la substance blanche. **2018**, 537-594.e14
- 203 Diagnosis of Multiple Sclerosis: 2017 McDonald Diagnostic Criteria. **2018**, 36, 273-279
- 202 Histoire naturelle de la sclérose en plaques. **2019**, 107-135
- 201 Clinical Features, Symptom Management, and Diagnosis. **2020**, 89-108
- 200 Multimodal Evoked Potentials as Candidate Prognostic and Response Biomarkers in Clinical Trials of Multiple Sclerosis. **2021**, 38, 171-180 3
- 199 Parkon® in the treatment of multiple sclerosis. A pilot study. **2020**, 001-005
- 198 Homozygosity Haplotype and Whole-Exome Sequencing Analysis to Identify Potentially Functional Rare Variants Involved in Multiple Sclerosis among Sardinian Families. **2021**, 43, 1778-1793 1
- 197 Multiple sclerosis diagnostic criteria: From Poser to the 2017 revised McDonald criteria. **2021**, 50, 104089 0
- 196 Interferon-beta injection in multiple sclerosis patients is related to the induction of headache and flu-like pain symptoms: a systematic review and meta-analysis of randomised controlled trials. **2021**, 19, 1000000 0
- 195 Multiple Sclerosis. **2020**, 1-35
- 194 Automatic detection of multiple sclerosis lesions using Mask R-CNN on magnetic resonance scans. **2020**, 14, 4277-4290 2
- 193 Delayed diagnosis of multiple sclerosis in a low prevalence country. **2021**, 43, 521-527 0
- 192 Literatur. **2022**, 468-512
- 191 Immunmedierte Erkrankungen des Nervensystems. **2020**, 37-87
- 190 Gray Matter alterations in MS and CIS: a Coordinate based Meta-analysis and regression.

189	The Increasing Role of Kappa Free Light Chains in the Diagnosis of Multiple Sclerosis. 2021 , 10,	4
188	Rituximab for people with multiple sclerosis. 2021 , 11, CD013874	1
187	M. 2005 , 725-843	
186	Acute Disseminated Encephalomyelitis. 2005 , 255-266	
185	Intracranial Pathology of the Visual Pathway. 2006 , 341-431	
184	Demyelinating Disorders. 2006 , 63-68	
183	Diagnosis of Multiple Sclerosis. 2007 , 133-144	
182	Demyelinating Diseases of the Central Nervous System. 2009 , 1033-1073	
181	Pediatric multiple sclerosis. 2006 , 3, 264-275	
180	Role of steroids and immunosuppression and effects of interferon beta-1b in multiple sclerosis. 1994 , 161, 292-8	10
179	Sexual dysfunction in relapsing-remitting multiple sclerosis: magnetic resonance imaging, clinical, and psychological correlates. 1996 , 21, 255-8	52
178	Downbeat nystagmus: characteristics and localization of lesions. 1989 , 87, 984-1032	15
177	Computer-assisted perimetry in visual pathway disease: neuro-ophthalmic applications. 1984 , 82, 899-942	4
176	The dyschromatopsia of optic neuritis: a descriptive analysis of data from the optic neuritis treatment trial. 1995 , 93, 685-708	32
175	Participation in general practice health screening by people with multiple sclerosis. 2004 , 54, 853-5	4
174	A primary care-based needs assessment of people with multiple sclerosis. 2005 , 55, 378-83	24
173	Effects of cyclosporin A on expression of IL-2 and IL-2 receptors in normal and multiple sclerosis patients. 1987 , 70, 570-7	17
172	The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure. 2004 , 75, 266-9	49

- 171 The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. **2004**, 75, 56-60 38
- 170 Neurology in practice: multiple sclerosis. **2001**, 71 Suppl 2, ii1-2
- 169 The diagnostic challenge of multiple sclerosis. **1984**, 30, 1499-502
- 168 Managing advanced multiple sclerosis. **1993**, 39, 1127-30, 1133-4, 1137-41 3
- 167 Review of teriflunomide and its potential in the treatment of multiple sclerosis. **2009**, 5, 333-40 44
- 166 Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis. **2009**, 3, 369-76 27
- 165 Early stage and long term treatment of multiple sclerosis with interferon-beta. **2009**, 3, 257-71 8
- 164 The prevalence of multiple sclerosis in 3 US communities. **2010**, 7, A12 52
- 163 Effects of low dose methotrexate on relapsing-remitting multiple sclerosis in comparison to Interferon β 1a randomized controlled trial. **2011**, 16, 457-62 16
- 162 Bone loss with multiple sclerosis: effect of glucocorticoid use and functional status. **2011**, 13, 9-14 4
- 161 Multiple Sclerosis and HERV-W/MSRV: A Multicentric Study. **2007**, 3, 292-7 17
- 160 Evaluating sex hormone levels in reproductive age women with multiple sclerosis and their relationship with disease severity. **2012**, 17, 882-5 9
- 159 Venous angioplasty in multiple sclerosis: neurological outcome at two years in a cohort of relapsing-remitting patients. **2012**, 27, 55-9 23
- 158 Cerebrospinal fluid flow dynamics in patients with multiple sclerosis: a phase contrast magnetic resonance study. **2011**, 26, 215-22 15
- 157 Efficacy of doxycycline as add-on to interferon beta-1a in treatment of multiple sclerosis. **2012**, 11, 70-3 3
- 156 Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. **2013**, 12, 136-43 17
- 155 Is it necessary to perform connective tissue disorders laboratory tests when a patient experiences the first demyelinating attack?. **2013**, 18, 617-20
- 154 Multiple sclerosis in children. **2013**, 7, 1-10 3

153	Molecular analysis of interleukin-25 exons 1 and 2 and its serum levels in Iranian patients with multiple sclerosis. 2014 , 3, 91-6	14
152	Effect of Air Pollutant Markers on Multiple Sclerosis Relapses. 2013 , 42, 1167-73	8
151	Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran. 2017 , 46, 699-704	38
150	Therapeutic effect of transplanted umbilical cord mesenchymal stem cells in a cynomolgus monkey model of multiple sclerosis. 2019 , 11, 2516-2531	6
149	A longitudinal MR study of the presymptomatic phase in a patient with clinically definite multiple sclerosis. 1999 , 20, 1268-72	3
148	Relevance of hypointense lesions on fast fluid-attenuated inversion recovery MR images as a marker of disease severity in cases of multiple sclerosis. 1999 , 20, 813-20	31
147	Combined magnetization transfer and proton spectroscopic imaging in the assessment of pathologic brain lesions in multiple sclerosis. 1999 , 20, 829-37	45
146	Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. 1999 , 20, 821-7	65
145	Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton MR spectroscopy. 1999 , 20, 1619-27	278
144	Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. 1999 , 20, 1710-6	59
143	The Future of Progressive Multiple Sclerosis Therapies. 2020 , 37, S43-S49	1
142	Evolution of multiple sclerosis lesions on serial contrast-enhanced T1-weighted and magnetization-transfer MR images. 1999 , 20, 1939-45	49
141	A comparison of MR imaging with fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR sequences in the assessment of patients with multiple sclerosis. 1999 , 20, 1931-8	10
140	MR lesion load and cognitive function in patients with relapsing-remitting multiple sclerosis. 1999 , 20, 1951-5	41
139	Serial analysis of magnetization-transfer histograms and Expanded Disability Status Scale scores in patients with relapsing-remitting multiple sclerosis. 1999 , 20, 1946-50	7
138	Memory dysfunction in multiple sclerosis corresponds to juxtacortical lesion load on fast fluid-attenuated inversion-recovery MR images. 1999 , 20, 1956-62	29
137	Analysis of normal-appearing white matter in multiple sclerosis: comparison of diffusion tensor MR imaging and magnetization transfer imaging. 2001 , 22, 1893-900	59
136	MR venography of multiple sclerosis. 2000 , 21, 1039-42	141

135	Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. 2000 , 21, 1034-8	94
134	Magnetization transfer histogram analysis of monosymptomatic episodes of neurologic dysfunction: preliminary findings. 2000 , 21, 1043-7	27
133	Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis. 2001 , 22, 284-91	3
132	Dynamic contrast-enhanced T2*-weighted MR imaging of tumefactive demyelinating lesions. 2001 , 22, 1109-16	105
131	Whole-brain N-acetylaspartate concentration: correlation with T2-weighted lesion volume and expanded disability status scale score in cases of relapsing-remitting multiple sclerosis. 2002 , 23, 371-5	17
130	Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiologic marker. 2002 , 23, 376-80	41
129	Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. 2000 , 21, 402-8	122
128	Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosis. 2002 , 23, 59-65	14
127	Enhancing patterns in multiple sclerosis: evolution and persistence. 2001 , 22, 664-9	59
126	Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. 2000 , 21, 702-6	242
125	Demyelinating plaques in relapsing-remitting and secondary-progressive multiple sclerosis: assessment with diffusion MR imaging. 2000 , 21, 862-8	72
124	Multiple sclerosis: comparison of trace apparent diffusion coefficients with MR enhancement pattern of lesions. 2000 , 21, 869-74	88
123	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. 2002 , 23, 989-94	48
122	Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. 2005 , 26, 951-6	78
121	Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. 2007 , 28, 767-72	49
120	Reproducibility of three whole-brain N-acetylaspartate decline cohorts in relapsing-remitting multiple sclerosis. 2007 , 28, 267-71	7
119	A diffusion longitudinal MR imaging study in normal-appearing white matter in untreated relapsing-remitting multiple sclerosis. 2007 , 28, 475-8	16
118	Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. 2006 , 27, 2005-11	49

117	Coefficient D(av) is more sensitive than fractional anisotropy in monitoring progression of irreversible tissue damage in focal nonactive multiple sclerosis lesions. 2003 , 24, 663-70	33
116	The ependymal "Dot-Dash" sign: an MR imaging finding of early multiple sclerosis. 2005 , 26, 2033-6	14
115	Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. 2003 , 24, 1941-5	52
114	Standardized, reproducible, high resolution global measurements of T1 relaxation metrics in cases of multiple sclerosis. 2003 , 24, 58-67	9
113	Short-term correlations between clinical and MR imaging findings in relapsing-remitting multiple sclerosis. 2003 , 24, 75-81	20
112	Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. 2000 , 21, 1220-7	58
111	Magnetization transfer imaging in patients with clinically isolated syndromes suggestive of multiple sclerosis. 2001 , 22, 947-51	30
110	Effects of Exercise Training on Neurotrophic Factors and Subsequent Neuroprotection in Persons with Multiple Sclerosis-A Systematic Review and Meta-Analysis. 2021 , 11,	3
109	Siponimod for multiple sclerosis. 2021 , 11, CD013647	2
108	The effects of HMG-CoA reductase inhibitors on disease activity in multiple sclerosis: A systematic review and meta-analysis.. 2022 , 58, 103395	1
107	Retinal inter-eye difference and atrophy progression in multiple sclerosis diagnostics. 2021 ,	0
106	Krankheitsbild Multiple Sklerose - Lernziele. 2022 , 15, 1-1	
105	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. 2022 , 13524585211061861	1
104	Development of a Prognostic Model for Predicting Multiple Sclerosis After Optic Neuritis: A Secondary Analysis of Data From the Optic Neuritis Treatment Trial. 2021 , 42,	0
103	Evaluation of upper extremity ataxia through image processing in individuals with multiple sclerosis.. 2021 ,	0
102	Krankheitsbild Multiple Sklerose. 2022 , 15, 2-16	
101	Evaluating Magnetic Resonance Diffusion Properties Together with Brain Volumetry May Predict Progression to Multiple Sclerosis.. 2022 ,	
100	Oligoclonal Band Straightening Based on Optimized Hierarchical Warping for Multiple Sclerosis Diagnosis.. 2022 , 22,	

99	Women's Health in Multiple Sclerosis: A Scoping Review.. 2021 , 12, 812147		1
98	Plasma Protein Levels Analysis in Multiple Sclerosis Sardinian Families Identified C9 and CYP24A1 as Candidate Biomarkers.. 2022 , 12,		1
97	Clinical and immunological indications of diffuse connective tissue diseases in patients with multiple sclerosis. 2003 , XXXV, 18-21		
96	Determination of CSF GFAP, CCN5, and vWF Levels Enhances the Diagnostic Accuracy of Clinically Defined MS From Non-MS Patients With CSF Oligoclonal Bands.. 2021 , 12, 811351		0
95	Comparing natural history of early and late onset pediatric multiple sclerosis.. <i>Annals of Neurology</i> , 2022 ,	9.4	2
94	The Neuroimmunology of Multiple Sclerosis: Fictions and Facts.. 2021 , 12, 796378		0
93	Autologous hematopoietic stem cell transplantation vs low-dose immunosuppression in secondary-progressive multiple sclerosis.. 2022 ,		1
92	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis.. 2022 , 13, 820256		2
91	Disease-modifying therapies and T1 hypointense lesions in patients with multiple sclerosis: A systematic review and meta-analysis.. 2022 ,		1
90	A Quantitative Synthesis of Eight Decades of Global Multiple Sclerosis Research Using Bibliometrics.. 2022 , 13, 845539		3
89	High prevalence of intrathecal IgA synthesis in multiple sclerosis patients.. 2022 , 12, 4247		
88	Oligoclonal bands: clinical utility and interpretation cues.. 2022 , 1-14		0
87	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression.. 2022 , 1		1
86	Association of Cerebrospinal Fluid Parameters and Neurofilament Light Chain With Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis.. 2022 , 13, 814734		0
85	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial Regional susceptibility in the conversion to multiple sclerosis at disease onset and their amenability to subcutaneous interferon beta-1a.. 2022 ,		0
84	Multiple sclerosis and myelin basic protein: insights into protein disorder and disease. 2021 , 54, 99		3
83	Early first-line treatment response and subsequent disability worsening in relapsing-remitting multiple sclerosis.. 2021 ,		
82	Multiple Sclerosis and Autoimmunity: A Veiled Relationship. 2022 ,		

- 81 Disease-modifying therapy for multiple sclerosis in clinical practice. 583-603
- 80 Image_1.JPEG. 2019,
- 79 Image_2.JPEG. 2019,
- 78 Image_3.jpg. 2019,
- 77 Table_1.DOCX. 2019,
- 76 Data_Sheet_1.docx. 2020,
- 75 One-year MR imaging follow-up of patients with multiple sclerosis under cortisone therapy. 1989, 31, 3-7 6
- 74 Orienting reaction in patients with multiple sclerosis. 1986, 21, 148-55
- 73 Oligoclonal bands: An immunological and clinical approach. 2022,
- 72 Improving pediatric multiple sclerosis interventional phase III study design: a meta-analysis.. 2022, 15, 17562864211070449
- 71 Low Contrast Visual Evoked Potentials for Early Detection of Optic Neuritis.. 2022, 13, 804395
- 70 Prior Optic Neuritis Detection on Peripapillary Ring Scans using Deep Learning.
- 69 Prognostic value of intrathecal IgM synthesis determined by various laboratory methods in patients with early multiple sclerosis - a prospective observational study.. 2022, 63, 103847 0
- 68 Differential Diagnosis of Surgical Disorders of the Spine. 2017, 132-141.e3
- 67 Increasing incidence and prevalence of multiple sclerosis in the Greater Hobart cohort of Tasmania, Australia.. 2022, 0
- 66 Molecular biomarkers in multiple sclerosis. 2022, 72, 127-148
- 65 Incidencia y prevalencia de la esclerosis múltiple en España. Una revisión sistemática. 2022,
- 64 Global assessment of characteristics of multiple sclerosis registries; A systematic review. 2022, 63, 103928 0

- 63 PCR Analysis of DNA from Multiple Sclerosis Patients for the Presence of HTLV-I. **1989**, 246, 821-823 ○
- 62 CSF TNF and osteopontin levels correlate with the response to dimethyl fumarate in early multiple sclerosis. **2022**, 15, 175628642210921 ○
- 61 The History of Diagnosis and Treatment of MS: a Brief Overview.
- 60 Does latent Toxoplasma infection have a protective effect against developing multiple sclerosis? Evidence from an updated meta-analysis. ○
- 59 The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. ○
- 58 Two years' effect of dimethyl fumarate on focal and diffuse gray matter pathology in multiple sclerosis. 135245852211040 ○
- 57 Grey matter atrophy in patients with benign multiple sclerosis. ○
- 56 Symptom-Level Disability Status Assessed with an Electronic Unsupervised Patient-Reported Expanded Disability Status Scale (ePR-EDSS) in Multiple Sclerosis Patients—the Example of Croatia. **2022**, 11, 4081
- 55 Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE) – systematic review protocol. **2022**, 11,
- 54 Prevalence of depression and anxiety in the different clinical forms of multiple sclerosis and associations with disability: A systematic review and meta-analysis. **2022**, 24, 100484 2
- 53 Heritability Estimation of Multiple Sclerosis Related Plasma Protein Levels in Sardinian Families with ImmunoChip Genotyping Data. **2022**, 12, 1101
- 52 Overall and patient-level comparative effectiveness of dimethyl fumarate and fingolimod: A precision medicine application to the Observatoire Français de la Sclérose en Plaques registry. **2022**, 8, 205521732211165
- 51 Neurodegeneration in multiple sclerosis. ○
- 50 Diagnosis of Multiple Sclerosis. **2022**, 28, 1006-1024
- 49 Peripheral Myeloid-Derived Suppressor Cells are good biomarkers of the efficacy of Fingolimod in Multiple Sclerosis.
- 48 The association between blood MxA mRNA and long-term disease activity in early multiple sclerosis. 13,
- 47 Biomarkers in Multiple Sclerosis.
- 46 The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades. **2022**, 68, 104103 1

- 45 Biosensing strategies (approaches) for diagnosis and monitoring of multiple sclerosis. **2023**, 252, 123794 ○
- 44 Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 years. **2022**, 67, 104187 ○
- 43 Prevalence of multiple sclerosis in Guangzhou, China: A population-based case-finding prospective study. **2022**, 68, 104151 ○
- 42 Multiple sclerosis. **2022**, 81, 173-183 ○
- 41 The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy. **2022**, 10, 2099 ○
- 40 Epstein-Barr Virus and multiple sclerosis in a Spanish cohort: A two-years longitudinal study. 13, ○
- 39 Neurofilament light chain in blood as a diagnostic and predictive biomarker for multiple sclerosis: A systematic review and meta-analysis. **2022**, 17, e0274565 ○
- 38 Diagnosis and classification of optic neuritis. **2022**, 3
- 37 Disease activity after discontinuation of disease-modifying therapies in patients with multiple sclerosis in Argentina: data from the nationwide registry RelevEM. 1-6 ○
- 36 What are the trends in the treatment of multiple sclerosis in recent studies? A bibliometric analysis with global productivity during 1980-2021. **2022**, 68, 104185 ○
- 35 Neurologic autoimmune diseases. **2022**, 887-975 ○
- 34 Age and sex differences on anti-hyperglycemic medication exposure and risk of newly diagnosed multiple sclerosis in propensity score matched type 2 diabetics. **2022**, 8, e11196 ○
- 33 Prior optic neuritis detection on peripapillary ring scans using deep learning. ○
- 32 Somatosensory evoked potentials and magnetic resonance imaging of the central nervous system in early multiple sclerosis. ○
- 31 CSF CXCL13 and Chitinase 3-like-1 Levels Predict Disease Course in Relapsing Multiple Sclerosis. 1
- 30 Contemporary study of multiple sclerosis disability in South East Wales. jnp-2022-330013 ○
- 29 The Control Center of Anger. **2022**, 51-77 ○
- 28 Cancer related mortality in multiple sclerosis. A population based cohort study. **2022**, 104417 ○

27	Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis. 2022 , 19,	0
26	Incidence and prevalence of multiple sclerosis in Spain: a systematic review. 2022 ,	0
25	Present and future of the diagnostic work-up of multiple sclerosis: the imaging perspective.	0
24	Association of paramagnetic rim lesions and retinal layer thickness in patients with multiple sclerosis. 135245852211384	0
23	Investigating the Long-term Effect of Pregnancy on the Course of Multiple Sclerosis Using Causal Inference. 10.1212/WNL.000000000206774	0
22	Immunity to T Cell Receptor Peptides in Multiple Sclerosis. III. Preferential Immunogenicity of Complementarity-Determining Region 2 Peptides from Disease-Associated T Cell Receptor BV Genes*. 1998 , 161, 1034-1044	5
21	Antagonistic Action of IFN- α and IFN- β on High Affinity Fc γ Receptor Expression in Healthy Controls and Multiple Sclerosis Patients. 1998 , 161, 1568-1574	4
20	Identification of Autoimmune T Cells Among In Vivo Expanded CD25+ T Cells in Multiple Sclerosis. 1999 , 162, 1811-1817	5
19	A Common TCR V-D-J Sequence in V β 3.1 T Cells Recognizing an Immunodominant Peptide of Myelin Basic Protein in Multiple Sclerosis. 1999 , 163, 3530-3538	11
18	Human Transaldolase and Cross-Reactive Viral Epitopes Identified by Autoantibodies of Multiple Sclerosis Patients. 1999 , 163, 4027-4032	4
17	Asian Adaptation and Validation of an English Version of the Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL). 2011 , 40, 67-73	0
16	Long Term Misdiagnosis of Neuromyelitis Optica Spectrum Disorder Patients with Multiple Sclerosis.	0
15	Determining the Prognostic Characteristics of People with Multiple Sclerosis with Bowel and Bladder Dysfunction as the Initial Presentation: A Cohort Study. 2023 , 2, 62-67	0
14	Chinese herbal medicine for people with multiple sclerosis: Protocol for a systematic review and meta-analysis. 2023 , 58, 102220	0
13	Cerebrospinal fluid neurofilament light chains and CXCL13 as predictive factors for clinical course of multiple sclerosis.	0
12	Nanodiagnosics and nanomedicines for neurodegenerative disorders. 2023 , 131-163	0
11	Application of the McDonald MRI Criteria in Multiple Sclerosis. 2007 , 36, 647-654	0
10	The prevalence and incidence of multiple sclerosis over the past 20 years in northern Japan. 2023 , 73, 104696	0

- 9 Laboratory Investigation of Immunoglobulin Abnormalities. **1985**, 5, 385-405 ○
- 8 Multiple Sclerosis: Where Do We Go From Here?. 84-95 ○
- 7 Multicenter Evaluation of AI-generated DIR and PSIR for Cortical and Juxtacortical Multiple Sclerosis Lesion Detection. **2023**, 307, ○
- 6 Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis. 135245852311514 ○
- 5 Multiple sclerosis in Indigenous Peoples of the Americas: A systematic review of incidence, prevalence, and outcomes. **2023**, 72, 104612 ○
- 4 Performance of McDonald 2017 multiple sclerosis diagnostic criteria and evaluation of genetic ancestry in patients with a first demyelinating event in Argentina. 135245852311572 ○
- 3 Multiple Sclerosis and Other Idiopathic Inflammatory-Demyelinating Diseases. **2013**, 909-943 ○
- 2 Energy minimization segmentation model based on MRI images. 17, ○
- 1 The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis. 17, ○